



DRUG UTILIZATION
REVIEW BOARD

Wednesday
Dec. 10, 2008
6:00 p.m.

Oklahoma Health Care Authority
4545 North Lincoln Boulevard, Suite 124
Oklahoma City, Oklahoma 73105
OHCA Board Room



THE UNIVERSITY OF OKLAHOMA

MEMORANDUM

TO: Drug Utilization Review Board Members
FROM: Shellie Keast, Pharm.D., M.S.
SUBJECT: Packet Contents for Board Meeting – December 10, 2008
DATE: December 4, 2008
NOTE: THE DUR BOARD WILL MEET AT 6:00 P.M.

Enclosed are the following items related to the December meeting. Material is arranged in order of the Agenda.

Call to Order

Public Comment Forum

Action Item – Approval of DUR Board Meeting Minutes – **See Appendix A.**

Update on DUR / MCAU Program – **See Appendix B.**

Action Item – Annual Review of Bladder Control PBPA Category and 30 Day Notice to Prior Authorize Toviaz[®] – **See Appendix C.**

Action Item – Annual Review of Statins/Zetia[®] PBPA Category and 30 Day Notice to Prior Authorize Simcor[®] – **See Appendix D.**

Action Item – Annual Review of Symlin[®] and Byetta[®] – **See Appendix E.**

Utilization Review of Oral Antifungals and 30 Day Notice to Apply Age Restriction to Lamisil[®] Granules – **See Appendix F.**

Utilization Report for First Quarter Fiscal Year 2009 and Fiscal Year 2008 Annual Review – **See Appendix G.**

Retrospective Drug Utilization Review Program Demonstration

FDA and DEA Updates – **See Appendix H.**

Future Business

Adjournment

Drug Utilization Review Board

(DUR Board)

Meeting – December 10, 2008 @ 6:00 p.m.

Oklahoma Health Care Authority

4545 N. Lincoln Suite 124

Oklahoma City, Oklahoma 73105

Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. McNeill, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. McNeill, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Item

Items to be presented by Dr. McNeill, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. November 12, 2008 DUR Minutes – Vote
 - B. Provider Correspondence

Items to be presented by Dr. Keast, Dr. McNeill, Chairman:

4. **Update on DUR/MCAU Program – See Appendix B.**
 - A. Retrospective Drug Utilization Review for September 2008
 - B. Retrospective Drug Utilization Review Responses for July 2008
 - C. Medication Coverage Activity Audit for November 2008
 - D. Help Desk Activity Audit for November 2008

Items to be presented by Dr. Chonlahan, Dr. McNeill, Chairman:

5. **Action Item – Annual Review of Bladder Control PBPA Category and 30 Day Notice to Prior Authorize Toviaz[®] – See Appendix C.**
 - A. Current PA Criteria
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Le, Dr. McNeill, Chairman:

6. **Action Item – Annual Review of Statins/Zetia[®] PBPA Category and 30 Day Notice to Prior Authorize Simcor[®] – See Appendix D.**
 - A. Current PA Criteria
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Patel, Dr. McNeill, Chairman

7. **Action Item – Annual Review of Symlin[®] and Byetta[®] – See Appendix E.**
 - A. Current PA Criteria
 - B. Utilization Review
 - B. COP Recommendations

Items to be presented by Dr. Moore, Dr. McNeill, Chairman

8. **Utilization Review of Oral Antifungals and 30 Day Notice to Apply Age Restriction to Lamisil[®] Granules – See Appendix F.**
 - A. Product Summary
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Keast, Dr. McNeill, Chairman


9. **Utilization Report for First Quarter Fiscal Year 2009 and Fiscal Year 2008 Annual Review – See Appendix G.**
 - A. First Quarter FY 2009 Top 25 Sub-Therapeutic Classes by Reimbursement
 - B. First Quarter FY 2009 Top Therapeutic Classes with Top Five Products by Reimbursement
 - C. FY 2008 Utilization Summary
 - D. FY 2008 Comparison of Top 100 Medications by Reimbursement
 - E. FY 2008 Top 50 Medications by Number of Claims
 - F. FY 2008 Comparison by Therapeutic Category

Items to be presented by Dr. Le, Dr. McNeill, Chairman

10. **Retrospective Drug Utilization Review Program Demonstration**

Items to be presented by Dr. Graham, Dr. McNeill, Chairman

11. **FDA and DEA Updates – See Appendix H.**
12. **Future Business**
 - A. Lock-In Report
 - B. Annual Review of Ocular Antibiotics
 - C. Annual Review of Brovana[®]
 - D. New Product Reviews
13. **Adjournment**



Appendix A

**OKLAHOMA HEALTH CARE AUTHORITY
DRUG UTILIZATION REVIEW BOARD MEETING
MINUTES of MEETING of November 12, 2008**

| BOARD MEMBERS: | PRESENT | ABSENT |
|------------------------------------|----------------|---------------|
| Brent Bell, D.O., D.Ph. | X | |
| Jay D. Cunningham, D.O. | | X |
| Mark Feightner, Pharm.D. | X | |
| Dorothy Gourley, D.Ph. | X | |
| Evelyn Knisely, Pharm.D. | X | |
| Thomas Kuhls, M.D. | X | |
| Dan McNeill, Ph.D., PA-C; Chairman | X | |
| Cliff Meece, D.Ph.; Vice-Chairman | X | |
| John Muchmore, M.D., Ph.D. | X | |
| James Rhymer, D.Ph | X | |

| COLLEGE of PHARMACY STAFF: | PRESENT | ABSENT |
|---|----------------|---------------|
| Leslie Browning, D.Ph.; PA Coordinator | X | |
| Metha Chonlahan, D.Ph.; Clinical Pharmacist | X | |
| Karen Egesdal, D.Ph.; SMAC-ProDUR Coordinator/OHCA Liaison | X | |
| Shellie Keast, Pharm.D.; DUR Manager | X | |
| Ronald Graham, D.Ph.; Pharmacy Director | X | |
| Chris Le, Pharm.D.; Clinical Pharmacist/Coordinator | X | |
| Carol Moore, Pharm.D.; Clinical Pharmacist | | X |
| Neeraj Patel, Pharm.D.; Clinical Pharmacist | | X |
| Lester A. Reinke, Ph.D.; Associate Dean for Graduate Studies & Research | | X |
| Visiting Pharmacy Students: Jodee Borah, Linda Thi | X | |

| OKLAHOMA HEALTH CARE AUTHORITY STAFF: | PRESENT | ABSENT |
|--|----------------|---------------|
| Mike Fogarty, J.D., M.S.W.; Chief Executive Officer | X | |
| Nico Gomez; Director of Gov't and Public Affairs | X | |
| Lynn Mitchell, M.D., M.P.H.; Director of Medicaid/Medical Services | | X |
| Nancy Nesser, Pharm.D., J.D.; Pharmacy Director | X | |
| Howard Pallotta, J.D.; Director of Legal Services | | X |
| Lynn Rambo-Jones, J.D.; Deputy General Counsel III | X | |
| Rodney Ramsey; Drug Reference Coordinator | X | |
| Jill Ratterman, D.Ph.; Pharmacy Specialist | X | |
| Kerri Wade, Senior Pharmacy Financial Analyst | X | |

| OTHERS PRESENT: | | |
|-----------------------------|-----------------------------|------------------------------------|
| Carlos Palasciano, Hawthorn | Mark DeClerk, Lilly | Vann Bennett, Boehringer Ingelheim |
| James Osborne, GSK | Shawn Mitchell, Alcon | Greg Brown, Alcon |
| Tommy Suter, Wyeth | Richard Ponder, J&J | Paul Davis, MHAT |
| Rebecca King, Taro | Pat Trahan, Taro | Erica Brumleve, GSK |
| Bobby White, UCB | Jim Fowler, AZ | Brian Shank, AZ |
| Carl Rose, Sepracor | Joseph Medina, Sepracor | Derek Salyer, Lilly |
| S. Cahill, Teva | Laura Stewart, Merck | Janie Huff, Takeda |
| Ed Hill, NAMI | Jim Dunlap, Lilly | Marcelo Kort, Lilly |
| Mario Munoz, Lilly | David Williams, Forest Labs | Jorge Nassar, BMS |
| Linda Cantu, BMS | Randy Clifton, Amgen | Kim Greenberg, Amylin |
| Lynne Matzell, Amgen | Donna Erwin, BMS | |

| PRESENT FOR PUBLIC COMMENT: | |
|------------------------------------|---|
| Agenda Item 10 | Paul Davis, Mental Health Association of Tulsa (MHAT) |

AGENDA ITEM NO. 1: CALL TO ORDER

1A: Roll Call

Dr. McNeill called the meeting to order. Roll call by Dr. Graham established a quorum.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 2: PUBLIC COMMENT FORUM

Paul Davis, MHAT: Agenda Item 10

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 3: APPROVAL OF DUR BOARD MINUTES

3A: August 13, 2008 DUR Minutes

Dr. Meece moved to approve as submitted; seconded by Dr. Gourley.

ACTION: MOTION CARRIED

3B: September 10, 2008 DUR Minutes

Dr. Meece moved to approve as submitted; seconded by Dr. Kuhls.

ACTION: MOTION CARRIED

AGENDA ITEM NO. 4: UPDATE ON DUR/MCAU PROGRAM

4A: Retrospective Drug Utilization Review: July, August 2008

4B: Retrospective Drug Utilization Review Responses: March, April 2008

4C: Medication Coverage Activity Audit: September, October 2008

4D: Help Desk Activity Audit: September, October 2008

Reports included in agenda packet; presented by Dr. Keast.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 5: VOTE ON 2009 MEETING DATES

Materials included in agenda packet; presented by Dr. Keast.

| | |
|-------------------|-------------------|
| January 14, 2009 | July 8, 2009 |
| February 11, 2009 | August 12, 2009 |
| March 11, 2009 | September 9, 2009 |
| April 8, 2009 | October 14, 2009 |
| May 13, 2009 | November 12, 2009 |
| June 10, 2009 | December 9, 2009 |

Dr. Gourley moved to approve with the November 2009 meeting date changed from November 11 to November 12, 2009; seconded by Dr. Meece.

ACTION: MOTION CARRIED

AGENDA ITEM NO. 6: VOTE TO PRIOR AUTHORIZE ERYTHROPOIESIS STIMULATING AGENTS

Materials included in agenda packet; presented by Dr. Keast.

Dr. Kuhls moved to approve; seconded by Dr. Gourley.

ACTION: MOTION CARRIED

AGENDA ITEM NO. 7: VOTE TO PRIOR AUTHORIZE PROTONIX® SUSPENSION

Materials included in agenda packet; presented by Dr. Keast.

Dr. Muchmore moved to approve; seconded by Dr. Bell.

ACTION: MOTION CARRIED

AGENDA ITEM NO. 8: VOTE TO PRIOR AUTHORIZE PATANASE®

Materials included in agenda packet; presented by Dr. Keast.

Dr. Muchmore moved to approve; seconded by Dr. Meece.

ACTION: MOTION CARRIED

AGENDA ITEM NO. 9: VOTE TO PRIOR AUTHORIZE RESCUE HFA PRODUCTS

Materials included in agenda packet; presented by Dr. Le.

Dr. Kuhls moved to approve; seconded by Dr. Muchmore.

ACTION: MOTION CARRIED

Dr. Kuhls moved to not apply grandfathering; seconded by Dr. Muchmore.

ACTION: MOTION CARRIED

AGENDA ITEM NO. 10: VOTE TO UPDATE ANTIDEPRESSANT PBPA CATEGORY AND PRIOR AUTHORIZE LUVOX CR®

For Public Comment, Paul Davis: *The Mental Health Association in Tulsa is charged with advocating on behalf of people who have a mental illness, and these are the people we are thinking of when we speak with you about the proposed changes to the formulary for antidepressants. It is our desire to see that the best treatment options are available for physicians and their patients in the same way we would desire for our own family and friends. Oklahoma has many special challenges in conquering mental illness and addiction, not the least of which is the lack of specialty mental health professionals. As a primary payer of mental health treatment in Oklahoma, the Health Care Authority has the ability to greatly influence the standards of care and access to treatment for many people. It is our desire that ensuring the highest quality of care is the top priority of the Health Care Authority and the Drug Utilization Review board. To ensure better services and therapeutic options we request that the following changes be made to the proposal: 1) All supplemental rebates for anti-depressant medicines that are received as a result of this proposal are earmarked at the Health Care Authority for expanding mental health treatment options. 2) A review is scheduled after finalizing supplemental rebates to ensure there is an appropriate balance of therapeutic options on the second tier of the Anti-Depressant Category. 3) All new clients who are stabilized on anti-depressants are allowed to maintain their current prescription. 4) That the Health Care Authority develop an active education program of both Medicaid clients and physicians about the best way to make successful petition for authorization of a higher tiered medication. We believe these are reasonable requests and will help the Health Care Authority better serve its clients and effectively manage costs. Your consideration is greatly appreciated and we look forward to continuing to advocate with you to create a just, humane and healthy society in which all people are accorded respect, dignity and the opportunity to achieve their full potential, free from stigma and prejudice.*

Board Member Kuhls: *Just one comment. I don't disagree with anything on here personally. I'm not sure the DUR Board has the, is the right, I would agree in general on all these, but for this DUR Board to sit there and say that the Health Care Authority will take the money and use it, I think that's perfect. I think it couldn't be better. I hope we can do that but I hope you realize that the DUR Board's not the one that you need to work with the rest of the Health Care Authority.*

Mr. Davis: *Right. But I wanted to lay out that with our full proposal. I understand that that's not the situation.*

Board Member Kuhls: *Number two, okay? And we're going to have a discussion here. But under Number Two, as long as, I think it's important to realize that the Tier 1 and Tier 2 system that we have presently, okay, is probably well balanced, okay?*

Mr. Davis: *Right. And most of the doctors I've spoken to have agreed with that.*

Board Member Kuhls: *And it's already well balanced. So there's not going to be tremendous change so that even with supplemental rebates, looking at the Tier 1 drugs that there are, it's probably already well balanced.*

Mr. Davis: *Well, please feel free to correct me if I'm wrong. But the way that I understand the current proposal the second tier would be filled with any medication that was, any company that had signed up for a supplemental rebate, and so ultimately, that could create a second tier that would be unbalanced. By second tier, I mean in the new proposal, so the third tier may remain balanced, but the middle tier wouldn't, and I would like a review*

Board Member Kuhls: *Right, well I just think it's important to talk about because if you look at the two groups, if there's, in the one group, if there's nothing moved to Tier 2 and then the second group of drugs, there are, I think that there's going to have to be ways of looking at how to switch when you need dual and those kind of things, right? Is that what you're saying?*

Mr. Davis: *And I recall from the last meeting where antidepressants were discussed that, I actually believe it was you that said why don't we wait for the supplemental rebates to come and then see what happens. And essentially, I realize that tonight we can't predict the future and realize which drug companies are going to pay out, but I would like to be assured that there will be a good balance of options on all three tiers, so that doctors aren't forced to prescribe medications that aren't appropriate.*

Board Member Kuhls: *So I think what you're saying then, and I don't disagree with you, I think what you're saying is then, is that after the supplemental rebates, if there are any to come in, that if that doesn't seem to be pretty balanced on a tiered system, then maybe we should scrap Tier 2's and just leave everything as those Tier 2's. Is that what you're saying?*

Mr. Davis: *I'm saying that essentially actually, let's guarantee today that no matter what happens with the supplemental rebates, we come back together. We'll get the categories and if they do come out well balanced, then we sign off on it and if they don't we need to revise it again.*

Board Member Kuhls: *I think that's awesome.*

Board Chairman McNeill: *Well, yeah, I think you bring up a good point, that if we do the supplemental rebates and you have everybody in the SSRI category moving to Tier 2, but no duals, you can't get to Tier 3, there's no way to get to Tier 3 if you want to use a dual.*

AGENDA ITEM NO. 12: FDA & DEA UPDATES

Materials included in agenda packet; presented by Dr. Graham.

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 13: FUTURE BUSINESS

Materials included in agenda packet; submitted by Dr. Graham.

13A: Lock-In Report

13B: Oral Antifungal Utilization Review

13C: Annual Reviews

13D: New Product Reviews

ACTION: NONE REQUIRED.

AGENDA ITEM NO. 14: ADJOURNMENT

The meeting was adjourned at 7:10 p.m.



The University of Oklahoma College of Pharmacy

Pharmacy Management Consultants

ORI W-4403; PO Box 26901

Oklahoma City, OK 73190

(405)-271-9039



Memorandum

Date: November 13, 2008

To: Nancy Nesser, Pharm.D., J.D.
Pharmacy Director
Oklahoma Health Care Authority

From: Shellie Keast, Pharm.D., M.S.
Drug Utilization Review Manager
Pharmacy Management Consultants

Subject: DUR Board Recommendations from Meeting of November 12, 2008

Recommendation 1: Vote on 2009 DUR Meeting Dates

MOTION CARRIED by unanimous approval.

Meetings are held the second Wednesday of each month, with the exception of the November meeting, which will be held on the second Thursday of November.

JANUARY 14, 2009

FEBRUARY 11, 2009

MARCH 11, 2009

APRIL 8, 2009

MAY 13, 2009

JUNE 10, 2009

JULY 8, 2009

AUGUST 12, 2009

SEPTEMBER 9, 2009

OCTOBER 14, 2009

NOVEMBER 12, 2009

DECEMBER 9, 2009

Recommendation 2: Vote to Prior Authorize Erythropoietin Stimulating Agents

MOTION CARRIED by unanimous approval.

1. FDA approved indication for specific products.
 - a. Treatment of Anemia of Chronic Renal Failure Patients
 - b. Treatment of Anemia in Zidovudine-treated HIV-infected Patients
 - c. Treatment of Anemia in Cancer Patients on Chemotherapy
 - i. Myelosuppressive Chemotherapy-Induced Anemia (Hb 8-10 g/dL) Non-Curative
 - d. Reduction of Allogeneic Blood Transfusion in Surgery Patients
2. Most recent Hb levels (and date obtained) should be included on petition. Each approval will be for 8 weeks in duration. Authorization can be granted for up to 8 weeks following the final dose of myelosuppressive chemotherapy in a chemotherapy regimen. Authorization for surgery patients will be for a maximum of 4 weeks.
3. Continuation Criteria:
 - a. Continue dose if Hb is ≤ 12.0 g/dL.
 - b. If Hb is increasing and approaching 12 g/dL then reduce dose by at least 25%.
 - c. If more than 1 g/dL increase (but Hb not greater than upper limits listed below) has occurred in a 2 week period reduce dose by 25 to 50 %.
4. Discontinuation Criteria:
 - a. ESRD – Discontinue treatment if **Hb is at or above 13.0 g/dL.**
 - b. All others – Discontinue treatment if **Hb is at or above 12 g/dL.**
 - c. If a minimum increase of 1 g/dL has not been achieved after initial 8 weeks of therapy.
5. Reinitiation Criteria:
 - a. If Hb decreases to ≤ 10 g/dL then therapy may be reinitiated at 25 to 50% of the prior dose.

Once the initial request has been submitted and approved, continuation of therapy may occur with submission of the continuation form.

Recommendation 3: Vote to Prior Authorize Protonix® Suspension

MOTION CARRIED by unanimous approval.

The College of Pharmacy recommends placing Protonix® Oral Suspension in Tier 2 of the Anti-ulcers PBPA Category. Approval requires documentation of medical necessity for this dosage form over available Tier 1 products. Quantity limit of 30 packets for 30 days would also be applied.

Recommendation 4: Vote to Prior Authorize Patanase®

MOTION CARRIED by unanimous approval.

The College of Pharmacy recommends prior authorization of Pantanase® and placement as a Tier 3 nasal allergy product.

Recommendation 5: Vote to Prior Authorize Rescue HFA Products

MOTION CARRIED by unanimous approval.

The College of Pharmacy recommends the addition of the Rescue HFA Inhalers to the Product Based Prior Authorization program. This category is unique in that, pharmacologically, all the agents considered consist of a form of albuterol, in an aerosolized delivery device with hydrofluoroalkane as the propellant. Therefore, the College of Pharmacy recommends initiation of a supplemental rebate offer to all manufacturers involved before arrangement of the products in the tier list. The manufacturer(s) returning the best economic offer will subsequently have their product placed on Tier 1, and all others will be placed on Tier 2. If no supplemental rebate offers are returned then the current lowest priced HFA product will be placed on tier-1. Once the Tier 1 product(s) have been determined, the College of Pharmacy will perform an educational outreach activity to inform providers of the SoonerCare preferred product(s).

| Short Acting B2 Agonists | |
|------------------------------------|----------------|
| Tier 1 | Tier 2 |
| Best Supplemental Rebate Agreement | ProAir® HFA |
| | Proventil® HFA |
| | Ventolin® HFA |
| | Xopenex® HFA |

The following is the proposed approval criteria:

1. Approved or clinically accepted indication, and
2. Specific reason member cannot use all available tier one products.

Recommendation 6: Vote to Update Antidepressant PBPA Category and Vote to Prior Authorize Luvox® CR

MOTION CARRIED by unanimous approval.

The College of Pharmacy recommends the following three tiered structure. In order to be considered for Tier 1 or Tier 2, new treatment options must have a proven advantage in safety, efficacy, or cost, over the numerous agents currently available. The class will be periodically reviewed and medications may be moved according to availability of emerging treatment options and comparative cost/benefit profile.

Criteria for Approval of a Tier 2 Medication:

1. A documented, recent (within 6 months) trial of a Tier 1 medication at least 4 weeks in duration and titrated to recommended dosing, that did not provide an adequate response. Tier 1 selection can be from any classification.
2. Prior stabilization on the Tier 2 medication documented within the last 100 days. A past history of success on the Tier 2 medication will also be considered with adequate documentation.
3. A unique FDA-approved indication not covered by Tier 1 products or other products from a different therapeutic class.
4. A petition may be submitted for consideration whenever a unique member specific situation exists.

Criteria for Approval of a Tier 3 Medication:

1. A documented, recent (within 6 months) trial with a Tier 1 and a Tier 2 medication at least 4 weeks in duration and titrated to recommended dose, that did not provide an adequate response. Tier 1 and Tier 2 selection can be from any classification.
2. Prior stabilization on the Tier 3 medication documented within the last 100 days. A past history of success on the Tier 3 medication will also be considered with adequate documentation.
3. A unique FDA-approved indication not covered by a lowered tiered product or other products from a different therapeutic class.
4. A petition may be submitted for consideration whenever a unique member specific situation exists.

| SSRIs (Selective Serotonin Reuptake Inhibitors) | | |
|--|---------------------------------|---------------------------------------|
| Tier 1 | Tier 2 | Tier 3 |
| citalopram (Celexa®) | Supplemental Rebated T-3 | escitalopram (Lexapro®) |
| fluoxetine (Prozac®, Sarafem®) | | fluvoxamine (Luvox® CR) |
| fluvoxamine (Luvox®) | | paroxetine (Pexeva®, Paxil CR®) |
| paroxetine (Paxil®) | | |
| sertraline (Zoloft®) | | |
| Dual Acting Antidepressants | | |
| Tier 1 | Tier 2 | Tier 3 |
| venlafaxine (Effexor®) | Supplemental Rebated T-3 | duloxetine (Cymbalta®) |
| trazodone (Desyre®) | | nefazodone (Serzone®) |
| mirtazapine (Remeron®, Remeron SolTab®) | | desvenlafaxine (Pristiq®) |
| bupropion (Wellbutrin®, Wellbutrin SR®, Wellbutrin XL®) | | venlafaxine XR (Effexor XR® Caps) |
| | | Venlafaxine Extended Release Tabs® |
| Monoamine Oxidase Inhibitors | | |
| Tier 1 | Tier 2 | Tier 3 |
| | | selegiline patch (Emsam®) |
| | | tranylcypromine (Parnate®) |
| | | phenelzine (Nardil®) |
| | | selegiline (Zelapar®) |

Mandatory generic plan applies.

OKLAHOMA DEPARTMENT OF MENTAL HEALTH
AND SUBSTANCE ABUSE SERVICES

November 12, 2008

DUR Board
C/O Lynn Mitchell, M.D., MPH
Oklahoma Health Care Authority
4545 N. Lincoln, Ste. 124
Oklahoma city, OK 73105

Dear DUR Board:

Thank you for the opportunity to provide input regarding the proposed introduction of a three-tier formulary for anti-depressants.

Generally, the Oklahoma Department of Mental Health and Substance Abuse Services (ODMHSAS) holds open access to psychotropic medications as the desired policy position. With mental illness and addiction, individuals can have widely varying responses to specific medications. The ideal approach for prescribing is to provide physician's discretion to make clinical decisions independently as opposed to using tiered formularies. However, if a formulary must be put in to place and considering the enumerated consumer protections and the number of agents listed as first tier products, ODMHSAS has concluded that the approach outlined in this proposal is reasonable.

As the DUR moves forward with this process, the ODMHSAS and our physicians will be monitoring exceptions very closely to make sure that consumers have access to the medications they need. It is our belief that documentation should not be onerous and that physician judgment should be given majority weight in prior authorization decisions. Also, the DUR should watch closely to make sure that access to commonly used and well tolerated medications is not blocked by a relatively low-volume manufacturer paying a supplemental rebate and occupying the second tier, effectively relegating the other medications to third tier status.

In closing, thank you again for reaching out to our agency and soliciting our feedback.

Sincerely,



Terri White, M.S.W.
Commissioner

BOARD OF DIRECTORS

President
David Reed
Reed's Consulting Services

President-elect
Kellie Wilson
Bank of America

Secretary
Mary Ann Gardner, CPA
Williams

Treasurer
Misty Jamison, CPA
Williams

Robert Althoff, LCSW, LMFT
Abbas Family

LeNissa Anyomi
Wellman Products Group

Sharon Beavers
Community Volunteer

Michelle Booth
Procom Marketing, Inc.

Kay Butchko, MS, LPC
Private Practice

Andrew Cherry, DSW, ACSW
OU-Tulsa

Sandra Clanton, ChFC, CLU, MBA
Rooney Insurance Agency, Inc.

Ann Dapice, Ph.D.
T.K. Wolf, Inc.

Stephen Fater
QuikTrip Corporation

Pat Fike
Community Volunteer

Michelle L. Griffith, MS
Dollar Thrifty Automotive Group, Inc.

Greg Guerrero
Apartment Services Company

Traci M. Harvel, APR
MidCon-Energy

Melanie Hasty-Grant
Waterstone Private Wealth Management

Donnie House
Community Service Council

Deborah J. Hunter
Advocate

Steve Jacoby
The Benham Companies

Ashley Johnson
Youth Advocate

Andrew Levinson
IBC Bank

Tracie Lewis
Tulsa Police Department

Michele Magalassi
Bank of Oklahoma

Monty Mueller
Fair Isaac

Cynthia Naff, LPC, LADC
Positive Behavioral Strategies

Joe Ray
Bank of Oklahoma

Karen Reed
Community Volunteer

Maria Reyes, CADAC
YWCA Multicultural Center

Tamra Sheehan
Community Volunteer

Cleatta Shumate-Johnson, M.Ed., LPC
Private Practice

Will Smith
SWS, LLC

Michael Strakal, PT, MBA
Injury Prevention Solutions, Inc.

Kurt VanMatre, LPC, LMFT
Laureate Psychiatric Clinic & Hospital

Richard A. Wansley, Ph.D.
OSU-Center for Health Sciences

Scott Williams
Advocate

Ben Windham
Community Volunteer

ADVISORY BOARD

Judy & Jeff Alexander
Cathey & Mike Barkley

Teresa & Robert Burkett
Paula & Gerard Clancy

Phyllis & George Dolson
Maggie Fox

Debi Friggel

Judi & Ken Klein

Rose & Sheldon Miller

Julie & Ted Mundi

Suzanne O'Brien

Robert Price

Gail & Kip Richards

Catherine Seger

Suzanne & William K. Warren, Jr.

Mollie Williford

Henry Zarrow

Maxine & Jack Zarrow

Debbie & Danny Zeligson

Building Lives



Dan McNiell, Ph.D., PA-C, Chariman
Drug Utilization Review Board
Oklahoma Health Care Authority
4545 North Lincoln Boulevard, Suite 124
Oklahoma City, Oklahoma 73105

11 November 2008

Dear Dr. McNiell:

The Mental Health Association in Tulsa is charged with advocating on behalf of people who have a mental illness, and these are the people we are thinking of when we speak with you about the proposed changes to the formulary for anti-depressants. It is our desire to see that the best treatment options are available for physicians and their patients in the same way we would desire for our own family and friends.

Oklahoma has many special challenges in conquering mental illness and addiction, not the least of which is the lack of specialty mental health professionals. As a primary payer of mental health treatment in Oklahoma, the Health Care Authority has the ability to greatly influence the standards of care and access to treatment for many people. It is our desire that ensuring the highest quality of care is the top priority of the Health Care Authority and the Drug Utilization Review board.

To ensure better services and therapeutic options we request that the following changes be made to the proposal:

- 1) All supplemental rebates for anti-depressant medicines that are received as a result of this proposal are earmarked at the Health Care Authority for expanding mental health treatment options.
- 2) A review is scheduled after finalizing supplemental rebates to ensure there is an appropriate balance of therapeutic options on the second tier of the Anti-Depressant Category.
- 3) All new clients who are stabilized on anti-depressants are allowed to maintain their current prescription.

1870 South Boulder, Tulsa, Oklahoma 74119
Telephone (918) 585-1213 • Fax (918) 585-1263
www.mhat.org



- 4) Develop an active education program by the Health Care Authority of both Medicaid clients and physicians about the best way to make successful petition for authorization of a higher tiered medication.

We believe these are reasonable requests will help the Health Care Authority better serve its clients and effectively manage costs. Your consideration is greatly appreciated and we look forward to continuing to advocate with you to create a just, humane and healthy society in which all people are accorded respect, dignity and the opportunity to achieve their full potential, free from stigma and prejudice.


Respectfully Submitted,




Cynthia Maff
Co-Chair of Public Policy Committee




Steve Jacoby
Co-Chair of Public Policy Committee



Michael W. Brose
Executive Director



Paul G. Davis
Director of Public Policy



Appendix B

Retrospective Drug Utilization Review Report
Claims Reviewed for September 2008

| Module | Drug Interaction | Duplication of Therapy | Drug-Disease Precautions | Dosing & Duration |
|---|--|--|---|--|
| Total # of <u>messages</u> returned by system when <u>no limits</u> were applied | 43,838 | 64,921 | 1,154,409 | 32,790 |
| <u>Limits</u> which were applied | Established, Major, Males and Females, Age 41-50 | Males and Females, Age 0-2, Antihistamines | Contraindicated, Males and Females, 0-150, Arrhythmia | High Dose only, males and females, 0-9 years old, Amphetamines |
| Total # of <u>messages</u> after <u>limits</u> were applied | 75 | 84 | 351 | 30 |
| Total # of <u>members</u> reviewed after <u>limits</u> were applied | 75 | 78 | 254 | 30 |
| LETTERS | | | | |
| Prescribers | | Pharmacies | | |
| Sent | Responded | Sent | Responded | |
| 80 | | 71 | | |


Retrospective Drug Utilization Review Report

Claims Reviewed for July 2008

| Module | Drug Interaction | Duplication of Therapy | Drug-Disease Precautions | Dosing & Duration |
|--|---|---|--|--|
| Limits which were applied | Established, Major, Males and Females, Age 0-18 | Antiplatelet Agents, Males and Females, Age 0-150 | Contraindicated, Hepatic Disease, Males and Females, Age 41-65 | High Dose only, Benzodiazepines, Males and Females, Age 0-18 |
| Response Summary (Prescriber) Letters Sent: 13 Response Forms Returned: 6 The response forms returned yielded the following results: | | | | |
| 0 (0%) | <i>Record Error—Not my patient.</i> | | | |
| 1 (17%) | <i>No longer my patient.</i> | | | |
| 2 (33%) | <i>Medication has been changed prior to date of review letter.</i> | | | |
| 1 (17%) | <i>I was unaware of this situation & will consider making appropriate changes in therapy.</i> | | | |
| 1 (17%) | <i>I am aware of this situation and will plan to continue monitoring therapy.</i> | | | |
| 1 (17%) | <i>Other</i> | | | |
| Response Summary (Pharmacy) Letters Sent: 2 Response Forms Returned: 2 The response forms returned yielded the following results: | | | | |
| 0 (0%) | <i>Record Error—Not my patient.</i> | | | |
| 0 (0%) | <i>No longer my patient.</i> | | | |
| 1 (50%) | <i>Medication has been changed prior to date of review letter.</i> | | | |
| 0 (0%) | <i>I was unaware of this situation & will consider making appropriate changes in therapy.</i> | | | |
| 1 (50%) | <i>I am aware of this situation and will plan to continue monitoring therapy.</i> | | | |
| 0 (0%) | <i>Other</i> | | | |


PRIOR AUTHORIZATION ACTIVITY REPORT

November 2008



PRIOR AUTHORIZATION REPORT

November 2007 – November 2008



Activity Audit for

November 01, 2008

Through

November 30, 2008

| | Average Length of Approvals in Days | Approved | Denied | Total |
|---------------------------------|--|-------------|-------------|-------------|
| ACE Inhibitors | 3 | 5 | 0 | 6 |
| Angiotensin Receptor Antagonist | 348 | 23 | 81 | 116 |
| Antidepressant | 234 | 166 | 198 | 440 |
| Antihistamine | 200 | 254 | 250 | 570 |
| Antiulcers | 24 | 15 | 6 | 22 |
| Anxiolytic | 92 | 2556 | 353 | 3229 |
| Calcium Channel Blockers | 26 | 8 | 2 | 11 |
| Growth Hormones | 165 | 36 | 3 | 44 |
| HTN Combos | 218 | 5 | 10 | 15 |
| Insomnia | 109 | 42 | 76 | 143 |
| Nsaids | 272 | 31 | 68 | 112 |
| Plavix | 355 | 87 | 11 | 149 |
| Stimulant | 192 | 545 | 237 | 921 |
| Others | 94 | 1249 | 898 | 2945 |
| Emergency PAs | | 3 | 0 | 3 |
| Total | | 5025 | 2193 | 8726 |
| Overrides | | | | |
| Brand | 215 | 29 | 11 | 49 |
| Dosage Change | 11 | 369 | 15 | 399 |
| High Dose | 106 | 6 | 1 | 8 |
| Lost/Broken Rx | 12 | 84 | 3 | 93 |
| Nursing Home Issue | 9 | 86 | 2 | 91 |
| Other | 12 | 19 | 5 | 27 |
| Quantity vs. Days Supply | 201 | 69 | 19 | 111 |
| Stolen | 3 | 6 | 0 | 6 |
| Wrong D.S. on Previous Rx | 0 | 0 | 2 | 2 |
| Overrides Total | | 668 | 58 | 786 |


Denial Reasons


| | |
|--|------|
| Lack required information to process request. | 2081 |
| Unable to verify required trials. | 1043 |
| Does not meet established criteria. | 203 |
| Considered duplicate therapy. Member has a prior authorization for similar medication. | 127 |
| Not an FDA approved indication/diagnosis. | 98 |
| Requested dose exceeds maximum recommended FDA dose. | 57 |
| Member has active PA for requested medication. | 44 |
| Drug Not Deemed Medically Necessary | 9 |
| Medication not covered as pharmacy benefit. | 5 |
| Duplicate Requests | 475 |
| * Changes to existing | 637 |

* Changes to existing PA's: Backdates, changing units, end dates, etc.

CALL VOLUME MONTHLY REPORT

November 2007 – November 2008





Appendix C

Annual Review of Bladder Control Medications and 30 Day Notice to Prior Authorize Toviaz™

Oklahoma Health Care Authority
December 2008

Current PA Criteria:

In order to get a tier-2 drug, member must meet one of the following criteria:

- Tier-1 drug failure (i.e. inadequate clinical response or adverse effect), or
- Contraindication to the tier-1 drugs, or
- Stabilization on the tier-2 drug, or
- A unique indication which the tier-1 drugs lack.

| Incontinence Medications* | |
|---|---|
| Tier 1 | Tier 2 |
| Darifenacin (Enablex ®) Flavoxate (Urispas ®) Oxybutynin (Ditropan ®) Solifenacin (VESIcare ®) Tolterodine Extended-Release (Detrol LA ®) Tolterodine (Detrol ®) | Oxybutinin Extended-Release (Ditropan XL ®) Oxybutynin (Oxytrol ®) Trospium (Sanctura, Sanctura XR ®) |

Color Indicates participation in Supplemental Rebate Program

Market News

FDA approved a new anticholinergic bladder control medication, Toviaz™ (fesoterodine), in October 2008.

Utilization

For the period of July 2007 through June 2008, a total of 12,215 members received bladder control products through the SoonerCare program.

| | FY 2007 versus FY 2008 | % Change |
|------------------------|---------------------------------|---------------|
| Cost FY '08 | *\$1,073,227.27 | 11.5 ↑ |
| | <i>Cost FY '07</i> \$949,785.89 | |
| Claims FY '08 | 12,215 | 8.0 ↑ |
| | <i>Claims FY '07</i> 11,233 | |
| Per Diem FY '08 | \$2.64 | 3.8 ↑ |
| | <i>Per Diem FY '07</i> \$2.54 | |
| Members FY '08 | 2,914 | 6.0 ↑ |
| | <i>Members FY '07</i> 2,739 | |

*Does not include supplemental rebate information


Utilization Trends of Bladder Control Medications

| Product | Claims | | % Change | Cost | | % Change |
|------------------------|--------|-------|----------|--------------|--------------|----------|
| | 2007 | 2008 | | 2007 | 2008 | |
| DETROL LA CAP 4MG | 2,858 | 3,390 | 15.69 | \$370,840.22 | \$480,872.28 | 22.88 |
| OXYBUTYNIN TAB 5MG | 3,158 | 3,345 | 5.59 | \$24,764.79 | \$30,829.77 | 19.67 |
| OXYBUTYNIN TAB 10MG ER | 415 | 919 | 54.84 | \$46,065.10 | \$76,746.19 | 39.98 |
| OXYBUTYNIN SYP 5MG/5ML | 701 | 799 | 12.27 | \$7,668.07 | \$10,124.48 | 24.26 |
| VESICARE TAB 5MG | 576 | 698 | 17.48 | \$73,133.89 | \$102,090.63 | 28.36 |
| DETROL TAB 2MG | 816 | 686 | -18.95 | \$91,241.66 | \$88,742.74 | -2.82 |
| VESICARE TAB 10MG | 209 | 433 | 51.73 | \$27,915.01 | \$63,788.26 | 56.24 |
| DETROL LA CAP 2MG | 359 | 411 | 12.65 | \$48,348.29 | \$63,805.30 | 24.23 |
| OXYBUTYNIN TAB 15MG ER | 124 | 294 | 57.82 | \$18,955.28 | \$33,062.28 | 42.67 |
| OXYBUTYNIN TAB 5MG ER | 139 | 212 | 34.43 | \$19,149.11 | \$23,717.05 | 19.26 |
| ENABLEX TAB 15MG | 187 | 193 | 3.11 | \$22,440.63 | \$26,364.63 | 14.88 |
| FLAVOXATE TAB 100MG | 210 | 190 | -10.53 | \$16,343.79 | \$9,597.01 | -70.30 |
| ENABLEX TAB 7.5MG | 148 | 118 | -25.42 | \$20,350.89 | \$18,674.94 | -8.97 |
| DETROL TAB 1MG | 95 | 89 | -6.74 | \$8,874.00 | \$9,123.08 | 2.73 |
| SANCTURA TAB 20MG | 74 | 59 | -25.42 | \$7,371.38 | \$6,985.29 | -5.53 |
| OXYTROL DIS 3.9MG/24 | 114 | 53 | -53.5 | \$12,006.28 | \$6,412.86 | -87.22 |
| DITROPAN XL TAB 10MG | 435 | 25 | -94.3 | \$63,499.47 | \$3,388.57 | -94.7 |
| DITROPAN XL TAB 5MG | 173 | 22 | -87.3 | \$28,515.89 | \$4,629.13 | -83.8 |
| HYOSCYAMINE TAB 0.15MG | 21 | 17 | -19.0 | \$723.49 | \$393.30 | -45.6 |
| DITROPAN XL TAB 15MG | 173 | 15 | -91.3 | \$26,587.95 | \$2,944.00 | -88.9 |
| DITROPAN TAB 5MG | 11 | 11 | 0.00 | \$694.32 | \$694.32 | 0.00 |
| SANCTURA XR CAP 60MG | 0 | 7 | n/a | \$0.00 | \$1,086.05 | n/a |

Total petitions submitted for this category during FY08: 362

Approved 117
 Denied 178
 Incomplete 67

Age and Gender FY08



Recommendations

The College of Pharmacy recommends placing Toviaz™ (fesoterodine) into the Tier 2 bladder control product category and to continue to monitor and evaluate the bladder control medication category.

Criteria:

- Tier 1 drug failure (i.e. inadequate clinical response or adverse effect), or
- Contraindication to the Tier 1 drugs , or
- Stabilization on the Tier 2 drug, or
- A unique indication which the Tier 1 drugs lack.

Members who are currently stabilized on a Tier 2 medication will be allowed to continue their current treatment without prior authorization.

| Bladder Control Products | |
|---------------------------------|---|
| <i>Tier 1</i> | <i>Tier 2</i> |
| Flavoxate (Urispas®) | Darifenacin (Enablex®) |
| Oxybutynin (Ditropan®) | Fesoterodine (Toviaz™) |
| | Oxybutynin Extended-Release (Ditropan XL®) |
| | Oxybutynin (Oxytrol®) |
| | Solifenacin (VESicare®) |
| | Trospium (Sanctura, Sanctura XR®) |
| | Tolterodine Extended-Release (Detrol LA®) |
| | Tolterodine (Detrol®) |

Toviaz (TM) (fesoterodine fumarate)1

| | |
|-----------------------|-----------------------|
| Manufacturer | Pfizer |
| Classification | Anticholinergic Agent |
| Status | Prescription only |

Summary

Toviaz^(TM) (fesoterodine fumarate) received FDA approval in October 2008. Toviaz^(TM) is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

- **Urge urinary incontinence** -- leaking or wetting accidents due to a strong need to urinate.
- **Urinary urgency** -- having a strong need to urinate right away,
- **Urinary frequency** -- having to urinate too often.

The recommended starting dose is 4mg once a day with a maximum of 8mg a day. Toviaz^(TM) should be taken whole with liquid and with or without food. The dose of 4mg a day should not be exceeded in the following populations:

- Patients with severe renal insufficiency ($CL_{CR} < 30$ mL/min).
- Patients taking potent CYP3A4 inhibitors, such as ketoconazole, itraconazole and clarithromycin.
- Toviaz^(TM) is not recommended for use in patients with severe hepatic impairment.

Fesoterodine is a competitive muscarinic receptor antagonist. After oral administration, fesoterodine is rapidly and extensively hydrolyzed by nonspecific esterases to its active metabolite, 5-hydroxymethyl tolterodine, which is responsible for the antimuscarinic activity of fesoterodine.

Muscarinic receptors play a role in contractions of urinary bladder smooth muscle and stimulation of salivary secretion. Inhibition of these receptors in the bladder is presumed to be the mechanism by which fesoterodine produces its effects.

Dosage Forms

4 and 8mg extended release tablets

Pregnancy Risk Factor C

Contraindications

Toviaz^(TM) is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. Toviaz^(TM) is also contraindicated in patients with known hypersensitivity to the drug or its ingredients.

Precautions

- Toviaz^(TM) should be administered with caution to patients with clinically significant bladder outlet obstruction because of the risk of urinary retention
- Toviaz^(TM), like other antimuscarinic drugs, should be used with caution in patients with decreased gastrointestinal motility, such as those with severe constipation
- Toviaz^(TM) should be used with caution in patients being treated for narrow-angle glaucoma, and only where the potential benefits outweigh the risks
- There are no dosing adjustments for patients with mild or moderate hepatic impairment. Toviaz^(TM) has not been studied in patients with severe hepatic impairment and therefore is not recommended for use in this patient population
- Toviaz^(TM) should be used with caution in patients with myasthenia gravis, a disease characterized by decreased cholinergic activity at the neuromuscular junction
- There are no dosing adjustments for patients with mild or moderate renal insufficiency. Doses of Toviaz^(TM) greater than 4 mg are not recommended in patients with severe renal insufficiency

Common Adverse Effects

- Dry mouth
- Constipation

Less Common Adverse effects

- Dry eyes
- Trouble emptying the bladder

Drug Interactions


Doses of Toviaz[™] greater than 4 mg are not recommended in patients taking a potent CYP3A4 inhibitor

Patient Information

- Use caution in driving, operating machinery, or doing other dangerous activities until you know how TOVIAZ™ affects you. Blurred vision and drowsiness are possible side effects of medicines such as TOVIAZ™.
- Use caution in hot environments. Decreased sweating and severe heat illness can occur when medicines such as TOVIAZ™ are used in a hot environment.
- Drinking alcohol while taking medicines such as TOVIAZ™ may cause increased drowsiness.

REFERENCE

Toviaz™ (fesoterodine) Product Information. Pfizer. www.toviaz.com Accessed 2008.



Appendix D

**Annual Review of HMG-CoA Reductase Inhibitors and Ezetimibe (Zetia®)
30 Day Notice to Prior Authorize simvastatin/Niaspan® (Simcor®)
Oklahoma HealthCare Authority
December 2008**

Current Prior Authorization Criteria for Statin Medications

The class of HMG-CoA Reductase Inhibitors (statins) was included in the Product Based Prior Authorization program during fiscal year 2004. The following is the current tier list and criteria:

| HMG-CoA Reductase Inhibitors (Statins)* | |
|--|--|
| <i>Tier One</i> | <i>Tier Two</i> |
| Lovastatin (Mevacor) Fluvastatin (Lescol® and Lescol XL®) Simvastatin (Zocor®) Pravastatin (Pravachol®) Atorvastatin (Lipitor®) | Rosuvastatin (Crestor®) Lovastatin (brand name Altoprev®) Lovastatin/Niacin (Advicor®) Pravastatin/Aspirin (Pravaguard®) Simvastatin/Ezetimibe (Vytorin®) |

*Mandatory generic plan in effect where generic is available.
 Blue Indicates Tier 1 due to Supplemental Rebate Participation

Criteria for Authorization

To qualify for a Tier 2 medication, there must be:

1. Previous failure to achieve desired LDL reduction with a Tier 1 statin - defined by at least 8 weeks of continuous therapy at standard to high dose.
2. Previous stabilization with Tier 2 medication.
3. Documented increased risk for drug interactions. Specifically: concurrent immunosuppressant therapy, HIV antiretroviral therapy, and therapy with other potent inhibitors of CYP450 system.
4. Documented adverse effect or contraindication to the Tier 1 products.
5. Clinical exception for atorvastatin 80mg: members hospitalized for recent acute myocardial infarction or acute coronary syndrome. (Criterion not in effect as atorvastatin is currently in Tier 1.)

Current Prior Authorization Criteria for Ezetimibe (Zetia®)


1. Diagnosis:
 - Hypercholesterolemia, primary or familial
 - Hyperlipidemia, mixed
 - Sitosterolemia, homozygous
2. Laboratory documentation that client has not met (LDL) cholesterol goals after therapeutic lifestyle changes and statin therapy for at least 6 months, or
3. Not a candidate for statin therapy due to:
 - Documented active liver disease.
 - Documented unexplained, persistent elevations of serum transaminases.
 - Documented statin related myopathy.

Utilization of Statins

Trends in Utilization of Statins

| Fiscal Year | Members | Claims | Cost | Cost/Claim | Perdiem | Units | Days |
|-------------|---------|--------|----------------|------------|---------|-----------|-----------|
| 2007 | 10,200 | 44,555 | \$5,271,128.69 | \$118.31 | \$2.81 | 1,859,624 | 1,874,288 |
| 2008 | 10,877 | 50,312 | \$4,403,183.63 | \$87.52 | \$2.15 | 2,040,378 | 2,046,462 |
| Change | 677 | 5,757 | -\$867,945.06 | -\$30.79 | -\$0.66 | 180,754 | 172,174 |
| % Change | 6.6% | 12.9% | -16.5% | -26.0% | -23.5% | 9.7% | 9.2% |

Demographics of Members Utilizing Statins: FY08



| Age Groups | 00-09 | 10-19 | 20-34 | 35-49 | 50-64 | 65-79 | 80-94 | 95 > |
|------------|-------|-------|-------|-------|-------|-------|-------|------|
| Male | 19 | 69 | 211 | 1,008 | 1,970 | 277 | 15 | 1 |
| Female | 10 | 104 | 410 | 1,986 | 3,854 | 615 | 36 | 1 |

*291 unknowns


Trends of Most Utilized Products

| Drug | Cost | | Claims | | Perdiem | |
|-------------|----------------|----------------|---------|---------|---------|---------|
| | FY 2008 | FY 2007 | FY 2008 | FY 2007 | FY 2008 | FY 2007 |
| Lipitor® | \$3,349,694.92 | \$3,197,993.06 | 22,179 | 22,585 | \$3.59 | \$3.42 |
| Vytorin® | \$425,392.74 | \$531,121.39 | 3,221 | 4,263 | \$3.08 | \$2.90 |
| Crestor® | \$345,964.62 | \$425,000.39 | 2,485 | 3,353 | \$3.23 | \$2.85 |
| Simvastatin | \$151,639.77 | \$653,313.87 | 16,336 | 9,468 | \$0.23 | \$1.06 |
| Pravastatin | \$43,980.29 | \$69,786.53 | 2,955 | 1,039 | \$0.82 | \$2.12 |
| Lovastatin | \$37,129.39 | \$58,849.39 | 2,769 | 1,812 | \$0.34 | \$0.70 |
| Pravachol | \$1,566.91 | \$27,208.22 | 8 | 118 | \$5.05 | \$3.97 |
| Zocor® | \$0.00 | \$248,983.89 | 0 | 1,427 | \$0.00 | \$2.56 |

Prior Authorization of Statins

During fiscal year 2008 there were a total of 793 prior authorizations received for the class of statin medications. The following table shows the status of the petitions received. There is a computer edit in place to detect recent Tier 1 medications in member's claims history at the point of sale.

Prior Authorization of Statins




Utilization of Ezetimibe


Trends in Utilization of Ezetimibe

| Fiscal Year | Members | Claims | Cost | Cost/Claim | Perdiem | Units | Days |
|-------------|---------|--------|--------------|------------|---------|--------|--------|
| 2007 | 417 | 1,298 | \$156,386.31 | \$120.48 | \$2.80 | 55,214 | 55,827 |
| 2008 | 296 | 1,257 | \$163,763.60 | \$130.28 | \$3.03 | 53,960 | 54,096 |
| Change | -121 | -41 | \$7,377.29 | \$9.80 | \$0.23 | -1,254 | -1,731 |
| % Change | -29% | -3.2% | 4.7% | 8.1% | 8.2% | -2.3% | -3.1% |

Demographics of Members Utilizing Ezetimibe: FY08




Prescribers of Ezetimibe: FY08



Prior Authorization of Ezetimibe

During fiscal year 2008 there were a total of 523 prior authorizations received for ezetimibe. The following table shows the status of the petitions received.

Prior Authorization of Ezetimibe: FY08



Market Update

- The patent for Lescol® and Lescol XL® is anticipated to expire October 2011.
- The results of the ENHANCE¹ study, released January 2008, showed the combination of simvastatin and ezetimibe (Vytorin®) did not reduce the progression of atherosclerosis, assessed by measurement of arterial intima-media thickness, despite significant incremental reductions in levels of both LDL cholesterol and C-reactive protein. In fact, the change in intima-media thickness (IMT) of the combination group was almost doubled that of the simvastatin alone group (0.0111mm vs. 0.0058mm). Large epidemiologic studies have provided strong associations between intima-media thickness and stroke, angina

pectoris, and myocardial infarctions hence it's used as a surrogate marker for cardiovascular event risk.

- In July 2008, the American Academy of Pediatrics (AAP) released revised recommendations for the management of hypercholesterolemia in children², which recommended more comprehensive screening beginning at 2 years of age, an emphasis on improving the quality of dietary fat rather than reducing total fat consumption, and a lowering of the age at which drug therapy may be instituted, from 10 to 8 years. Statins were also recommended among first line options, which spurred some controversy between measures necessary to stave off the obesity epidemic and using powerful adult medicines in children which may have unknown adverse effects in the normal development of the child when initiated so early and used for such a long duration.
- In August 2008, the FDA launched an investigation of whether the use of simvastatin/ezetimibe (Vytorin[®]) can increase the risk of developing cancers³. This action followed the results of the SEAS study which showed use of Vytorin did not slow progression of aortic stenosis in asymptomatic patients, however, it did show a larger percentage of subjects treated with Vytorin were diagnosed with and died from all types of cancer combined (including skin cancer) when compared to placebo during the 5-year study. The FDA anticipates receiving a final SEAS study report from the sponsors and will fully evaluate the clinical trial data and other relevant information.
- In November 2008, the results of the JUPITER⁴ study was released showing rosuvastatin (Crestor[®]) significantly reduced the incidence of major cardiovascular events in healthy people without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels. It is unknown how this data may affect the standard of care for management of hyperlipidemia.
- A new product by Abbott Laboratories containing a combination of simvastatin and Niaspan[®] (Simcor[®]) has been approved by the FDA and marketed in February of 2008. Simcor[®] is approved for use along with diet and exercise to lower levels of elevated total cholesterol, LDL cholesterol, and triglycerides, and to raise HDL cholesterol in patients with complex lipid disease when treatment with simvastatin or Niaspan[®] monotherapies are not considered adequate. The following is a cost comparison between currently available products:

| Medication | EAC per Tab | SMAC per Tab | Cost per Month |
|-------------------------------------|-------------|--------------|---------------------|
| Simvastatin 20mg Tabs | | \$0.11 | \$7.45 |
| Niaspan [®] 500mg Tabs | \$2.09 | | \$66.85 |
| Niaspan [®] 750mg Tabs | \$2.98 | | \$93.55 |
| Niaspan [®] 1000mg Tabs | \$3.70 | | \$115.15 - \$226.15 |
| Simcor [®] 500/20mg Tabs | \$2.09 | | \$66.85 |
| Simcor [®] 750/20mg Tabs | \$2.98 | | \$93.55 |
| Simcor [®] 1000/20mg Tabs | \$3.67 | | \$114.25 - \$224.35 |
| Advicor [®] 500/20mg Tabs | \$2.98 | | \$93.55 |
| Advicor [®] 750/20mg Tabs | \$3.21 | | \$100.45 |
| Advicor [®] 1000/20mg Tabs | \$3.43 | | \$107.05 - \$209.95 |
| Advicor [®] 1000/40mg Tabs | \$3.97 | | \$123.25 - \$242.35 |

EAC=estimated acquisition cost, SMAC=state maximum allowable cost

Conclusion and Recommendation

The College of Pharmacy recommends dividing the HMG-CoA Reductase Inhibitors (Statins) PBPA category into two subcategories and addition of a third tier with modification of criteria as shown below. The College also recommends a quantity limits be placed on all strengths Advicor® and Simcor®.

| HMG-CoA Reductase Inhibitors (Statins) | | |
|--|---------------------------------|-----------------------------------|
| <i>Tier One</i> | <i>Tier Two</i> | <i>Tier Three</i> |
| Lovastatin (Mevacor) | Atorvastatin (Lipitor®) | Lovastatin (brand Altoprev®) |
| Pravastatin (Pravachol®) | Rosuvastatin (Crestor®) | Pravastatin/Aspirin (Pravaguard®) |
| Simvastatin (Zocor®) | | Simvastatin/Ezetimibe (Vytorin®) |
| | | Ezetimibe (Zetia®) |
| Statin/Niaspan® Combination Products | | |
| Tier 1 Statins and/or Niaspan® | Lovastatin/Niacin CR (Advicor®) | |
| | Simvastatin/Niacin CR (Simcor®) | |

Mandatory generic plan in effect where generic is available.

Criteria for Authorization

To qualify for a Tier 1 medication, there must be:

1. A trial, defined by at least 8 weeks of continuous therapy titrated to recommended dose, of a Tier 1 medication that did not yield adequate LDL reduction.
2. Previous stabilization.
3. Documented adverse effect or contraindication to all available lower tiered products.
4. Clinical exception for atorvastatin 80mg: members hospitalized for recent acute myocardial infarction or acute coronary syndrome.
5. Clinical exceptions for Ezetimibe:
 - a. Documented active liver disease.
 - b. Documented unexplained, persistent elevations of serum transaminases.
 - c. Documented statin related myopathy.

To qualify for a Tier 2 medication, there must be:

1. A trial, defined by at least 8 weeks of continuous therapy titrated to recommended dose, of a Tier 2 medication that did not yield adequate LDL reduction.
2. Previous stabilization.
3. Documented adverse effect or contraindication to all available lower tiered products.
4. Clinical exceptions for Ezetimibe:
 - a. Documented active liver disease.
 - b. Documented unexplained, persistent elevations of serum transaminases.
 - c. Documented statin related myopathy.

Utilization Details FY 2008

| Medication | Claims | Members | Units | Days | Cost | Claims/ Member | Perdiem | % Cost |
|----------------------|---------------|---------------|------------------|------------------|-----------------------|-------------------|---------------|----------------|
| ADVICOR TAB 500-20MG | 64 | 15 | 2,450 | 2,420 | \$6,967.87 | 4.27 | \$2.88 | 0.16% |
| ADVICOR TAB 750-20MG | 2 | 1 | 60 | 60 | \$177.38 | 2 | \$2.96 | 0.00% |
| ADVICOR TAB 1000-20 | 13 | 1 | 390 | 390 | \$1,285.40 | 13 | \$3.30 | 0.03% |
| ADVICOR TAB 1000-40 | 12 | 1 | 360 | 360 | \$1,365.72 | 12 | \$3.79 | 0.03% |
| ALTOPREV TAB 40MG ER | 2 | 1 | 60 | 60 | \$253.13 | 2 | \$4.22 | 0.01% |
| ALTOPREV TAB 60MG ER | 27 | 4 | 1,540 | 1,540 | \$6,770.28 | 6.75 | \$4.40 | 0.15% |
| CRESTOR TAB 5MG | 224 | 45 | 9,172 | 9,262 | \$29,625.05 | 4.98 | \$3.20 | 0.67% |
| CRESTOR TAB 10MG | 1,481 | 305 | 63,836 | 64,396 | \$207,042.76 | 4.86 | \$3.22 | 4.70% |
| CRESTOR TAB 20MG | 599 | 139 | 26,735 | 26,309 | \$87,665.74 | 4.31 | \$3.33 | 1.99% |
| CRESTOR TAB 40MG | 181 | 46 | 6,589 | 6,859 | \$21,631.07 | 3.93 | \$3.15 | 0.49% |
| LESCOL CAP 20MG | 35 | 9 | 1,728 | 1,728 | \$4,186.44 | 3.89 | \$2.42 | 0.10% |
| LESCOL CAP 40MG | 48 | 14 | 2,478 | 2,088 | \$5,987.33 | 3.43 | \$2.87 | 0.14% |
| LESCOL XL TAB 80MG | 149 | 31 | 6,780 | 6,780 | \$20,241.66 | 4.81 | \$2.99 | 0.46% |
| LIPITOR TAB 10MG | 6,400 | 1,533 | 266,193 | 265,211 | \$735,698.39 | 4.17 | \$2.77 | 16.71% |
| LIPITOR TAB 20MG | 8,556 | 2,139 | 357,465 | 358,527 | \$1,396,018.02 | 4 | \$3.89 | 31.70% |
| LIPITOR TAB 40MG | 5,669 | 1,482 | 241,938 | 241,680 | \$950,033.15 | 3.83 | \$3.93 | 21.58% |
| LIPITOR TAB 80MG | 1,554 | 413 | 68,258 | 71,302 | \$267,945.36 | 3.76 | \$3.76 | 6.09% |
| LOVASTATIN TAB 10MG | 355 | 101 | 12,733 | 12,793 | \$3,175.02 | 3.51 | \$0.25 | 0.07% |
| LOVASTATIN TAB 20MG | 1,404 | 405 | 55,546 | 52,996 | \$13,829.24 | 3.47 | \$0.26 | 0.31% |
| LOVASTATIN TAB 40MG | 1,010 | 236 | 44,307 | 39,931 | \$20,125.13 | 4.28 | \$0.50 | 0.46% |
| PRAVACHOL TAB 80MG | 8 | 4 | 310 | 310 | \$1,566.91 | 2 | \$5.05 | 0.04% |
| PRAVASTATIN TAB 10MG | 195 | 79 | 7,017 | 7,017 | \$1,635.13 | 2.47 | \$0.23 | 0.04% |
| PRAVASTATIN TAB 20MG | 907 | 304 | 34,589 | 34,270 | \$8,526.16 | 2.98 | \$0.25 | 0.19% |
| PRAVASTATIN TAB 40MG | 1,709 | 567 | 66,926 | 63,427 | \$18,230.44 | 3.01 | \$0.29 | 0.41% |
| PRAVASTATIN TAB 80MG | 144 | 48 | 6,050 | 6,180 | \$15,588.56 | 3 | \$2.52 | 0.35% |
| SIMCOR TAB 500-20MG | 7 | 3 | 270 | 210 | \$579.78 | 2.33 | \$2.76 | 0.01% |
| SIMVASTATIN TAB 10MG | 1,168 | 317 | 41,541 | 40,869 | \$9,272.79 | 3.68 | \$0.23 | 0.21% |
| SIMVASTATIN TAB 20MG | 6,467 | 1,622 | 242,367 | 241,463 | \$57,468.55 | 3.99 | \$0.24 | 1.31% |
| SIMVASTATIN TAB 20MG | 122 | 58 | 5,129 | 5,129 | \$987.31 | 2.1 | \$0.19 | 0.02% |
| SIMVASTATIN TAB 40MG | 6,376 | 1,677 | 249,207 | 253,296 | \$61,296.79 | 3.8 | \$0.24 | 1.39% |
| SIMVASTATIN TAB 5MG | 35 | 11 | 1,246 | 1,260 | \$254.03 | 3.18 | \$0.20 | 0.01% |
| SIMVASTATIN TAB 80MG | 2,168 | 597 | 80,351 | 90,200 | \$22,360.30 | 3.63 | \$0.25 | 0.51% |
| VYTORIN TAB 10-10MG | 167 | 30 | 6,594 | 6,554 | \$20,948.25 | 5.57 | \$3.20 | 0.48% |
| VYTORIN TAB 10-20MG | 1,022 | 206 | 43,467 | 43,562 | \$135,097.78 | 4.96 | \$3.10 | 3.07% |
| VYTORIN TAB 10-40MG | 1,451 | 311 | 62,795 | 62,810 | \$196,471.08 | 4.67 | \$3.13 | 4.46% |
| VYTORIN TAB 10-80MG | 581 | 121 | 23,901 | 25,213 | \$72,875.63 | 4.8 | \$2.89 | 1.66% |
| Totals | 50,312 | 10,877 | 2,040,378 | 2,046,462 | \$4,403,183.63 | 4.63 | \$2.15 | 100.00% |

¹ Schering-Plough Pharmaceuticals. News Releases. Last Accessed September 2008.


Available online at: http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=1095943

² Ferranti, S. Ludwig, D. Storm over Statins — The Controversy Surrounding Pharmacologic Treatment of Children. NEJM 359;13 September 25, 2008

³ Food and Drug Administration. Center for Drug Evaluation and Research. Early Communication. Last Accessed September 2008.

Available online at: http://www.fda.gov/Cder/Drug/early_comm/ezetimibe_simvastatin_SEAS.htm

⁴ Ridker, P. Danielson, E., et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. NEJM 359;21 November 20, 2008.



Appendix E

Prior Authorization Annual Review - Fiscal Year 2008

Symlin® And Byetta®

Oklahoma Health Care Authority
December 2008

CURRENT SYMLIN® PRIOR AUTHORIZATION CRITERIA

Members must meet FDA approved selection criteria:

Members with type 1 and 2 diabetes using insulin must:

1. have failed to achieve adequate glycemic control;
2. are receiving ongoing care under the guidance of a health care professional

Members meeting the following criteria should **NOT** be considered for Symlin® therapy:

1. Poor compliance with insulin regimen
2. Poor compliance with self-blood glucose monitoring
3. HbA1c > 9%
4. Recurrent severe hypoglycemia requiring assistance in past 6 months
5. Presence of hypoglycemia unawareness
6. Diagnosis of gastroparesis
7. Require use of drugs that stimulate GI motility:
Anticholinergics (e.g. Atropine)
Glyset® (Miglitol)
Precose® (Acarbose)
8. Pediatric patients (≤ 15 years old)

CURRENT CRITERIA FOR BYETTA APPROVAL

There is a step therapy edit in the system to detect metformin, sulfonylurea, or thiazolidinedione usage for at least 30 days within the previous 120 days. Members without a metformin, sulfonylurea, or thiazolidinedione claim in the system would be eligible to petition.

Authorization will be based on the following criteria:

1. Patients must have Type 2 diabetes and currently taking metformin, sulfonylurea, thiazolidinediones, or a combination, for at least 90 days within the last 180 days, and have not achieved adequate glycemic control.
2. Clinical exception may be allowed if Byetta® is prescribed by an endocrinologist.

Utilization – Fiscal Year 2008

For the period of July 2007 through June 2008, a total of 242 members received Byetta or Symlin through the Oklahoma Medicaid fee-for-service program.

| Product | # of Claims | Total Units | Total Days | Units /Day | Total Cost | Total Members | Cost/ Member | Cost/ Claim | Per diem |
|---------|-------------|-------------|------------|------------|---------------|---------------|--------------|-------------|----------|
| Symlin | 25 | 279 | 744 | 0.38 | \$ 6,374.47 | 8 | \$ 796.81 | \$254.79 | \$8.57 |
| Byetta | 1,034 | 2,320 | 34,675 | 0.07 | \$ 239,004.21 | 235 | \$ 1017.04 | \$231.15 | \$6.89 |
| Total | 1,059 | 2,599 | 35,419 | 0.07 | \$245,378.68 | 242* | \$1013.96 | \$231.71 | \$6.93 |

*Total unduplicated members for FY08

| | |
|-----------------------------|---------------------|
| Total Cost FY '08 | \$245,378.68 |
| <i>Total Cost FY '07</i> | <i>\$222,178.83</i> |
| Total Claims FY '08 | 1,059 |
| <i>Total Claims FY '07</i> | <i>1,025</i> |
| Total Members FY '08 | 242 |
| <i>Total Clients FY '07</i> | <i>237</i> |
| Per Diem FY '08 | \$6.93 |
| <i>Per Diem FY '07</i> | <i>\$6.64</i> |

Claims were reviewed to determine the age/gender of the members on Byetta®.

| Age | Female | Male | Totals |
|---------------|------------|-----------|-------------|
| 0 to 9 | 0 | 0 | 0 |
| 10 to 19 | 10 | 3 | 13 |
| 20 to 34 | 22 | 8 | 30 |
| 35 to 49 | 64 | 20 | 84 |
| 50 to 64 | 82 | 16 | 98 |
| 65 to 79 | 2 | 2 | 4 |
| 80 to 94 | 0 | 0 | 0 |
| 95 and Over | 0 | 0 | 0 |
| Totals | 180 | 49 | 229* |

*6 members no longer eligible. Therefore, a total of 235 members

Claims were reviewed to determine the age/gender of the members on Symlin®.

| Age | Female | Male | Totals |
|---------------|----------|----------|----------|
| 0 to 9 | 0 | 0 | 0 |
| 10 to 19 | 0 | 0 | 0 |
| 20 to 34 | 0 | 1 | 1 |
| 35 to 49 | 1 | 1 | 2 |
| 50 to 64 | 4 | 1 | 5 |
| 65 to 79 | 0 | 0 | 0 |
| 80 to 94 | 0 | 0 | 0 |
| 95 and Over | 0 | 0 | 0 |
| Totals | 5 | 3 | 8 |

Prior Authorizations

| Prior Authorizations (Byetta) | No. of Petitions FY07 | No. of Petitions FY08 |
|------------------------------------|--------------------------|--------------------------|
| Approved | 50 | 45 |
| Denied | 65 | 59 |
| Incomplete | 20 | 27 |
| Faxed-awaiting physician signature | 0 | 0 |
| | 135 | 131 |

| Prior Authorizations (Symlin) | No. of Petitions FY07 | No. of Petitions FY08 |
|------------------------------------|--------------------------|--------------------------|
| Approved | 14 | 7 |
| Denied | 20 | 9 |
| Incomplete | 24 | 11 |
| Faxed-awaiting physician signature | 0 | 0 |
| | 58 | 27 |

Market News


- SymlinPen® pen-injector is now available in:
 - SymlinPen®- 60 pen-injector for doses of 15mcg, 30mcg, 45mcg and 60mcg
 - SymlinPen® 120 pen-injector for doses of 60mcg and 120mcg.¹
- **08/18/08-** FDA has been monitoring cases of acute pancreatitis in its postmarketing review of adverse event reports associated with the use of exenatide. Spontaneous adverse event reports of acute pancreatitis were described in the *Adverse Reactions* section of product labeling. Further postmarketing review of exenatide identified additional cases of acute pancreatitis associated with use of the drug. The product labeling has been updated to include information about acute pancreatitis in the *Precautions* section of the label, and information for healthcare professionals has been posted on FDA's Web site.²
- **10/21/08-** Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced they have entered into a product supply agreement for exenatide once weekly, a development compound that, if approved, would become the first once weekly therapy to treat type 2 diabetes.³

Recommendations

The College of Pharmacy recommends no changes at this time.

References

1. Symlin® Product Information. Amylin Pharmaceuticals, Inc. Literature revised July 2008
2. U.S. Food and Drug Administration. Available on the internet at: http://www.fda.gov/cder/dsn/2008_winter/postmarketing.htm
3. Amylin Pharmaceuticals, Inc. Available on the internet at: <http://investors.amylin.com/phoenix.zhtml?c=101911&p=irol-newsArticle&ID=1215294&highlight=>



Appendix F

Utilization Review of Oral Antifungals and 30 Day Notice to Apply Age

Restriction to Lamisil® Granules

Oklahoma Health Care Authority

December 2008

Introduction^{1,2}

In the past, fungal infections were generally superficial, treatable with topical medications. However, with the advent of organ transplant, cytotoxic chemotherapy, and immunosuppressive illnesses like AIDS, invasive fungal infections are becoming more common.

Fungi are eukaryotic organisms of two major morphologic groups; filamentous molds and unicellular yeasts.

Oral antifungal agents include:

- Griseofulvin
- Polyenes: nystatin, amphotericin B
- Imidazoles: ketoconazole, clotrimazole
- Triazoles: voriconazole, posaconazole, fluconazole, itraconazole
- Allylamines: terbinafine
- Flucytosine

Utilization data – FY 2008


| Drug | Claims | Units | Days | Members | Cost/ claim | Per Diem | Cost |
|------------------------------|---------------|------------------|----------------|----------------|----------------|---------------|-----------------------|
| ANCOBON CAP 500MG | 1 | 128 | 30 | 1 | \$2,794.47 | \$93.15 | \$2,794.47 |
| FULVICIN U/F TAB MICRO 250 | 1 | 30 | 30 | 1 | \$31.52 | \$1.05 | \$31.52 |
| GRIFULVIN V TAB 500MG | 505 | 17,401 | 15,947 | 363 | \$105.51 | \$3.34 | \$53,284.95 |
| GRISEOFULVIN SUSP 125/5ML | 3,046 | 876,764 | 79,639 | 2,021 | \$66.15 | \$2.53 | \$201,487.81 |
| GRIFULVIN V SUSP 125/5ML | 3 | 1,624 | 112 | 3 | \$277.87 | \$7.44 | \$833.60 |
| GRIS-PEG TAB 125MG | 70 | 3,983 | 2,050 | 50 | \$91.30 | \$3.12 | \$6,390.81 |
| GRIS-PEG TAB 250MG | 318 | 14,919 | 9,291 | 248 | \$98.98 | \$3.39 | \$31,474.29 |
| NYSTATIN TAB 500000 | 63 | 3,840 | 1,292 | 31 | \$29.93 | \$1.46 | \$1,885.31 |
| NYSTATIN POWDER | 13 | 263 | 175 | 12 | \$59.83 | \$4.44 | \$777.82 |
| TERBINAFINE TAB 250MG | 1,065 | 34,628 | 36,410 | 632 | \$100.35 | \$2.94 | \$106,874.13 |
| LAMISIL TAB 250MG | 110 | 3,587 | 3,714 | 80 | \$419.19 | \$12.42 | \$46,110.46 |
| LAMISIL GRANULES 125MG | 6 | 238 | 156 | 5 | \$279.19 | \$10.74 | \$1,675.14 |
| LAMISIL GRANULES 187.5MG | 1 | 30 | 30 | 1 | \$320.42 | \$10.68 | \$320.42 |
| KETOCONAZOLE TAB 200MG | 404 | 7,101 | 6,911 | 288 | \$9.58 | \$0.56 | \$3,869.43 |
| FLUCONAZOLE TAB 50MG | 16 | 136 | 99 | 13 | \$6.37 | \$1.03 | \$101.98 |
| FLUCONAZOLE TAB 100MG | 1,669 | 18,814 | 18,585 | 1,174 | \$8.77 | \$0.79 | \$14,636.47 |
| FLUCONAZOLE TAB 150MG | 9,213 | 16,406 | 30,848 | 6,629 | \$7.26 | \$2.17 | \$66,901.57 |
| DIFLUCAN TAB 150MG | 1 | 3 | 9 | 1 | \$52.13 | \$5.79 | \$52.13 |
| FLUCONAZOLE TAB 200MG | 2,010 | 18,364 | 23,568 | 1,423 | \$8.78 | \$0.75 | \$17,647.66 |
| DIFLUCAN TAB 200MG | 11 | 152 | 304 | 1 | \$235.09 | \$8.51 | \$2,586.04 |
| FLUCONAZOLE SUS 10MG/ML | 2,451 | 101,037 | 27,998 | 1,809 | \$18.01 | \$1.58 | \$44,136.93 |
| DIFLUCAN SUS 10MG/ML | 1 | 35 | 7 | 1 | \$44.89 | \$6.41 | \$44.89 |
| FLUCONAZOLE SUS 40MG/ML | 1,387 | 57,312 | 17,525 | 1,010 | \$28.48 | \$2.25 | \$39,496.77 |
| ITRACONAZOLE CAP 100MG | 258 | 17,921 | 6,894 | 100 | \$440.24 | \$16.48 | \$113,581.78 |
| SPORANOX SOL 10MG/ML | 46 | 18,243 | 1,123 | 19 | \$377.24 | \$15.45 | \$17,352.96 |
| NOXAFIL SUSP 40MG/ML | 10 | 4,125 | 236 | 5 | \$2,163.64 | \$91.68 | \$21,636.38 |
| VFEND TAB 50MG | 14 | 1,188 | 313 | 6 | \$720.87 | \$32.24 | \$10,092.17 |
| VFEND TAB 200MG | 74 | 3,862 | 1,999 | 30 | \$1,900.40 | \$70.35 | \$140,629.72 |
| VFEND SUS 40MG/ML | 14 | 2,400 | 354 | 5 | \$1,479.40 | \$58.51 | \$20,711.59 |
| NYSTATIN SUS 100000 | 13,607 | 1,248,670 | 158,049 | 10,390 | \$19.75 | \$1.70 | \$268,774.77 |
| CLOTRIMAZOLE TROCHE 10MG | 127 | 6,473 | 1,686 | 97 | \$43.10 | \$3.25 | \$5,473.13 |
| CLOTRIMAZOLE LOZENGE 10MG | 76 | 3,795 | 867 | 55 | \$41.69 | \$3.65 | \$3,168.52 |
| TOTALS | 36,591 | 2,483,471 | 446,551 | 24,250* | \$34.02 | \$2.79 | \$1,244,826.62 |

*Unduplicated Members

Trends in Utilization of Antifungals

| Fiscal Year | Total Members | Total Claims | Total Cost | Cost per Claim | Per-Diem Cost | Total Units | Total Days |
|-----------------------|---------------|---------------|----------------|----------------|----------------|--------------|--------------|
| 2007 | 24,333 | 36,706 | \$1,696,040.49 | \$46.21 | \$3.81 | 2,463,254 | 445,056 |
| 2008 | 24,250 | 36,591 | \$1,244,826.62 | \$34.02 | \$2.79 | 2,483,471 | 446,551 |
| Percent Change | -0.34% | -0.31% | -26.60% | -26.38% | -26.77% | 0.82% | 0.34% |
| Change | -83 | -115 | -\$451,213.87 | -\$12.19 | -\$1.02 | 20,217 | 1,495 |

Demographic Data



Utilization of Select Antifungals

Forty-two members were prescribed agents with high per-diem cost. Evaluation of their diagnoses was carried out. Underlying diagnoses included cancer, S/P transplant (organ, bone marrow, or stem cell), cystic fibrosis, and HIV, indicating severe immunodeficiency. One member had diagnoses of asthma/allergic rhinitis.

| Antifungal Agent | # of Members* | % w/ appropriate diagnoses |
|------------------------|---------------|----------------------------|
| Posaconazole (Noxafil) | 4 | 100.0% |
| Voriconazole (Vfend) | 38 | 97.4% |


*Unduplicated Members

Lamisil® Granules utilization - April 1, 2008 - October 31, 2008 (Approved 3/2008)

| Drug | Claims | Units | Days | Members* | Cost/Claim | Per-Diem | Cost |
|---------------------------|--------------|---------------|---------------|------------|-----------------|---------------|--------------------|
| TERBINIFINE TABS 250 MG | 990 | 33,815 | 34,902 | 619 | \$9.87 | \$0.28 | \$9,771.23 |
| LAMISIL GRANULES 125 MG | 23 | 820 | 782 | 15 | \$228.71 | \$6.73 | \$4,574.28 |
| LAMISIL GRANULES 187.5 MG | 29 | 1,082 | 1,085 | 11 | \$397.49 | \$10.62 | \$11,527.20 |
| TOTALS | 1,042 | 35,717 | 36,769 | 643 | \$328.59 | \$9.12 | \$26,602.35 |

*Unduplicated Members

Demographic Data for Lamisil® Granules



Market News

- Terbinafine tabs became available in generic on July 2, 2007. SMAC (State Maximum Allowable Cost) was applied in October, 2007.
- Lamisil® Granules were approved in March, 2008.

Conclusions

- Most of the antifungals have been available for years and are available in generic
- Based on evaluation of the diagnoses of the selected costly antifungal agents, their utilization appears to be appropriate.
- Because of the cost of Lamisil granules, this dosage form should be reserved for pediatric patients who have difficulty swallowing tablets or capsules.

Recommendations

The College of Pharmacy recommends continuing to monitor this drug class and setting an age restriction of 12 years of age for Lamisil® Granules.


Clinical Information of Antifungals

| GENERIC NAME | TRADE NAME | FDA INDICATIONS | DOSAGE FORMS AVAILABLE | ADULT DOSING RANGE PER DAY | DOSING FREQUENCY |
|---|--|--|----------------------------------|--|------------------|
| Griseofulvin Microsize Griseofulvin Ultramicrosize | Fulvicin P/G® Gris-PEG® | -Onychomycosis due to Tinea unguium -Tinea barbae -Tinea capitis -Tinea corporis -Tinea cruris -Tinea pedis | Tabs, caps, suspension | Griseofulvin Microsize: 500-1000 mg Griseofulvin Ultramicrosize: 375-750 mg | QD |
| Nystatin | Mycostatin® Bio-Statin® Nystop® Pedi-Dri® | -Candidal vulvovaginitis -Candidiasis of skin, cutaneous and mucocutaneous infections -GI candidiasis (non-oesophageal) -Oral candidiasis | Oral tabs, suspension, caps, | 400,000-600,000 units | QID |
| Terbinafine | Lamisil® Lamisil AT® | -Dermal mycosis -Onychomycosis due to dermatophytes -Tinea capitis | Tabs | 250 mg | QD |
| Ketoconazole | Nizoral® Nizoral A-D® Xolegel® Extina® | -Candidiasis -Oral thrush - Blastomycosis - Histoplasmosis, - Paracoccidioidomycosis - Coccidioidomycosis - Chromomycosis - Candiduria -Chronic mucocutaneous candidiasis -Recalcitrant cutaneous dermatophytoses | Tabs | 200-400 mg | QD |
| Fluconazole | Diflucan® | -Bone marrow transplant-Candidiasis prophylaxis -Candidal vulvovaginitis -Candidiasis of mouth, esophagus, urogenital site -Cryptococcal meningitis | Oral powder for suspension, tabs | 400 mg | QD |
| Itraconazole | Sporanox® | -Aspergillosis -Blastomycosis -Candidiasis of mouth and esophagus -Febrile neutropenia -Histoplasmosis -Onychomycosis due to Dermatophytes | Caps, oral solution | 200-400 mg | QD |
| Posaconazole | Noxafil® | -Disseminated candidiasis, severely immune-compromised pts, prophylaxis -Aspergillus species prophylaxis -Oropharyngeal candidiasis | Suspension | 200 mg (5 ml) | TID |
| Voriconazole | Vfend® | -Invasive aspergillosis -Candidemia -Candidiasis of esophagus -Disseminated candidiasis of the skin and infections in abdomen, kidney, bladder wall, and wounds -Mycosis | oral powder for suspension, tabs | 6 mg/kg IV | Q 12 h x 2 doses |

| GENERIC NAME | TRADE NAME | FDA INDICATIONS | DOSAGE FORMS AVAILABLE | ADULT DOSING RANGE PER DAY | DOSING FREQUENCY |
|--------------|--|--|------------------------|----------------------------|------------------|
| Clotrimazole | Mycelex ® Lotrimin ® Gyne-Lotrimin ® Cruex Prescription Strength ® | -Candidal vulvovaginitis -Topical candidiasis -Oral candidiasis, treatment and prophylaxis -Pityriasis versicolor -Tinea corporis -Tinea cruris -Tinea pedis | Lozenge, troche, | 10 mg | TID |
| Flucytosine | Ancobon | Systemic candidiasis Systemic cryptococcosis | Caps | 50 to 150 mg/kg/day | Q6H |

References

1. Carver PL. Invasive fungal infections, in DePiro JT (ed): Pharmacotherapy; a Pathophysiologic Approach, 3rd edition, Stamford, CT Appleton and Lange.
2. Facts & Comparisons 4.0, 2008 Wolters Kluwer Health, Inc. Available online at <http://online.factsandcomparisons.com/index.aspx>
3. Micromedex. Copyright © 1974-2008 Thomson Healthcare. Available online at <http://lib3-websrv.hsc.net.ou.edu:81/hcs/librarian/PFPUI/4iWfP>



Appendix G

Top 25 Sub-Therapeutic Classes by Total Reimbursement

First Quarter Fiscal Year 2009

| Rank 1st Qtr FY09 | Rank 4th Qtr FY08 | Sub-Therapeutic Class | Total Cost 1st Qtr FY09 | Total Cost 4th Qtr FY08 | Total Claims | Total Members | Cost / Day | Change in Total Cost | Percent Generic | Current Restrictions |
|-------------------|-------------------|--|-------------------------|-------------------------|--------------|---------------|------------|----------------------|-----------------|----------------------|
| 1 | 1 | Misc. Hematological - Antihemophilic | \$6,746,498 | \$5,952,346 | 176 | 42 | \$2,169.99 | \$794,152 | 0% | None |
| 2 | 2 | Antipsychotics - Dibenzodiazepines | \$6,157,384 | \$5,946,033 | 16,552 | 6,100 | \$12.16 | \$211,352 | 6% | Qty Limits |
| 3 | 3 | Anticonvulsants - Miscellaneous | \$5,431,635 | \$5,141,911 | 33,486 | 12,503 | \$5.39 | \$289,723 | 48% | None |
| 4 | 5 | Antiasthmatics - Beta Adrenergics | \$4,612,060 | \$4,458,195 | 63,453 | 33,268 | \$3.17 | \$153,865 | 41% | None |
| 5 | 4 | Antipsychotics - Benzisoxazoles | \$4,570,005 | \$4,556,672 | 14,998 | 5,625 | \$9.93 | \$13,333 | 56% | Qty Limits |
| 6 | 6 | Antipsychotics - Quinolone Derivatives | \$4,438,661 | \$4,155,337 | 9,823 | 4,459 | \$14.29 | \$283,324 | 0% | Qty Limits |
| 7 | 7 | Antiasthmatics - Leukotriene Modulators | \$3,869,520 | \$3,931,099 | 35,601 | 20,933 | \$3.64 | (\$61,579) | 0% | None |
| 8 | 8 | Analgesics - Narcotic Agonists | \$2,997,700 | \$2,899,121 | 23,736 | 9,941 | \$5.69 | \$98,578 | 79% | Step Therapy |
| 9 | 9 | Ulcer Drugs - Proton Pump Inhibitors | \$2,429,899 | \$2,278,696 | 25,191 | 12,427 | \$3.06 | \$151,203 | 52% | Step Therapy |
| 10 | 10 | ADHD - Miscellaneous | \$2,210,569 | \$2,180,522 | 20,590 | 8,283 | \$3.60 | \$30,046 | 24% | Step Therapy |
| 11 | 11 | ADHD - Amphetamines | \$2,096,920 | \$2,004,653 | 20,048 | 8,372 | \$3.52 | \$92,267 | 24% | Step Therapy |
| 12 | 12 | Antiasthmatics - Steroid Inhalants | \$1,951,614 | \$1,963,538 | 11,224 | 7,685 | \$6.09 | (\$11,924) | 0% | None |
| 13 | 13 | Antidiabetic - Insulin | \$1,858,716 | \$1,715,786 | 12,007 | 4,026 | \$5.29 | \$142,930 | 0% | Qty Limits |
| 14 | 14 | Anticonvulsants - Valproic Acid | \$1,267,309 | \$1,474,095 | 9,713 | 3,678 | \$4.37 | (\$206,786) | 30% | None |
| 15 | 15 | Analgesics - Narcotic Combinations | \$1,222,526 | \$1,163,958 | 93,458 | 46,795 | \$1.13 | \$58,568 | 100% | Step Therapy |
| 16 | 17 | Antidepressants - SNRIs | \$1,126,144 | \$1,061,308 | 7,133 | 3,232 | \$4.66 | \$64,836 | 12% | Step Therapy |
| 17 | 16 | Antivirals - Antiretrovirals | \$1,080,861 | \$1,071,087 | 1,458 | 289 | \$24.62 | \$9,774 | 6% | None |
| 18 | 19 | Antihyperlipidemic - HMG CoA Reductase | \$1,022,184 | \$1,000,265 | 12,985 | 6,852 | \$1.97 | \$21,920 | 51% | Step Therapy |
| 19 | 18 | Antipsychotics - Miscellaneous | \$981,778 | \$1,029,720 | 2,897 | 1,209 | \$10.93 | (\$47,942) | 0% | Qty Limits |
| 20 | 20 | Systemic and Topical Nasal Products - Nasal Steroids | \$934,977 | \$977,625 | 15,468 | 11,745 | \$1.90 | (\$42,648) | 38% | Step Therapy |
| 21 | 23 | Antivirals - Hepatitis C Agents | \$906,239 | \$828,250 | 673 | 148 | \$46.24 | \$77,990 | 40% | None |
| 22 | 24 | Contraceptives - Combinations | \$878,573 | \$811,601 | 16,770 | 8,679 | \$1.48 | \$66,972 | 52% | None |
| 23 | 22 | Misc. Endocrine - Growth Hormone | \$867,265 | \$864,183 | 373 | 149 | \$82.23 | \$3,082 | 0% | Prior Auth |
| 24 | 21 | Antidepressants - SSRIs | \$864,562 | \$897,764 | 37,159 | 18,409 | \$0.70 | (\$33,202) | 88% | Step Therapy |
| 25 | 25 | Anticoagulants - Heparins | \$826,540 | \$743,588 | 882 | 375 | \$61.79 | \$82,952 | 26% | None |

Top 25 Drugs by Total Reimbursement

First Quarter Fiscal Year 2009

| Rank 1st Qtr FY09 | Rank 4th Qtr FY08 | Product Name | Therapeutic Class | Total Cost 1st Qtr FY09 | Total Cost 4th Qtr FY08 | Total Claims | Total Members | Cost / Day | Change in Total Cost |
|-------------------|-------------------|-------------------------------------|---|-------------------------|-------------------------|--------------|---------------|------------|----------------------|
| 1 | 1 | Abilify® | Antipsychotics - Quinolone Derivatives | \$4,438,661 | \$4,155,337 | 9,823 | 4,459 | \$14.29 | \$283,324 |
| 2 | 2 | Singulair® | Antiasthmatics - Leukotriene Modulators | \$3,853,127 | \$3,917,621 | 35,462 | 20,880 | \$3.64 | (\$64,494) |
| 3 | 3 | Seroquel® | Antipsychotics - Dibenzodiazepines | \$3,835,082 | \$3,730,939 | 11,664 | 4,609 | \$10.48 | \$104,143 |
| 4 | 4 | Risperdal® | Antipsychotics - Benzisoxazoles | \$3,152,864 | \$3,168,625 | 12,236 | 4,653 | \$8.30 | (\$15,761) |
| 5 | 5 | Novoseven® | Misc. Hematological - Antihemophilic | \$2,419,764 | \$2,296,972 | 11 | 3 | \$7,332.62 | \$122,792 |
| 6 | 6 | Zyprexa® | Antipsychotics - Dibenzodiazepines | \$2,057,700 | \$1,978,660 | 3,383 | 1,363 | \$18.52 | \$79,040 |
| 7 | 7 | Oxycodone | Analgesics - Narcotic Agonists | \$1,988,871 | \$1,889,429 | 6,816 | 1,988 | \$10.54 | \$99,442 |
| 8 | 8 | Advair® | Antiasthmatics - Beta Adrenergics | \$1,823,784 | \$1,775,481 | 9,445 | 5,928 | \$6.41 | \$48,303 |
| 9 | 9 | Feiba® | Misc. Hematological - Antihemophilic | \$1,471,150 | \$1,735,488 | 19 | 4 | \$3,421.28 | (\$264,338) |
| 10 | 23 | Antihemophilic Factor (Recombinant) | Misc. Hematological - Antihemophilic | \$1,441,659 | \$838,270 | 81 | 21 | \$980.05 | \$603,388 |
| 11 | 11 | Methylphenidate | ADHD - Miscellaneous | \$1,414,092 | \$1,371,077 | 13,934 | 5,924 | \$3.40 | \$43,015 |
| 12 | 12 | Prevacid® | Ulcer Drugs - Proton Pump Inhibitors | \$1,405,174 | \$1,356,315 | 8,812 | 4,567 | \$5.39 | \$48,859 |
| 13 | 16 | Topamax® | Anticonvulsants - Miscellaneous | \$1,372,324 | \$1,252,016 | 4,394 | 1,879 | \$10.30 | \$120,309 |
| 14 | 14 | Lamotrigine | Anticonvulsants - Miscellaneous | \$1,371,401 | \$1,332,935 | 5,155 | 2,018 | \$8.64 | \$38,466 |
| 15 | 13 | Amphetamine | ADHD - Amphetamines | \$1,288,389 | \$1,333,820 | 13,195 | 5,474 | \$3.28 | (\$45,431) |
| 16 | 10 | Divalproex | Anticonvulsants - Valproic Acid | \$1,229,855 | \$1,438,391 | 8,488 | 3,221 | \$4.82 | (\$208,536) |
| 17 | 17 | Albuterol HFA and Neb | Antiasthmatics - Beta Adrenergics | \$1,210,070 | \$1,140,153 | 32,489 | 21,307 | \$1.79 | \$69,917 |
| 18 | 15 | Pulmicort® | Antiasthmatics - Steroid Inhalants | \$1,202,358 | \$1,260,649 | 4,747 | 3,237 | \$9.52 | (\$58,291) |
| 19 | 19 | Keppra® | Anticonvulsants - Miscellaneous | \$1,045,417 | \$987,055 | 3,800 | 1,450 | \$9.37 | \$58,362 |
| 20 | 18 | Geodon® | Antipsychotics - Miscellaneous | \$969,209 | \$1,015,311 | 2,782 | 1,171 | \$11.16 | (\$46,102) |
| 21 | 25 | Advate® | Misc. Hematological - Antihemophilic | \$896,475 | \$712,728 | 21 | 6 | \$2,023.65 | \$183,747 |
| 22 | 20 | Invega® | Antipsychotics - Benzisoxazoles | \$889,190 | \$888,055 | 2,003 | 891 | \$14.02 | \$1,135 |
| 23 | 21 | Lipitor® | Antihyperlipidemic - HMG CoA Reductase Inhibitors | \$863,470 | \$849,486 | 5,649 | 3,081 | \$3.69 | \$13,984 |
| 24 | 22 | Somatropin | Misc. Endocrine - Growth Hormone | \$863,332 | \$843,893 | 372 | 148 | \$82.08 | \$19,439 |
| 25 | 24 | Hydrocodone / APAP | Analgesics - Narcotic Combinations | \$811,864 | \$762,796 | 64,006 | 31,449 | \$1.01 | \$49,069 |

Top Therapeutic Classes with Top 5 Products by Total Reimbursement

First Quarter Fiscal Year 2009

| Rank 1st Qtr FY09 | Rank 4th Qtr FY08 | Therapeutic Class | Total Cost 1st Qtr FY09 | Total Cost 4th Qtr FY08 | Total Claims | Total Members | Generic % | Cost / Day | Change in Total Cost |
|-------------------|-------------------|--------------------------------------|-------------------------|-------------------------|--------------|---------------|-----------|------------|----------------------|
| 1 | 1 | Misc. Hematological - Antihemophilic | \$6,746,498.08 | \$5,952,345.79 | 176 | 42 | 0% | \$2,169.99 | \$794,152.29 |
| 1 | 1 | Novoseven® | \$2,419,764.05 | \$2,296,972.37 | 11 | 3 | 0% | \$7,332.62 | \$122,791.68 |
| 2 | 2 | Feiba® | \$1,471,149.90 | \$1,735,487.61 | 19 | 4 | 0% | \$3,421.28 | (\$264,337.71) |
| 3 | 3 | Antihemophilic Factor (Recombinant) | \$1,441,658.71 | \$838,270.39 | 81 | 21 | 0% | \$980.05 | \$603,388.32 |
| 4 | 4 | Advate® | \$896,474.88 | \$712,727.97 | 21 | 6 | 0% | \$2,023.65 | \$183,746.91 |
| 5 | 7 | Alphanine® | \$184,987.60 | \$65,484.10 | 5 | 1 | 0% | \$6,166.25 | \$119,503.50 |
| 2 | 2 | Antipsychotics - Dibenzodiazepines | \$6,157,384.45 | \$5,946,032.59 | 16,552 | 6,100 | 6% | \$12.16 | \$211,351.86 |
| 1 | 1 | Seroquel® | \$3,835,082.09 | \$3,730,938.86 | 11,664 | 4,609 | 0% | \$10.48 | \$104,143.23 |
| 2 | 2 | Zyprexa® | \$2,057,699.98 | \$1,978,660.43 | 3,383 | 1,363 | 0% | \$18.52 | \$79,039.55 |
| 3 | 3 | Clozapine | \$257,659.52 | \$231,145.39 | 1,396 | 262 | 59% | \$9.88 | \$26,514.13 |
| 4 | 4 | Loxapine | \$6,942.86 | \$5,287.91 | 109 | 36 | 100% | \$2.11 | \$1,654.95 |
| 3 | 3 | Anticonvulsants - Miscellaneous | \$5,431,634.57 | \$5,141,911.35 | 33,486 | 12,503 | 48% | \$5.39 | \$289,723.22 |
| 1 | 2 | Topamax® | \$1,372,324.41 | \$1,332,935.24 | 4,394 | 1,879 | 0% | \$10.30 | \$39,389.17 |
| 2 | 1 | Lamotrigine | \$1,371,400.95 | \$1,252,015.75 | 5,155 | 2,018 | 47% | \$8.64 | \$119,385.20 |
| 3 | 3 | Keppra® | \$1,045,416.85 | \$987,054.60 | 3,800 | 1,450 | 0% | \$9.37 | \$58,362.25 |
| 4 | 4 | Oxcarbazepine | \$656,678.15 | \$658,543.75 | 4,184 | 1,661 | 77% | \$5.28 | (\$1,865.60) |
| 5 | 5 | Lyrica® | \$631,961.78 | \$576,171.49 | 4,141 | 2,046 | 0% | \$5.10 | \$55,790.29 |
| 4 | 4 | Antiasthmatics - Beta Adrenergics | \$4,612,060.35 | \$4,458,195.12 | 63,453 | 33,268 | 41% | \$3.17 | \$153,865.23 |
| 1 | 1 | Advair® | \$1,823,784.09 | \$1,775,481.41 | 9,525 | 5,949 | 0% | \$6.16 | \$48,302.68 |
| 2 | 2 | Albuterol HFA and Neb | \$1,210,070.13 | \$1,140,153.43 | 31,058 | 20,219 | 37% | \$1.81 | \$69,916.70 |
| 3 | 3 | Xopenex® | \$561,034.73 | \$585,382.14 | 3,641 | 2,618 | 0% | \$9.77 | (\$24,347.41) |
| 4 | 4 | Ipratropium-Albuterol | \$432,091.33 | \$442,334.61 | 3,348 | 1,819 | 39% | \$4.97 | (\$10,243.28) |
| 5 | 5 | Albuterol CFC | \$255,154.91 | \$236,501.76 | 11,251 | 7,670 | 100% | \$0.92 | \$18,653.15 |
| 5 | 5 | Antipsychotics - Benzisoxazoles | \$4,570,005.29 | \$4,556,672.18 | 14,998 | 5,625 | 56% | \$9.93 | \$13,333.11 |
| 1 | 1 | Risperdal® | \$3,152,864.29 | \$3,168,625.36 | 47,419 | 7,479 | 69% | \$8.30 | (\$15,761.07) |
| 2 | 2 | Invega® | \$889,190.17 | \$888,054.71 | 6,340 | 1,586 | 0% | \$14.02 | \$1,135.46 |
| 3 | 3 | Risperdal® Injection | \$527,950.83 | \$499,992.11 | 2,652 | 323 | 0% | \$31.72 | \$27,958.72 |

Pharmacy Utilization Summary Fiscal Year 2008

| Eligibility | Jul-07 | Aug-07 | Sep-07 | Oct-07 | Nov-07 | Dec-07 | Jan-08 | Feb-08 | Mar-08 | Apr-08 | May-08 | Jun-08 |
|-----------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Total Enrollment | 612,095 | 613,556 | 613,188 | 613,089 | 611,179 | 608,033 | 605,485 | 603,033 | 601,709 | 600,810 | 598,396 | 599,598 |
| SoonerCare Traditional | 183,157 | 195,660 | 190,611 | 187,894 | 184,230 | 182,006 | 187,620 | 187,637 | 190,413 | 192,519 | 192,088 | 190,538 |
| SoonerCare Choice | 408,439 | 397,113 | 401,541 | 404,078 | 405,709 | 405,728 | 398,550 | 396,771 | 393,543 | 390,894 | 389,691 | 392,519 |
| SoonerPlan | 20,499 | 20,783 | 21,036 | 21,117 | 21,240 | 20,299 | 19,315 | 18,625 | 17,753 | 17,397 | 16,617 | 16,541 |
| LTC Residents | 16,293 | 16,419 | 16,426 | 16,449 | 16,347 | 16,237 | 16,147 | 16,039 | 16,042 | 15,911 | 15,896 | 15,949 |
| Dual Eligibility | 77,222 | 77,265 | 77,081 | 76,986 | 76,497 | 76,238 | 75,842 | 75,513 | 75,092 | 74,713 | 74,411 | 74,197 |
| 18 and Under | 406,063 | 406,069 | 405,453 | 405,268 | 404,406 | 402,791 | 401,440 | 400,222 | 399,471 | 398,847 | 397,002 | 397,295 |
| 19 to 64 | 150,263 | 151,436 | 151,568 | 151,546 | 150,607 | 149,035 | 147,901 | 146,862 | 146,425 | 146,268 | 145,664 | 146,455 |
| 65 and Over | 55,769 | 56,051 | 56,167 | 56,275 | 56,166 | 56,207 | 56,144 | 55,949 | 55,814 | 55,695 | 55,730 | 55,848 |
| Pharmacy Benefit Utilizers | | | | | | | | | | | | |
| Total Utilizers | 141,888 | 150,549 | 151,051 | 163,279 | 163,118 | 151,563 | 173,585 | 176,277 | 156,387 | 156,854 | 148,143 | 137,765 |
| Female | 85,267 | 89,425 | 88,472 | 95,158 | 94,903 | 88,200 | 100,288 | 101,577 | 91,096 | 91,175 | 86,433 | 82,032 |
| 18 and Under | 79,948 | 87,648 | 90,632 | 100,883 | 102,170 | 93,874 | 108,899 | 112,578 | 93,601 | 93,764 | 85,550 | 76,489 |
| 19 to 64 | 56,167 | 57,084 | 55,006 | 56,614 | 55,304 | 52,263 | 58,261 | 57,552 | 56,682 | 56,977 | 56,476 | 55,384 |
| 65 and Over | 5,773 | 5,817 | 5,413 | 5,782 | 5,644 | 5,426 | 6,425 | 6,147 | 6,104 | 6,113 | 6,117 | 5,892 |
| Utilization | | | | | | | | | | | | |
| Total Cost | \$27,144,882 | \$28,014,188 | \$26,781,507 | \$30,859,788 | \$30,927,817 | \$28,808,308 | \$33,076,254 | \$31,610,373 | \$30,916,925 | \$30,241,801 | \$29,800,853 | \$27,957,717 |
| Total Claims | 385,102 | 413,228 | 398,297 | 446,515 | 441,578 | 407,010 | 478,412 | 461,934 | 415,820 | 423,295 | 407,311 | 372,401 |
| Cost/Claim | \$70.49 | \$67.79 | \$67.24 | \$69.11 | \$70.04 | \$70.78 | \$69.14 | \$68.43 | \$74.35 | \$71.44 | \$73.16 | \$75.07 |
| Generic | \$18.90 | \$18.61 | \$18.73 | \$18.91 | \$19.26 | \$19.44 | \$19.64 | \$19.98 | \$19.17 | \$18.38 | \$18.32 | \$18.30 |
| Brand | \$176.11 | \$167.28 | \$166.57 | \$172.94 | \$177.78 | \$179.11 | \$177.05 | \$172.78 | \$194.88 | \$190.38 | \$196.90 | \$205.40 |
| Generic % | 0.67 | 0.67 | 0.67 | 0.67 | 0.68 | 0.68 | 0.69 | 0.68 | 0.69 | 0.69 | 0.69 | 0.70 |

Top 100 Medications by Pharmacy Reimbursement Fiscal Year Comparison

| Product | 2008 | | 2007 | | 2006 | |
|-------------------------------------|------|-----------------|------|-----------------|------|-----------------|
| | Rank | Amount Paid | Rank | Amount Paid | Rank | Amount Paid |
| Singulair® | 1 | \$16,416,852.26 | 1 | \$13,832,779.66 | 5 | \$11,499,700.16 |
| Abilify® | 2 | \$15,179,160.50 | 2 | \$12,823,096.44 | 4 | \$12,854,171.17 |
| Seroquel® | 3 | \$14,005,340.07 | 3 | \$11,469,048.59 | 1 | \$13,303,905.66 |
| Risperdal® | 4 | \$12,192,698.82 | 4 | \$10,970,515.16 | 2 | \$13,102,192.14 |
| Novoseven® | 5 | \$7,865,507.07 | 11 | \$5,012,659.71 | 52 | \$1,668,334.83 |
| Zyprexa® | 6 | \$7,675,558.55 | 5 | \$7,519,358.76 | 3 | \$12,910,023.82 |
| Advair® | 7 | \$7,267,463.01 | 6 | \$6,511,822.06 | 6 | \$7,511,573.34 |
| Feiba® | 8 | \$6,690,147.33 | 8 | \$5,621,551.94 | 18 | \$4,360,408.78 |
| Oxycodone | 9 | \$6,491,762.57 | 18 | \$3,881,327.00 | 11 | \$6,127,981.84 |
| Pulmicort® | 10 | \$5,649,638.33 | 14 | \$4,527,528.50 | 24 | \$3,749,093.14 |
| Methylphenidate | 11 | \$5,647,432.29 | 9 | \$5,228,911.01 | 21 | \$4,005,600.83 |
| Depakote® | 12 | \$5,537,949.66 | 12 | \$4,881,018.75 | 8 | \$6,294,464.58 |
| Albuterol HFA and Neb | 13 | \$5,394,387.41 | 19 | \$3,847,563.32 | 58 | \$1,470,128.75 |
| Amphetamine | 14 | \$5,347,613.54 | 10 | \$5,099,977.41 | 19 | \$4,142,260.54 |
| Prevacid® | 15 | \$5,078,472.34 | 16 | \$4,119,087.18 | 13 | \$5,374,799.19 |
| Lamotrigine | 16 | \$4,812,292.61 | 17 | \$3,960,255.69 | 26 | \$3,454,470.21 |
| Synagis® | 17 | \$4,666,076.06 | 7 | \$6,080,364.04 | 7 | \$6,945,161.43 |
| Topamax® | 18 | \$4,650,347.84 | 20 | \$3,833,381.49 | 20 | \$4,113,677.99 |
| Azithromycin | 19 | \$4,389,475.27 | 13 | \$4,697,398.79 | 12 | \$5,751,795.62 |
| Geodon® | 20 | \$3,936,678.25 | 23 | \$3,348,095.06 | 23 | \$3,815,960.30 |
| Antihemophilic Factor (Recombinant) | 21 | \$3,669,174.44 | 15 | \$4,414,365.34 | 15 | \$4,523,615.99 |
| Somatropin | 22 | \$3,439,697.42 | 22 | \$3,370,134.73 | 27 | \$3,438,062.90 |
| Keppra® | 23 | \$3,375,946.68 | 30 | \$2,411,874.14 | 45 | \$2,284,959.06 |
| Lipitor® | 24 | \$3,349,943.16 | 24 | \$3,199,160.77 | 10 | \$6,132,143.05 |
| Omnicef® | 25 | \$3,135,486.64 | 21 | \$3,604,791.56 | 38 | \$2,528,132.79 |
| Xopenex® | 26 | \$2,903,502.35 | 32 | \$2,337,128.53 | 42 | \$2,381,593.39 |
| Trileptal® | 27 | \$2,845,536.33 | 29 | \$2,412,510.78 | 48 | \$2,030,208.24 |
| Advate® | 28 | \$2,671,717.59 | 38 | \$1,815,959.74 | 76 | \$1,165,113.85 |
| Invega® | 29 | \$2,618,010.84 | ** | **** | ** | **** |
| Hydrocodone / APAP | 30 | \$2,616,661.42 | 33 | \$2,168,723.78 | 35 | \$2,762,725.68 |
| Strattera® | 31 | \$2,602,174.77 | 26 | \$2,757,417.64 | 32 | \$3,011,107.84 |
| Lovenox® | 32 | \$2,466,803.56 | 41 | \$1,699,763.38 | 62 | \$1,418,226.41 |
| Amoxicillin & K Clavulanate | 33 | \$2,434,898.59 | 25 | \$2,775,365.24 | 31 | \$3,027,601.12 |
| Venlafaxine | 34 | \$2,288,912.02 | 31 | \$2,399,289.35 | 25 | \$3,725,137.19 |
| Enbrel® | ** | **** | ** | **** | 40 | \$2,435,549.60 |
| Flovent® | 36 | \$2,191,140.63 | 37 | \$1,880,190.36 | 54 | \$1,590,874.81 |
| Focalin® | 37 | \$2,133,493.92 | 56 | \$1,338,596.69 | ** | **** |
| Lantus® | 38 | \$2,114,650.60 | 44 | \$1,637,779.01 | 49 | \$1,973,747.88 |
| Lyrica® | 39 | \$1,964,732.02 | 60 | \$1,211,947.65 | ** | **** |

| Product | 2008 | | 2007 | | 2006 | |
|---------------------------------|------|----------------|------|----------------|------|----------------|
| | Rank | Amount Paid | Rank | Amount Paid | Rank | Amount Paid |
| Lexapro® | 40 | \$1,894,433.89 | 27 | \$2,726,343.91 | 16 | \$4,379,199.03 |
| Actos® | 41 | \$1,890,006.72 | 50 | \$1,511,457.60 | 34 | \$2,798,053.30 |
| Ipratropium-Albuterol | 42 | \$1,883,928.76 | 36 | \$1,963,192.56 | 33 | \$2,820,892.44 |
| Zyrtec® | 43 | \$1,802,152.60 | 43 | \$1,664,081.47 | 60 | \$1,437,839.58 |
| Cymbalta® | 44 | \$1,744,739.05 | 58 | \$1,337,889.68 | 56 | \$1,496,192.53 |
| Risperdal® Injection | 45 | \$1,730,285.44 | 54 | \$1,399,912.16 | 59 | \$1,451,577.10 |
| Nasonex® | 46 | \$1,703,620.27 | 47 | \$1,551,987.78 | 68 | \$1,283,671.31 |
| Nexium® | 47 | \$1,696,646.24 | 39 | \$1,806,405.60 | 14 | \$4,778,844.90 |
| Plavix® | 48 | \$1,694,708.32 | 53 | \$1,424,738.09 | 22 | \$3,923,782.25 |
| Amoxicillin | 49 | \$1,689,131.21 | 46 | \$1,587,601.39 | 63 | \$1,396,359.17 |
| Bupropion | 50 | \$1,652,971.98 | 34 | \$2,160,025.74 | 36 | \$2,577,060.93 |
| Protonix® | 51 | \$1,615,574.38 | 63 | \$1,091,464.64 | 30 | \$3,125,025.53 |
| Vyvanse® | 52 | \$1,551,344.64 | ** | **** | ** | **** |
| Pegasys® | 53 | \$1,385,957.98 | 52 | \$1,447,298.02 | 74 | \$1,184,199.34 |
| Pulmozyme® | 54 | \$1,382,235.97 | 59 | \$1,228,414.10 | 77 | \$1,159,508.76 |
| Fentanyl Patch | 55 | \$1,371,648.67 | 51 | \$1,495,639.14 | 29 | \$3,307,385.05 |
| Ciprodex® | 56 | \$1,335,975.43 | 65 | \$1,057,341.80 | ** | **** |
| Drospirenone-Ethinyl Estradiol | 57 | \$1,325,793.10 | 80 | \$801,658.37 | ** | **** |
| Tobi® Neb | 58 | \$1,280,921.61 | 55 | \$1,354,443.32 | 73 | \$1,188,979.80 |
| Novolog® | 59 | \$1,278,310.52 | 72 | \$860,467.72 | ** | **** |
| Chantix® | 60 | \$1,231,664.13 | 83 | \$772,876.76 | ** | **** |
| Clozapine | 61 | \$1,225,111.12 | 61 | \$1,169,808.19 | 75 | \$1,174,113.25 |
| Loratadine | 62 | \$1,224,558.50 | 64 | \$1,084,587.17 | 78 | \$1,137,678.54 |
| Desmopressin | 63 | \$1,156,198.02 | 40 | \$1,767,581.10 | 47 | \$2,051,656.33 |
| Humira® | 64 | \$1,148,551.46 | ** | **** | ** | **** |
| Albuterol CFC | 65 | \$1,146,008.06 | 42 | \$1,666,961.34 | 67 | \$1,292,158.37 |
| Imitrex® | 66 | \$1,130,555.60 | 75 | \$841,068.02 | 100 | \$852,335.86 |
| Levaquin® | 67 | \$1,126,303.95 | 66 | \$1,035,789.22 | 50 | \$1,766,295.28 |
| Diastat® Gel | 68 | \$1,032,512.34 | 68 | \$924,388.87 | ** | **** |
| Tamiflu® | 69 | \$1,029,425.61 | ** | **** | ** | **** |
| Spiriva® | 70 | \$1,014,631.74 | 84 | \$757,558.53 | 85 | \$983,039.73 |
| Exjade® | 71 | \$974,836.77 | 77 | \$817,788.71 | ** | **** |
| Valtrex® | 72 | \$969,160.32 | 89 | \$713,852.59 | ** | **** |
| Interferon Beta-1a | 73 | \$954,776.60 | 95 | \$696,138.02 | 69 | \$1,260,577.06 |
| Ranitidine | 74 | \$948,247.19 | 62 | \$1,109,734.51 | 70 | \$1,246,829.73 |
| Humalog® | 75 | \$948,175.05 | 78 | \$814,521.78 | 84 | \$989,331.61 |
| Copaxone® | 76 | \$944,737.34 | 96 | \$693,410.27 | 83 | \$1,009,826.20 |
| Omeprazole | 77 | \$939,247.85 | 67 | \$931,305.64 | 44 | \$2,285,364.34 |
| Zyvox® | 78 | \$923,558.66 | 94 | \$697,447.89 | 86 | \$974,728.81 |
| Amylase-Lipase-Protease | 79 | \$839,709.97 | 92 | \$710,109.66 | ** | **** |
| Peg-Intron® | 80 | \$832,727.59 | ** | **** | ** | **** |
| Spacer/Aerosol-Holding Chambers | 81 | \$826,690.36 | 90 | \$711,429.98 | ** | **** |
| Ofloxacin Otic Soln | 82 | \$807,855.62 | 87 | \$735,847.51 | ** | **** |
| Neupogen® | 83 | \$796,559.40 | 74 | \$845,053.48 | 81 | \$1,054,239.95 |

| Product | 2008 | | 2007 | | 2006 | |
|-----------------------------------|------|--------------|------|----------------|----------|-----------------------|
| | Rank | Amount Paid | Rank | Amount Paid | Rank | Amount Paid |
| Morphine Sulfate | 84 | \$791,591.04 | 85 | \$752,390.10 | 66 | \$1,302,552.90 |
| Prograf® | 85 | \$762,123.47 | 97 | \$689,732.15 | ** | **** |
| Alprazolam | 86 | \$760,423.49 | ** | **** | ** | **** |
| Avandia® | 87 | \$744,721.69 | 48 | \$1,520,325.55 | 28 | \$3,357,443.89 |
| Veramyst® | 88 | \$742,099.68 | ** | **** | ** | **** |
| Antihemophilic Factor/VWF (Human) | 89 | \$736,787.28 | ** | **** | ** | **** |
| Promethazine | 90 | \$732,589.34 | 79 | \$809,567.18 | 87 | \$972,763.66 |
| Oxycodone w/ Acetaminophen | 91 | \$725,442.59 | 88 | \$726,443.08 | 95 | \$916,270.23 |
| Lindane® | 92 | \$722,121.11 | 81 | \$783,362.80 | 97 | \$878,806.08 |
| Sulfa-Trimethoprim | 93 | \$716,072.60 | ** | **** | ** | **** |
| Tracleer® | 94 | \$700,762.25 | ** | **** | ** | **** |
| Cellcept® | 95 | \$690,226.75 | ** | **** | ** | **** |
| Kaletra® | 96 | \$685,027.10 | ** | **** | ** | **** |
| Zolpidem | 97 | \$673,633.74 | 49 | \$1,516,686.59 | 41 | \$2,385,479.65 |
| Clonidine | 98 | \$671,536.52 | ** | **** | 88 | \$966,874.50 |
| Atripla® | 99 | \$658,656.04 | ** | **** | ** | **** |
| Temodar® | 100 | \$651,099.78 | ** | **** | ** | **** |
| Sertraline | ** | **** | 28 | \$2,437,549.25 | 9 | \$6,229,839.46 |
| Antihemophilic Factor (Human) | ** | **** | 45 | \$1,591,772.01 | 37 | \$2,546,348.67 |
| Fluticasone Nasal | ** | **** | 57 | \$1,338,236.03 | 46 | \$2,123,835.07 |
| Simvastatin | ** | **** | 69 | \$902,861.71 | 17 | \$4,362,199.60 |
| Ondansetron | ** | **** | 70 | \$895,377.78 | 93 | \$922,547.97 |
| Norgestimate-Eth Estradiol | ** | **** | 71 | \$893,271.17 | ** | **** |
| Aciphex® | ** | **** | 73 | \$853,838.03 | 94 | \$920,872.28 |
| Paroxetine | ** | **** | 76 | \$832,675.72 | 57 | \$1,491,934.62 |
| Gabapentin | ** | **** | 82 | \$778,660.44 | 39 | \$2,516,548.79 |
| Fentanyl Citrate | ** | **** | 86 | \$740,611.75 | 90 | \$954,036.09 |
| Coreg® | ** | **** | 91 | \$710,821.93 | 55 | \$1,513,909.11 |
| Ondansetron ODT | ** | **** | 93 | \$706,082.01 | ** | **** |
| Elidel® | ** | **** | 98 | \$688,341.70 | 65 | \$1,315,451.47 |
| Skelaxin® | ** | **** | 99 | \$686,013.89 | ** | **** |
| Cefprozil | ** | **** | 100 | \$682,648.48 | 92 | \$930,843.95 |
| Aricept® | ** | **** | ** | **** | 43 | \$2,380,601.41 |
| Epoetin Alfa | ** | **** | ** | **** | 51 | \$1,731,719.91 |
| Detrol® | ** | **** | ** | **** | 53 | \$1,648,809.86 |
| Celebrex® | ** | **** | ** | **** | 61 | \$1,437,129.59 |
| Metoprolol | ** | **** | ** | **** | 64 | \$1,387,603.41 |
| Meloxicam | ** | **** | ** | **** | 71 | \$1,228,565.90 |
| Namenda® | ** | **** | ** | **** | 72 | \$1,191,168.72 |
| Levothyroxine | ** | **** | ** | **** | 79 | \$1,099,646.63 |
| Amlodipine | ** | **** | ** | **** | 80 | \$1,078,364.88 |
| Amlodipine Besylate-Benazepril | ** | **** | ** | **** | 82 | \$1,020,043.55 |
| Premarin® | ** | **** | ** | **** | 89 | \$961,547.12 |
| Alendronate | ** | **** | ** | **** | 91 | \$936,597.45 |

| Product | 2008 | | 2007 | | 2006 | |
|---------------|------|-------------|------|-------------|------|--------------|
| | Rank | Amount Paid | Rank | Amount Paid | Rank | Amount Paid |
| Lidoderm® | ** | **** | ** | **** | 96 | \$896,881.57 |
| Nifedipine | ** | **** | ** | **** | 98 | \$865,380.02 |
| Carbamazepine | ** | **** | ** | **** | 99 | \$863,638.45 |

Top 50 Medications by Number of Pharmacy Claims Fiscal Year 2008

| RANK CLAIMS | RANK COST | Product | CLAIMS | COST | UNITS/ DAY | CLAIMS/ CLIENT | COST/ DAY | PERCENT COST |
|-------------|-----------|-----------------------------|---------|-----------------|---------------|-------------------|--------------|-----------------|
| 1 | 30 | Hydrocodone/APAP | 235,424 | \$2,616,553.69 | 4.99 | 3.12 | \$0.88 | 1.92% |
| 2 | 49 | Amoxicillin | 187,096 | \$1,689,123.15 | 11.23 | 1.48 | \$0.93 | 1.24% |
| 3 | 19 | Azythromycin | 161,419 | \$4,389,458.67 | 3.13 | 1.48 | \$5.39 | 3.21% |
| 4 | 13 | Albuterol HFA and Neb | 151,863 | \$5,394,174.68 | 3.73 | 2.31 | \$1.75 | 3.95% |
| 5 | 1 | Singulair® | 151,509 | \$16,416,852.26 | 1 | 3.49 | \$3.50 | 12.02% |
| 6 | 62 | Loratadine | 108,479 | \$1,224,549.60 | 2.56 | 2.15 | \$0.39 | 0.90% |
| 7 | 114 | Ibuprofen | 81,944 | \$590,330.38 | 5.36 | 1.54 | \$0.50 | 0.43% |
| 8 | 86 | Alprazolam | 81,209 | \$760,388.84 | 2.7 | 4.84 | \$0.35 | 0.56% |
| 9 | 93 | Sulfa-Trimethoprim | 76,224 | \$716,072.60 | 8.01 | 1.37 | \$0.83 | 0.52% |
| 10 | 33 | Amoxicillin & K Clavulanate | 64,574 | \$2,434,898.59 | 9.08 | 1.35 | \$3.71 | 1.78% |
| 11 | 11 | Methylphenidate | 60,102 | \$5,647,432.29 | 1.46 | 6.19 | \$3.12 | 4.14% |
| 12 | 14 | Amphetamine | 59,760 | \$5,347,613.54 | 1.25 | 6.22 | \$2.98 | 3.92% |
| 13 | 90 | Promethazine | 57,853 | \$732,589.34 | 5.39 | 1.56 | \$2.15 | 0.54% |
| 14 | 118 | Clonazepam | 54,211 | \$554,242.79 | 2.4 | 5.85 | \$0.35 | 0.41% |
| 15 | 65 | Albuterol CFC | 49,569 | \$1,145,929.92 | 0.87 | 2.17 | \$0.99 | 0.84% |
| 16 | 107 | Cephalexin | 49,119 | \$612,270.66 | 8.57 | 1.25 | \$1.35 | 0.45% |
| 17 | 4 | Risperidone | 47,412 | \$12,189,617.50 | 1.46 | 6.34 | \$8.24 | 8.93% |
| 18 | 98 | Clonidine | 47,272 | \$671,526.56 | 1.55 | 5.44 | \$0.45 | 0.49% |
| 19 | 3 | Seroquel® | 45,238 | \$14,004,423.07 | 1.55 | 5.83 | \$9.83 | 10.26% |
| 20 | 43 | Cetirizine | 43,421 | \$1,802,135.06 | 2.65 | 2.58 | \$1.36 | 1.32% |
| 21 | 25 | Cefdinir | 42,472 | \$3,135,486.64 | 7.1 | 1.38 | \$7.34 | 2.30% |
| 22 | 136 | Sertraline | 40,910 | \$459,184.45 | 1.17 | 3.91 | \$0.34 | 0.34% |
| 23 | 189 | APAP / Codeine | 39,356 | \$290,786.84 | 12.28 | 1.29 | \$1.24 | 0.21% |
| 24 | 7 | Advair® | 39,249 | \$7,267,305.16 | 1.88 | 3.19 | \$5.99 | 5.32% |
| 25 | 170 | Lisinipril | 38,995 | \$345,253.64 | 1.12 | 4.34 | \$0.23 | 0.25% |

| RANK CLAIMS | RANK COST | Product | CLAIMS | COST | UNITS/ DAY | CLAIMS/ CLIENT | COST/ DAY | PERCENT COST |
|-------------|-----------|----------------------------|------------------|-------------------------|---------------|-------------------|---------------|-----------------|
| 26 | 152 | Lorazepam | 38,056 | \$391,026.57 | 2.41 | 3.98 | \$0.45 | 0.29% |
| 27 | 77 | Omeprazole | 36,577 | \$939,228.21 | 1.34 | 3.52 | \$0.75 | 0.69% |
| 28 | 91 | Oxycodone w/ Acetaminophen | 36,571 | \$725,337.15 | 4.71 | 1.70 | \$1.83 | 0.53% |
| 29 | 182 | Cyclobenzaprine | 35,993 | \$314,168.59 | 2.49 | 2.16 | \$0.43 | 0.23% |
| 30 | 186 | Trazodone | 35,414 | \$307,607.58 | 1.32 | 3.93 | \$0.27 | 0.23% |
| 31 | 173 | Tramadol | 35,147 | \$338,178.47 | 4.36 | 2.35 | \$0.61 | 0.25% |
| 32 | 2 | Abilify® | 35,097 | \$15,178,330.26 | 1.01 | 4.97 | \$13.58 | 11.11% |
| 33 | 148 | Levothyroxine | 33,639 | \$403,329.98 | 1.01 | 5.22 | \$0.30 | 0.30% |
| 34 | 74 | Ranitidine | 33,637 | \$948,247.19 | 2.65 | 2.68 | \$0.91 | 0.69% |
| 35 | 12 | Depakote® | 33,212 | \$5,537,817.00 | 2.95 | 6.43 | \$5.47 | 4.06% |
| 36 | 167 | Fluoxetine | 32,967 | \$358,207.65 | 1.36 | 3.85 | \$0.33 | 0.26% |
| 37 | 143 | Prednisolone | 31,838 | \$436,936.06 | 6.85 | 1.42 | \$2.31 | 0.32% |
| 38 | 15 | Prevacid® | 31,721 | \$5,078,472.34 | 1.02 | 3.70 | \$5.14 | 3.72% |
| 39 | 231 | Propoxyphene-N w/ APAP | 31,564 | \$214,243.01 | 4 | 1.86 | \$0.63 | 0.16% |
| 40 | 230 | Diazepam | 30,148 | \$215,256.56 | 2.59 | 3.61 | \$0.29 | 0.16% |
| 41 | 184 | Metformin | 30,083 | \$310,840.75 | 2.17 | 4.47 | \$0.30 | 0.23% |
| 42 | 198 | Citalopram | 29,907 | \$265,377.80 | 1.08 | 3.21 | \$0.27 | 0.19% |
| 43 | 297 | Prednisone | 29,244 | \$145,690.87 | 2.12 | 1.46 | \$0.43 | 0.11% |
| 44 | 235 | Acetaminophen | 27,603 | \$210,257.61 | 8.79 | 1.51 | \$0.70 | 0.15% |
| 45 | 213 | Triamcinolone | 27,089 | \$240,637.99 | 5.82 | 1.53 | \$0.63 | 0.18% |
| 46 | 262 | Furosemide | 26,203 | \$176,609.73 | 1.47 | 3.98 | \$0.19 | 0.13% |
| 47 | 9 | Oxycodone | 25,844 | \$6,491,762.57 | 2.76 | 7.43 | \$8.97 | 4.75% |
| 48 | 10 | Pulmicort® | 25,300 | \$5,649,638.33 | 2.88 | 2.18 | \$8.44 | 4.14% |
| 49 | 116 | Gabapentin | 25,003 | \$571,776.89 | 3.2 | 4.30 | \$0.73 | 0.42% |
| 50 | 97 | Zolpidem | 23,171 | \$673,533.24 | 0.99 | 3.40 | \$1.02 | 0.49% |
| | | | 2,795,708 | \$136,560,712.32 | 2.87 | 8.00 | \$2.33 | |

Pharmacy Claims by Therapeutic Category

Fiscal Year Comparison

(01) PENICILLINS

| | 2006 | | 2007 | | 2008 | |
|---------------------------------------|----------------|-----------------------|----------------|-----------------------|----------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Penicillins (0100) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Natural Penicillins (0110) | 19,112 | \$181,140.25 | 17,962 | \$159,825.51 | 17,778 | \$159,850.69 |
| Ampicillins (0120) | 170,605 | \$1,628,250.72 | 184,459 | \$1,609,992.57 | 188,605 | \$1,709,340.75 |
| Penicillinase-resistant (0130) | 986 | \$41,522.95 | 645 | \$47,910.26 | 641 | \$42,474.05 |
| Extended Spectrum (0140) | 16 | \$7,281.95 | 4 | \$718.56 | 3 | \$617.11 |
| Penicillin Combinations (0199) | 59,418 | \$3,106,167.94 | 62,206 | \$2,824,231.27 | 64,728 | \$2,509,290.58 |
| (01) PENICILLINS TOTAL | 250,137 | \$4,964,363.81 | 265,276 | \$4,642,678.17 | 271,755 | \$4,421,573.18 |

(02) CEPHALOSPORINS

| | 2006 | | 2007 | | 2008 | |
|---|----------------|-----------------------|----------------|-----------------------|----------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Cephalosporins (0200) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Cephalosporins - 1st Generation (0210) | 64,677 | \$987,394.35 | 53,686 | \$722,873.68 | 52,474 | \$737,033.37 |
| Cephalosporins - 2nd Generation (0220) | 24,307 | \$1,288,157.03 | 24,174 | \$1,112,432.68 | 25,115 | \$957,383.58 |
| Cephalosporins - 3rd Generation (0230) | 35,408 | \$3,179,316.14 | 43,652 | \$3,943,074.49 | 47,723 | \$3,770,148.42 |
| Cephalosporins - 4th Generation (0240) | 66 | \$24,507.54 | 60 | \$25,316.65 | 69 | \$23,104.21 |
| (02) CEPHALOSPORINS TOTAL | 124,458 | \$5,479,375.06 | 121,572 | \$5,803,697.50 | 125,381 | \$5,487,669.58 |

(03) MACROLIDE ANTIBIOTICS

| | 2006 | | 2007 | | 2008 | |
|---|----------------|-----------------------|----------------|-----------------------|----------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Macrolide antibiotics (0300) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Erythromycins (0310) | 8,658 | \$89,551.52 | 7,049 | \$76,897.11 | 6,513 | \$73,380.01 |
| Troleandomycin (0320) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Lincomycins (0330) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Azithromycin (0340) | 132,559 | \$5,751,795.62 | 142,469 | \$4,697,398.79 | 161,419 | \$4,389,458.67 |
| Clarithromycin (0350) | 5,656 | \$344,689.77 | 5,238 | \$285,499.93 | 4,698 | \$205,573.88 |
| Dirithromycin (0352) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (03) MACROLIDE ANTIBIOTICS TOTAL | 146,873 | \$6,186,036.91 | 154,756 | \$5,059,795.83 | 172,630 | \$4,668,412.56 |

(04) TETRACYCLINES

| | 2006 | | 2007 | | 2008 | |
|---------------------------------|---------------|---------------------|---------------|---------------------|---------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Tetracyclines (0400) | 23,784 | \$450,148.52 | 20,954 | \$325,236.22 | 22,057 | \$314,622.42 |
| (04) TETRACYCLINES TOTAL | 23,784 | \$450,148.52 | 20,954 | \$325,236.22 | 22,057 | \$314,622.42 |

(05) FLUOROQUINOLONES

| | 2006 | | 2007 | | 2008 | |
|------------------------------------|---------------|-----------------------|---------------|-----------------------|---------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Fluoroquinolones (0500) | 41,964 | \$2,318,268.33 | 25,752 | \$1,387,262.58 | 27,429 | \$1,524,365.18 |
| (05) FLUOROQUINOLONES TOTAL | 41,964 | \$2,318,268.33 | 25,752 | \$1,387,262.58 | 27,429 | \$1,524,365.18 |

(07) AMINOGLYCOSIDES

| | 2006 | | 2007 | | 2008 | |
|-----------------------------------|--------------|-----------------------|--------------|-----------------------|--------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Aminoglycosides (0700) | 1,297 | \$1,269,531.82 | 1,152 | \$1,406,876.98 | 1,127 | \$1,348,647.47 |
| (07) AMINOGLYCOSIDES TOTAL | 1,297 | \$1,269,531.82 | 1,152 | \$1,406,876.98 | 1,127 | \$1,348,647.47 |

(08) SULFONAMIDES

| | 2006 | | 2007 | | 2008 | |
|--------------------------------|--------------|------------|--------------|------------|--------------|------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Sulfonamides (0800) | 59 | \$5,857.66 | 52 | \$5,788.88 | 56 | \$1,747.07 |
| (08) SULFONAMIDES TOTAL | 59 | \$5,857.66 | 52 | \$5,788.88 | 56 | \$1,747.07 |

(09) ANTIMYCOBACTERIAL AGENTS

| | 2006 | | 2007 | | 2008 | |
|--|--------------|-------------|--------------|-------------|--------------|-------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antimycobacterial agents (0900) | 1,230 | \$96,225.23 | 815 | \$55,540.09 | 795 | \$66,586.90 |
| Anti TB Combinations (0999) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (09) ANTIMYCOBACTERIAL AGENTS TOTAL | 1,230 | \$96,225.23 | 815 | \$55,540.09 | 795 | \$66,586.90 |

(11) ANTIFUNGALS

| | 2006 | | 2007 | | 2008 | |
|---|--------------|----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antifungals (1100) | 6,636 | \$1,166,561.51 | 5,602 | \$944,482.93 | 5,541 | \$629,514.24 |
| Imidazole-Related Antifungals (1140) | 19,707 | \$592,873.85 | 17,520 | \$456,980.30 | 17,600 | \$519,652.68 |
| Antifungal - Glucan Synthesis Inhibitors (Echinocandi) | 17 | \$32,939.93 | 33 | \$131,362.89 | 37 | \$153,951.90 |
| (11) ANTIFUNGALS TOTAL | 26,360 | \$1,792,375.29 | 23,155 | \$1,532,826.12 | 23,178 | \$1,303,118.82 |

(12) ANTIVIRAL

| | 2006 | | 2007 | | 2008 | |
|---|---------------|-----------------------|---------------|-----------------------|---------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antiviral (1200) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antiretrovirals (1210) | 10,049 | \$5,638,168.69 | 5,699 | \$3,585,992.72 | 5,567 | \$3,993,007.86 |
| CMV Agents (1220) | 260 | \$373,702.43 | 172 | \$257,925.81 | 197 | \$326,902.72 |
| Hepatitis Agents (1235) | 1,697 | \$2,287,180.97 | 2,077 | \$2,621,211.43 | 2,414 | \$2,940,207.34 |
| Herpes Agents (1240) | 9,560 | \$773,449.29 | 9,812 | \$940,895.67 | 10,710 | \$1,170,568.73 |
| Influenza Agents (1250) | 5,065 | \$313,868.93 | 9,921 | \$679,412.93 | 13,627 | \$1,030,479.28 |
| Respiratory Syncytial Virus (RSV) Agents (1260) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antiviral Combinations (1299) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (12) ANTIVIRAL TOTAL | 26,631 | \$9,386,370.31 | 27,681 | \$8,085,438.56 | 32,515 | \$9,461,165.93 |

(13) ANTIMALARIAL

| | 2006 | | 2007 | | 2008 | |
|----------------------------------|--------------|---------------------|--------------|--------------------|--------------|--------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antimalarial (1300) | 9,642 | \$143,147.36 | 3,421 | \$69,118.56 | 1,960 | \$33,585.75 |
| Antimalarial Combinations (1399) | 21 | \$3,897.13 | 20 | \$2,969.66 | 15 | \$2,292.85 |
| (13) ANTIMALARIAL TOTAL | 9,663 | \$147,044.49 | 3,441 | \$72,088.22 | 1,975 | \$35,878.60 |

(14) AMEBICIDES

| | 2006 | | 2007 | | 2008 | |
|------------------------------|--------------|---------------|--------------|---------------|--------------|---------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Amebicides (1400) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (14) AMEBICIDES TOTAL | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |

(15) ANTHELMINTIC

| | 2006 | | 2007 | | 2008 | |
|--------------------------------|--------------|-------------|--------------|-------------|--------------|-------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Anthemintic (1500) | 3,322 | \$57,294.04 | 3,375 | \$53,088.92 | 3,784 | \$59,490.71 |
| (15) ANTHELMINTIC TOTAL | 3,322 | \$57,294.04 | 3,375 | \$53,088.92 | 3,784 | \$59,490.71 |

(16) MISC. ANTI-INFECTIVES

| | 2006 | | 2007 | | 2008 | |
|---|--------------|----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Misc. anti-infectives (1600) | 18,181 | \$694,563.99 | 17,124 | \$549,198.04 | 16,880 | \$555,003.67 |
| Polymyxins (1610) | 5 | \$118.09 | 0 | \$0.00 | 1 | \$4,580.15 |
| Carbapenems (1615) | 252 | \$228,086.16 | 198 | \$212,471.80 | 296 | \$200,347.39 |
| Chloramphenicols (1620) | 0 | \$0.00 | 1 | \$294.43 | 1 | \$1,263.41 |
| Ketolides (1621) | 3,154 | \$187,146.90 | 675 | \$43,055.59 | 35 | \$2,380.74 |
| Lincosamides (1622) | 8,696 | \$217,408.28 | 9,600 | \$384,416.23 | 10,736 | \$347,606.87 |
| Oxazolidinones (1623) | 645 | \$974,728.81 | 471 | \$697,447.89 | 555 | \$923,558.66 |
| Streptogramins (1625) | 1 | \$4,068.49 | 1 | \$555.28 | 0 | \$0.00 |
| Cyclic Lipopeptides (1627) | 9 | \$23,704.63 | 22 | \$37,088.82 | 30 | \$60,150.47 |
| Tigecycline (1629) | 2 | \$452.10 | 1 | \$997.25 | 26 | \$36,360.43 |
| Leprostatics (1630) | 403 | \$3,796.65 | 297 | \$2,593.15 | 273 | \$2,301.60 |
| Antiprotozoal Agents (1640) | 166 | \$39,369.14 | 101 | \$37,674.58 | 101 | \$19,839.37 |
| Sepsis Syndrome Agents (1660) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Misc. Anti-infective Combinations (1699) | 62,952 | \$535,370.89 | 68,147 | \$690,355.43 | 78,610 | \$782,992.85 |
| (16) MISC. ANTI-INFECTIVES TOTAL | 94,466 | \$2,908,814.13 | 96,638 | \$2,656,148.49 | 107,544 | \$2,936,385.61 |

(17) VACCINES

| | 2006 | | 2007 | | 2008 | |
|--|--------------|-------------|--------------|-------------|--------------|-------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Vaccines (1700) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Viral Vaccines (1710) | 2,834 | \$58,461.73 | 688 | \$33,679.87 | 581 | \$22,476.55 |
| Bacterial Vaccines (1720) | 636 | \$26,174.42 | 84 | \$3,843.29 | 90 | \$6,191.96 |
| Mixed Vaccine Combinations (1799) | 0 | \$0.00 | 0 | \$0.00 | 2 | \$196.00 |
| (17) VACCINES TOTAL | 3,470 | \$84,636.15 | 772 | \$37,523.16 | 673 | \$28,864.51 |

(18) TOXOIDS

| | 2006 | | 2007 | | 2008 | |
|-----------------------------------|--------------|------------|--------------|------------|--------------|------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Toxoids (1800) | 7 | \$1,074.49 | 14 | \$349.38 | 23 | \$726.96 |
| Toxoid Combinations (1899) | 36 | \$1,249.78 | 19 | \$1,113.86 | 17 | \$593.18 |
| (18) TOXOIDS TOTAL | 43 | \$2,324.27 | 33 | \$1,463.24 | 40 | \$1,320.14 |

(19) PASSIVE IMMUNIZING AGENTS

| | 2006 | | 2007 | | 2008 | |
|---|--------------|----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Passive immunizing agents (1900) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Immune Serums (1910) | 387 | \$443,217.40 | 553 | \$504,247.95 | 585 | \$798,630.83 |
| Antitoxins-Antivenins (1920) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Monoclonal Antibodies (1950) | 5,427 | \$6,945,161.43 | 4,750 | \$6,080,364.04 | 3,375 | \$4,666,076.06 |
| (19) PASSIVE IMMUNIZING AGENTS TOTAL | 5,814 | \$7,388,378.83 | 5,303 | \$6,584,611.99 | 3,960 | \$5,464,706.89 |

(20) BIOLOGICALS MISC

| | 2006 | | 2007 | | 2008 | |
|------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Biologicals misc (2000) | 16 | \$283,262.60 | 26 | \$480,763.90 | 20 | \$521,043.00 |
| Allergenic Extracts (2010) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (20) BIOLOGICALS MISC TOTAL | 16 | \$283,262.60 | 26 | \$480,763.90 | 20 | \$521,043.00 |

(21) ANTINEOPLASTICS

| | 2006 | | 2007 | | 2008 | |
|--|--------------|----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antineoplastics (2100) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alkylating Agents (2110) | 351 | \$367,855.99 | 344 | \$466,897.42 | 375 | \$668,485.10 |
| Antineoplastic Antibiotics (2120) | 5 | \$441.78 | 1 | \$126.41 | 0 | \$0.00 |
| Antineoplastic Enzymes (2125) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antimetabolites (2130) | 5,058 | \$442,398.31 | 3,134 | \$411,526.82 | 3,350 | \$470,977.33 |
| Antineoplastic - Angiogenesis Inhibitors (2133) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antineoplastic - Antibodies (2135) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antineoplastic - Hormonal Agents (2140) | 14,830 | \$2,423,423.84 | 6,180 | \$1,492,853.87 | 6,380 | \$1,591,884.63 |
| Antineoplastic - Immunomodulators (2145) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Mitotic Inhibitors (2150) | 30 | \$21,989.49 | 45 | \$20,386.35 | 48 | \$41,884.56 |
| Antineoplastic Enzyme Inhibitors (2153) | 359 | \$973,426.58 | 238 | \$802,375.35 | 401 | \$1,549,068.62 |
| Topoisomerase I Inhibitors (2155) | 22 | \$14,608.57 | 3 | \$475.38 | 7 | \$4,484.13 |
| Antineoplastic Radiopharmaceuticals (2160) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antineoplastics Misc. (2170) | 542 | \$287,875.61 | 308 | \$321,176.52 | 307 | \$276,063.43 |
| Chemotherapy Rescue/Antidote Agents (2175) | 139 | \$27,569.93 | 94 | \$25,324.31 | 77 | \$18,784.78 |
| Chemotherapy Adjuvants (2176) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antineoplastic Combinations (2199) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (21) ANTINEOPLASTICS TOTAL | 21,336 | \$4,559,590.10 | 10,347 | \$3,541,142.43 | 10,945 | \$4,621,632.58 |

(22) CORTICOSTEROIDS

| | 2006 | | 2007 | | 2008 | |
|------------------------------------|---------------|-----------------------|---------------|-----------------------|----------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Corticosteroids (2200) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Glucocorticosteroids (2210) | 94,638 | \$996,203.85 | 96,895 | \$1,032,749.77 | 107,514 | \$1,076,454.64 |
| Mineralocorticoids (2220) | 1,262 | \$35,344.56 | 729 | \$19,639.20 | 787 | \$20,471.44 |
| (22) CORTICOSTEROIDS TOTAL | 95,900 | \$1,031,548.41 | 97,624 | \$1,052,388.97 | 108,301 | \$1,096,926.08 |

(23) ANDROGEN-ANABOLIC

| | 2006 | | 2007 | | 2008 | |
|-------------------------------------|--------------|---------------------|--------------|--------------------|--------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Androgen-anabolic (2300) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Androgens (2310) | 894 | \$138,787.95 | 571 | \$81,812.81 | 660 | \$117,203.87 |
| Anabolic Steroids (2320) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (23) ANDROGEN-ANABOLIC TOTAL | 894 | \$138,787.95 | 571 | \$81,812.81 | 660 | \$117,203.87 |

(24) ESTROGENS

| | 2006 | | 2007 | | 2008 | |
|-------------------------------------|---------------|-----------------------|---------------|---------------------|---------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Estrogens (2400) | 25,885 | \$1,179,599.71 | 14,065 | \$645,390.16 | 13,979 | \$664,003.63 |
| Estrogen Combinations (2499) | 5,061 | \$318,787.84 | 2,877 | \$172,135.98 | 1,871 | \$121,959.26 |
| (24) ESTROGENS TOTAL | 30,946 | \$1,498,387.55 | 16,942 | \$817,526.14 | 15,850 | \$785,962.89 |

(25) CONTRACEPTIVES

| | 2006 | | 2007 | | 2008 | |
|---|---------------|-----------------------|---------------|-----------------------|---------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Contraceptives (2500) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Progestin OC's (2510) | 4,591 | \$189,392.70 | 4,639 | \$175,212.87 | 4,179 | \$141,791.10 |
| Progestin Contraceptives - Injectable (2515) | 6,404 | \$347,399.77 | 6,597 | \$358,913.40 | 6,592 | \$311,632.64 |
| Progestin IUD (2520) | 25 | \$11,095.22 | 56 | \$25,256.50 | 44 | \$18,263.94 |
| Progestin Implants (2530) | 0 | \$0.00 | 10 | \$5,753.00 | 93 | \$55,554.57 |
| Emergency Contraceptives (2540) | 593 | \$18,184.15 | 810 | \$27,411.09 | 721 | \$26,690.50 |
| Combination Contraceptives - Transdermal (2596) | 12,335 | \$675,531.50 | 6,098 | \$371,263.75 | 4,320 | \$275,999.98 |
| Combination Contraceptives - Vaginal (2597) | 3,614 | \$186,513.77 | 5,877 | \$330,066.12 | 6,282 | \$417,238.77 |
| Combination Contraceptives - Injectable (2598) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Combinations OC's (2599) | 50,317 | \$2,211,809.26 | 60,450 | \$2,854,666.62 | 64,274 | \$3,100,578.07 |
| (25) CONTRACEPTIVES TOTAL | 77,879 | \$3,639,926.37 | 84,537 | \$4,148,543.35 | 86,505 | \$4,347,749.57 |

(26) PROGESTINS

| | 2006 | | 2007 | | 2008 | |
|------------------------------|--------------|---------------------|--------------|---------------------|--------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Progestins (2600) | 4,215 | \$205,391.30 | 3,404 | \$184,396.68 | 3,504 | \$280,345.56 |
| (26) PROGESTINS TOTAL | 4,215 | \$205,391.30 | 3,404 | \$184,396.68 | 3,504 | \$280,345.56 |

(27) ANTI-DIABETIC

| | 2006 | | 2007 | | 2008 | |
|--|--------------|-----------------|--------------|----------------|--------------|-----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Anti-diabetic (2700) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Insulin (2710) | 64,064 | \$5,979,274.72 | 40,744 | \$4,732,733.14 | 44,629 | \$6,219,474.50 |
| Pramlintide (2715) | 28 | \$6,905.33 | 46 | \$13,627.29 | 25 | \$6,374.47 |
| Exanatide (2717) | 796 | \$181,601.22 | 979 | \$208,551.54 | 1,034 | \$239,004.21 |
| Sulfonylureas (2720) | 39,642 | \$754,380.47 | 16,938 | \$211,140.13 | 18,096 | \$204,271.74 |
| Anti-diabetic - Amino Acid Derivatives (2723) | 1,219 | \$129,300.82 | 337 | \$39,730.26 | 252 | \$34,892.07 |
| Biguanides (2725) | 46,234 | \$582,525.26 | 27,690 | \$256,589.44 | 30,083 | \$310,840.75 |
| Meglitinide Analogues (2728) | 612 | \$69,742.65 | 161 | \$19,443.85 | 177 | \$21,701.57 |
| Diabetic Other (2730) | 1,678 | \$243,849.43 | 1,299 | \$192,554.26 | 1,622 | \$256,087.46 |
| Alpha-Glucosidase Inhibitors (2750) | 458 | \$31,604.15 | 221 | \$17,809.19 | 221 | \$21,223.41 |
| Dipeptidyl Peptidase-4 Inhibitor (2755) | 0 | \$0.00 | 368 | \$76,591.60 | 1,695 | \$372,681.79 |
| Insulin Sensitizing Agents (2760) | 31,428 | \$6,155,497.19 | 14,151 | \$3,031,783.15 | 11,437 | \$2,634,728.41 |
| Anti-diabetic Combinations (2799) | 10,341 | \$738,911.69 | 6,111 | \$551,949.84 | 6,157 | \$706,798.24 |
| (27) ANTI-DIABETIC TOTAL | 196,500 | \$14,873,592.93 | 109,045 | \$9,352,503.69 | 115,428 | \$11,028,078.62 |

(28) THYROID

| | 2006 | | 2007 | | 2008 | |
|-----------------------------------|--------------|----------------|--------------|--------------|--------------|--------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Thyroid (2800) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Thyroid Hormones (2810) | 69,612 | \$1,122,841.12 | 32,742 | \$458,298.09 | 34,279 | \$417,457.54 |
| Anti-thyroid Agents (2830) | 876 | \$19,664.93 | 551 | \$13,067.11 | 630 | \$16,250.00 |
| (28) THYROID TOTAL | 70,488 | \$1,142,506.05 | 33,293 | \$471,365.20 | 34,909 | \$433,707.54 |

(29) OXYTOCICS

| | 2006 | | 2007 | | 2008 | |
|---|--------------|-------------|--------------|-------------|--------------|-------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Oxytocics (2900) | 965 | \$10,781.54 | 926 | \$11,428.53 | 908 | \$11,372.46 |
| Abortifacients/Agents for Cervical Ripening (2920) | 1 | \$839.06 | 0 | \$0.00 | 0 | \$0.00 |
| (29) OXYTOCICS TOTAL | 966 | \$11,620.60 | 926 | \$11,428.53 | 908 | \$11,372.46 |

(30) MISC. ENDOCRINE

| | 2006 | | 2007 | | 2008 | |
|---|--------------|----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Misc. endocrine (3000) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Adrenal Steroid Inhibitors (3002) | 8 | \$2,000.40 | 5 | \$311.79 | 0 | \$0.00 |
| Calcium Regulators (3004) | 27,835 | \$2,442,056.50 | 7,500 | \$681,840.72 | 7,479 | \$784,370.24 |
| Hormone Receptor Modulators (3005) | 3,957 | \$495,665.10 | 806 | \$103,693.34 | 736 | \$101,773.88 |
| Fertility Regulators (3006) | 8 | \$496.16 | 6 | \$263.84 | 8 | \$557.30 |
| Luteinizing Hormone Releasing-Hormone (LHRH/GnRH) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| LHRH/GnRH Agonist Analog Pituitary Suppressants (3003) | 35 | \$21,531.65 | 41 | \$27,238.59 | 16 | \$12,017.88 |
| GnRH/LHRH Antagonists (3009) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Growth Hormone (3010) | 1,650 | \$3,567,367.26 | 1,607 | \$3,499,088.25 | 1,538 | \$3,532,340.55 |
| Growth Hormone Releasing Hormone (GHRH) (3015) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Growth Hormone (3016) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Somatostatic Agents (3017) | 102 | \$269,078.07 | 56 | \$101,002.44 | 32 | \$28,697.66 |
| Growth Hormone Receptor Antagonist (3018) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Posterior Pituitary (3020) | 11,164 | \$2,309,162.21 | 11,660 | \$2,008,424.28 | 12,093 | \$1,332,609.74 |
| Corticotropin (3030) | 8 | \$16,556.96 | 55 | \$144,728.55 | 12 | \$341,872.80 |
| Prolactin Inhibitors (3040) | 98 | \$50,341.18 | 73 | \$26,651.92 | 77 | \$21,411.12 |
| Progesterone Receptor Antagonists (3050) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |

| | 2006 | | 2007 | | 2008 | |
|-----------------------------------|--------------|----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Uterine Relaxants (3080) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Metabolic Modifiers (3090) | 1,468 | \$612,864.88 | 967 | \$419,385.76 | 1,155 | \$895,206.21 |
| (30) MISC. ENDOCRINE TOTAL | 46,333 | \$9,787,120.37 | 22,776 | \$7,012,629.48 | 23,146 | \$7,050,857.38 |

(31) CARDIOTONICS

| | 2006 | | 2007 | | 2008 | |
|--|--------------|--------------|--------------|-------------|--------------|-------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Cardiotonics (3100) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Phosphodiesterase Inhibitors (3110) | 0 | \$0.00 | 0 | \$0.00 | 1 | \$702.47 |
| Cardiac Glycosides (3120) | 22,648 | \$234,626.50 | 5,538 | \$70,228.39 | 5,278 | \$67,820.40 |
| (31) CARDIOTONICS TOTAL | 22,648 | \$234,626.50 | 5,538 | \$70,228.39 | 5,279 | \$68,522.87 |

(32) ANTIANGINAL AGENTS

| | 2006 | | 2007 | | 2008 | |
|--------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antianginal agents (3200) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Nitrates (3210) | 31,369 | \$435,037.61 | 8,456 | \$113,754.22 | 8,292 | \$129,433.80 |
| Ranolazine (3220) | 3 | \$550.95 | 70 | \$12,295.86 | 301 | \$69,573.33 |
| (32) ANTIANGINAL AGENTS TOTAL | 31,372 | \$435,588.56 | 8,526 | \$126,050.08 | 8,593 | \$199,007.13 |

(33) BETA BLOCKERS

| | 2006 | | 2007 | | 2008 | |
|--|--------------|----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Beta blockers (3300) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Beta Blockers Non-Selective (3310) | 14,948 | \$359,644.24 | 10,050 | \$209,478.42 | 10,050 | \$195,311.26 |
| Beta Blockers Cardio-Selective (3320) | 79,610 | \$1,729,040.26 | 40,564 | \$852,249.32 | 43,206 | \$730,849.86 |
| Alpha-Beta Blockers (3330) | 17,198 | \$1,573,983.00 | 8,539 | \$761,491.45 | 9,948 | \$472,701.61 |
| (33) BETA BLOCKERS TOTAL | 111,756 | \$3,662,667.50 | 59,153 | \$1,823,219.19 | 63,204 | \$1,398,862.73 |

(34) CALCIUM BLOCKERS

| | 2006 | | 2007 | | 2008 | |
|------------------------------------|--------------|----------------|--------------|----------------|--------------|--------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Calcium blockers (3400) | 62,913 | \$3,366,147.43 | 24,013 | \$1,229,871.65 | 27,960 | \$958,513.05 |
| (34) CALCIUM BLOCKERS TOTAL | 62,913 | \$3,366,147.43 | 24,013 | \$1,229,871.65 | 27,960 | \$958,513.05 |

(35) ANTIARRHYTHMIC

| | 2006 | | 2007 | | 2008 | |
|--|--------------|--------------|--------------|-------------|--------------|-------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antiarrhythmic (3500) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antiarrhythmics Type I - Nonspecific (3505) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antiarrhythmics Type I-A (3510) | 490 | \$26,627.15 | 68 | \$2,666.28 | 65 | \$2,033.07 |
| Antiarrhythmics Type I-B (3520) | 63 | \$1,600.56 | 22 | \$582.53 | 38 | \$1,011.96 |
| Antiarrhythmics Type I-C (3530) | 769 | \$44,843.75 | 250 | \$11,347.92 | 262 | \$11,228.78 |
| Antiarrhythmics Type III (3540) | 4,603 | \$76,820.73 | 1,440 | \$31,882.16 | 1,376 | \$27,422.47 |
| Misc. Antiarrhythmic (3550) | 1 | \$69.01 | 1 | \$69.01 | 4 | \$209.38 |
| (35) ANTIARRHYTHMIC TOTAL | 5,926 | \$149,961.20 | 1,781 | \$46,547.90 | 1,745 | \$41,905.66 |

(36) ANTIHYPERTENSIVE

| | 2006 | | 2007 | | 2008 | |
|---|----------------|-----------------------|----------------|-----------------------|----------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antihypertensive (3600) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| ACE Inhibitors (3610) | 104,827 | \$1,466,794.90 | 51,048 | \$604,726.42 | 57,647 | \$595,088.34 |
| Angiotensin II Receptor Antagonist (3615) | 24,463 | \$1,976,786.83 | 8,088 | \$682,178.85 | 6,599 | \$605,112.60 |
| Direct Renin Inhibitor (3617) | 0 | \$0.00 | 20 | \$1,705.51 | 185 | \$17,474.82 |
| Antiadrenergic Antihypertensives (3620) | 60,604 | \$1,094,490.51 | 48,125 | \$678,519.41 | 55,307 | \$765,480.27 |
| Selective Aldosterone Receptor Antagonists (SARAs) | 166 | \$24,892.82 | 85 | \$14,391.79 | 81 | \$17,681.52 |
| Agents for Pheochromocytoma (3630) | 3 | \$341.52 | 1 | \$53.07 | 0 | \$0.00 |
| Vasodilators (3640) | 3,475 | \$85,098.80 | 1,475 | \$35,276.00 | 1,771 | \$41,833.57 |
| Misc. Antihypertensives (3660) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antihypertensive Combinations (3699) | 41,306 | \$2,840,647.99 | 20,491 | \$1,327,738.50 | 21,457 | \$1,216,924.52 |
| (36) ANTIHYPERTENSIVE TOTAL | 234,844 | \$7,489,053.37 | 129,333 | \$3,344,589.55 | 143,047 | \$3,259,595.64 |

(37) DIURETICS

| | 2006 | | 2007 | | 2008 | |
|---|----------------|-----------------------|---------------|---------------------|---------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Diuretics (3700) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Carbonic Anhydrase Inhibitors (3710) | 880 | \$28,383.75 | 532 | \$24,382.21 | 607 | \$32,643.34 |
| Loop Diuretics (3720) | 88,571 | \$766,279.29 | 28,345 | \$226,215.45 | 28,447 | \$225,066.46 |
| Osmotic Diuretics (3740) | 1 | \$7.28 | 0 | \$0.00 | 0 | \$0.00 |
| Potassium Sparing Diuretics (3750) | 12,089 | \$246,091.05 | 5,384 | \$118,913.49 | 5,479 | \$101,690.85 |
| Thiazides and Thiazide-Like Diuretics (3760) | 39,774 | \$366,351.07 | 21,442 | \$152,785.60 | 22,288 | \$178,700.36 |
| Miscellaneous Diuretics (3790) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Combination Diuretics (3799) | 12,112 | \$90,721.48 | 4,512 | \$36,346.48 | 4,303 | \$36,938.62 |
| (37) DIURETICS TOTAL | 153,427 | \$1,497,833.92 | 60,215 | \$558,643.23 | 61,124 | \$575,039.63 |

(38) PRESSORS

| | 2006 | | 2007 | | 2008 | |
|--|--------------|--------------|--------------|--------------|--------------|--------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Pressors (3800) | 719 | \$106,464.88 | 249 | \$28,844.28 | 259 | \$18,024.32 |
| Anaphylaxis Therapy Agents (3890) | 2,408 | \$196,663.48 | 2,816 | \$235,513.61 | 3,481 | \$315,661.99 |
| (38) PRESSORS TOTAL | 3,127 | \$303,128.36 | 3,065 | \$264,357.89 | 3,740 | \$333,686.31 |

(39) ANTIHYPERLIPIDEMIC

| | 2006 | | 2007 | | 2008 | |
|--|--------------|-----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antihyperlipidemic (3900) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Bile Sequestrants (3910) | 2,044 | \$128,990.71 | 1,160 | \$58,699.63 | 1,281 | \$79,196.45 |
| Fibric Acid Derivatives (3920) | 9,487 | \$636,909.41 | 5,530 | \$372,435.76 | 6,525 | \$447,059.28 |
| Intestinal Cholesterol Absorption Inhibitors (3930) | 3,763 | \$440,982.11 | 1,298 | \$156,386.31 | 1,257 | \$163,763.60 |
| HMG CoA Reductase Inhibitors (3940) | 84,610 | \$12,296,770.22 | 40,292 | \$4,740,007.30 | 47,107 | \$3,978,170.10 |
| Nicotinic Acid Derivatives (3945) | 1,145 | \$119,008.63 | 621 | \$65,225.79 | 883 | \$96,048.81 |
| Misc. Antihyperlipidemics (3950) | 127 | \$13,149.64 | 422 | \$45,174.10 | 950 | \$114,365.10 |
| Antihyperlipidemic Combinations (3999) | 6,778 | \$824,587.95 | 4,263 | \$531,121.39 | 3,221 | \$425,392.74 |
| (39) ANTIHYPERLIPIDEMIC TOTAL | 107,954 | \$14,460,398.67 | 53,586 | \$5,969,050.28 | 61,224 | \$5,303,996.08 |

(40) MISC. CARDIOVASCULAR

| | 2006 | | 2007 | | 2008 | |
|--|--------------|--------------|--------------|--------------|--------------|--------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Misc. cardiovascular (4000) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Peripheral Vasodilators (4010) | 249 | \$4,534.23 | 50 | \$869.70 | 39 | \$492.78 |
| Pulmonary Hypertension - PDE5 Inhibitor (4014) | 55 | \$24,171.22 | 189 | \$105,126.29 | 334 | \$221,446.83 |
| Pulmonary Hypertension - Endothelin Receptor Anta | 82 | \$282,404.00 | 129 | \$512,388.40 | 166 | \$705,230.40 |
| Prostaglandin Vasodilators (4017) | 76 | \$679,234.62 | 91 | \$575,004.66 | 93 | \$672,762.40 |
| Vasoactive Natriuretic Peptides (4018) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |

| | 2006 | | 2007 | | 2008 | |
|--|--------------|-----------------------|--------------|-----------------------|--------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Cardioplegic Soln (4020) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Impotence Agents (4030) | 92 | \$9,389.72 | 10 | \$301.10 | 15 | \$113.63 |
| Misc. Cardiovascular Combinations (4099) | 2,232 | \$409,216.92 | 1,586 | \$288,889.79 | 1,979 | \$387,381.96 |
| (40) MISC. CARDIOVASCULAR TOTAL | 5,018 | \$1,818,167.63 | 3,641 | \$1,771,469.73 | 4,605 | \$2,374,809.96 |

(41) ANTIHISTAMINES

| | 2006 | | 2007 | | 2008 | |
|--|----------------|-----------------------|----------------|-----------------------|----------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antihistamines (4100) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antihistamines - Alkylamines (4110) | 135 | \$5,399.77 | 88 | \$4,225.10 | 51 | \$2,420.87 |
| Antihistamines - Ethanolamines (4120) | 1,041 | \$13,553.24 | 1,007 | \$11,125.02 | 1,147 | \$11,690.95 |
| Antihistamines - Ethylenediamines (4130) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antihistamines - Phenothiazines (4140) | 64,251 | \$972,763.66 | 56,496 | \$809,567.18 | 57,853 | \$732,589.34 |
| Antihistamines - Piperidines (4150) | 3,821 | \$53,945.91 | 2,942 | \$42,804.47 | 3,224 | \$51,038.43 |
| Antihistamines - Non-Sedating (4155) | 118,820 | \$2,994,769.15 | 137,898 | \$3,021,630.85 | 158,321 | \$3,291,637.31 |
| Antihistamines - Combinations (4199) | 11 | \$217.68 | 2 | \$81.46 | 0 | \$0.00 |
| (41) ANTIHISTAMINES TOTAL | 188,079 | \$4,040,649.41 | 198,433 | \$3,889,434.08 | 220,596 | \$4,089,376.90 |

(42) SYSTEMIC AND TOPICAL NASAL PRODUCTS

| | 2006 | | 2007 | | 2008 | |
|--|--------------|----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Systemic and topical nasal products (4200) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Sympathomimetic Decongestants (4210) | 13 | \$390.76 | 1,187 | \$8,998.62 | 2,110 | \$15,094.31 |
| Nasal Steroids (4220) | 63,305 | \$4,640,511.36 | 59,034 | \$4,135,205.11 | 63,191 | \$4,171,621.77 |
| Nasal Anti-infectives (4225) | 211 | \$17,236.43 | 294 | \$24,300.01 | 517 | \$53,205.49 |
| Nasal Anticholinergics (4230) | 820 | \$21,168.67 | 579 | \$12,532.32 | 730 | \$13,363.21 |

| | 2006 | | 2007 | | 2008 | |
|---|---------------|-----------------------|---------------|-----------------------|---------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Nasal Antiallergy (4240) | 2,604 | \$177,693.40 | 2,405 | \$180,067.05 | 2,178 | \$180,266.37 |
| Misc. Nasal Preparations (4250) | 1 | \$13.17 | 7 | \$96.30 | 4 | \$37.31 |
| Nasal Combinations (4299) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (42) SYSTEMIC AND TOPICAL NASAL PRODUCTS TOTAL | 66,954 | \$4,857,013.79 | 63,506 | \$4,361,199.41 | 68,730 | \$4,433,588.46 |

(43) COUGH/COLD/ALLERGY

| | 2006 | | 2007 | | 2008 | |
|---|--------------|--------------------|---------------|---------------------|---------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Cough/cold/allergy (4300) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antitussives (4310) | 103 | \$7,700.51 | 2,637 | \$27,954.28 | 1,266 | \$10,671.83 |
| Expectorants (4320) | 21 | \$115.06 | 1,090 | \$9,168.09 | 4,605 | \$37,887.71 |
| Mucolytics (4330) | 250 | \$20,099.75 | 193 | \$22,084.65 | 202 | \$15,399.27 |
| Misc. Respiratory Inhalants (4340) | 730 | \$12,068.89 | 736 | \$13,300.58 | 912 | \$16,774.26 |
| Cough/Cold/Allergy Combinations (4399) | 486 | \$7,999.26 | 6,931 | \$57,380.97 | 17,112 | \$144,110.23 |
| (43) COUGH/COLD/ALLERGY TOTAL | 1,590 | \$47,983.47 | 11,587 | \$129,888.57 | 24,097 | \$224,843.30 |

(44) ANTI-ASTHMATIC

| | 2006 | | 2007 | | 2008 | |
|---|--------------|-----------------|--------------|-----------------|--------------|-----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antiasthmatic (4400) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antiasthmatics - Anticholinergics (4410) | 15,723 | \$1,342,111.78 | 11,270 | \$969,210.02 | 12,185 | \$1,214,776.33 |
| Anti-inflammatory Agents (4415) | 1,141 | \$62,174.08 | 1,076 | \$67,603.68 | 905 | \$56,941.17 |
| Sympathomimetics (4420) | 277,040 | \$16,025,316.58 | 269,108 | \$16,981,165.23 | 286,834 | \$19,601,970.18 |
| Xanthines (4430) | 5,811 | \$130,400.60 | 2,156 | \$59,370.09 | 1,957 | \$54,115.05 |
| Steroid Inhalants (4440) | 43,559 | \$6,044,705.78 | 48,494 | \$7,102,850.44 | 53,897 | \$8,666,152.45 |
| Leukotriene Modulators (4450) | 122,680 | \$11,592,386.95 | 139,435 | \$13,881,821.73 | 152,050 | \$16,471,282.71 |
| Antiasthmatic - Monoclonal Antibodies (4460) | 49 | \$88,130.02 | 98 | \$200,661.44 | 85 | \$169,950.08 |

| | 2006 | | 2007 | | 2008 | |
|-----------------------------------|--------------|-----------------|--------------|-----------------|--------------|-----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Asthma Combinations (4499) | 229 | \$4,019.80 | 212 | \$2,942.95 | 216 | \$2,599.38 |
| (44) ANTI-ASTHMATIC TOTAL | 466,232 | \$35,289,245.59 | 471,849 | \$39,265,625.58 | 508,129 | \$46,237,787.35 |

(45) MISC. RESPIRATORY

| | 2006 | | 2007 | | 2008 | |
|--|--------------|----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Misc. respiratory (4500) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alpha-Proteinase Inhibitor (Human) (4510) | 32 | \$173,116.84 | 10 | \$84,041.31 | 29 | \$260,274.82 |
| Cystic Fibrosis Agents (4530) | 721 | \$1,159,508.76 | 835 | \$1,228,414.10 | 788 | \$1,382,235.97 |
| Pleural Sclerosing Agents (4550) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (45) MISC. RESPIRATORY TOTAL | 753 | \$1,332,625.60 | 845 | \$1,312,455.41 | 817 | \$1,642,510.79 |

(46) LAXATIVES

| | 2006 | | 2007 | | 2008 | |
|---------------------------------------|--------------|----------------|--------------|--------------|--------------|--------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Laxatives (4600) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Saline Laxatives (4610) | 270 | \$17,258.30 | 187 | \$10,821.44 | 195 | \$11,471.26 |
| Stimulant Laxatives (4620) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Bulk Laxatives (4630) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Lubricant Laxatives (4640) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Surfactant Laxatives (4650) | 1 | \$28.77 | 0 | \$0.00 | 0 | \$0.00 |
| Miscellaneous Laxatives (4660) | 30,286 | \$764,474.83 | 22,245 | \$606,159.23 | 19,234 | \$376,054.52 |
| Laxative Combinations (4699) | 2,018 | \$566,427.73 | 1,459 | \$39,560.19 | 1,626 | \$195,705.59 |
| (46) LAXATIVES TOTAL | 32,575 | \$1,348,189.63 | 23,891 | \$656,540.86 | 21,055 | \$583,231.37 |

(47) ANTIDIARRHEALS

| | 2006 | | 2007 | | 2008 | |
|-----------------------------------|--------------|--------------------|--------------|--------------------|--------------|--------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antidiarrheals (4700) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antiperistaltic Agents (4710) | 8,209 | \$59,846.99 | 3,853 | \$32,126.92 | 4,118 | \$40,032.84 |
| GI Adsorbents (4720) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Misc. Antidiarrheal Agents (4730) | 2 | \$17.21 | 3 | \$17.61 | 7 | \$42.38 |
| Antidiarrheal Combinations (4799) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (47) ANTIDIARRHEALS TOTAL | 8,211 | \$59,864.20 | 3,856 | \$32,144.53 | 4,125 | \$40,075.22 |

(48) ANTACIDS

| | 2006 | | 2007 | | 2008 | |
|-----------------------------------|--------------|-------------------|--------------|-------------------|--------------|-------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antacids (4800) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antacids - Aluminum Salts (4810) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antacids - Bicarbonate (4820) | 2 | \$112.21 | 0 | \$0.00 | 1 | \$153.76 |
| Antacids - Calcium Salts (4830) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antacids - Magnesium Salts (4840) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antacids - Sodium Citrate (4850) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antacid Combinations (4899) | 324 | \$3,066.64 | 288 | \$2,465.75 | 257 | \$2,031.94 |
| (48) ANTACIDS TOTAL | 326 | \$3,178.85 | 288 | \$2,465.75 | 258 | \$2,185.70 |

(49) ULCER DRUGS

| | 2006 | | 2007 | | 2008 | |
|--|----------------|------------------------|----------------|------------------------|----------------|------------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Ulcer drugs (4900) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antispasmodics (4910) | 19,910 | \$332,733.53 | 16,783 | \$276,018.59 | 17,024 | \$394,692.46 |
| H-2 Antagonists (4920) | 71,802 | \$1,606,374.45 | 46,845 | \$1,525,136.96 | 46,277 | \$1,437,823.96 |
| Ulcer Drugs - Prostaglandins (4925) | 340 | \$13,166.71 | 201 | \$4,251.28 | 383 | \$6,901.16 |
| Proton Pump Inhibitors (4927) | 154,893 | \$16,662,872.87 | 92,488 | \$8,967,028.30 | 94,744 | \$9,810,472.78 |
| Misc. Anti-Ulcer (4930) | 6,876 | \$272,458.03 | 3,552 | \$150,762.57 | 3,902 | \$155,216.27 |
| Ulcer Therapy Combinations (4999) | 1,076 | \$249,628.81 | 1,755 | \$320,806.91 | 2,102 | \$398,478.86 |
| (49) ULCER DRUGS TOTAL | 254,897 | \$19,137,234.40 | 161,624 | \$11,244,004.61 | 164,432 | \$12,203,585.49 |

(50) ANTIEMETICS

| | 2006 | | 2007 | | 2008 | |
|---|---------------|-----------------------|---------------|-----------------------|---------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antiemetics (5000) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antiemetics - Antidopaminergic (5010) | 1 | \$13.91 | 0 | \$0.00 | 0 | \$0.00 |
| Antiemetics - Anticholinergic (5020) | 8,979 | \$145,006.62 | 3,933 | \$85,176.16 | 3,678 | \$80,903.92 |
| 5-HT3 Receptor Antagonists (5025) | 4,760 | \$1,708,182.03 | 6,485 | \$1,780,183.14 | 11,191 | \$571,812.42 |
| Substance P/Neurokinin 1 (NK1) Receptor Antagonist | 172 | \$52,317.92 | 264 | \$76,597.76 | 317 | \$115,510.35 |
| Antiemetics Miscellaneous (5030) | 705 | \$383,791.05 | 514 | \$319,549.82 | 499 | \$371,505.93 |
| (50) ANTIEMETICS TOTAL | 14,617 | \$2,289,311.53 | 11,196 | \$2,261,506.88 | 15,685 | \$1,139,732.62 |

(51) DIGESTIVE AIDS

| | 2006 | | 2007 | | 2008 | |
|----------------------------------|--------------|---------------------|--------------|---------------------|--------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Digestive aids (5100) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Digestive Enzymes (5120) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Gastric Acidifiers (5130) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Digestive Aids - Mixtures (5199) | 2,195 | \$827,585.32 | 1,485 | \$710,109.66 | 1,576 | \$839,709.97 |
| (51) DIGESTIVE AIDS TOTAL | 2,195 | \$827,585.32 | 1,485 | \$710,109.66 | 1,576 | \$839,709.97 |

(52) MISC. GI

| | 2006 | | 2007 | | 2008 | |
|--|---------------|-----------------------|---------------|---------------------|---------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Miscellaneous GI (5200) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Gallstone Solubilizing Agents (5210) | 1,100 | \$88,197.78 | 715 | \$66,941.26 | 701 | \$59,827.14 |
| GI Antiallergy Agents (5216) | 73 | \$8,435.24 | 78 | \$13,463.91 | 11 | \$1,542.03 |
| Antiflatulents (5220) | 0 | \$0.00 | 2 | \$9.20 | 1 | \$4.76 |
| GI Stimulants (5230) | 25,633 | \$267,625.53 | 17,752 | \$138,311.90 | 17,617 | \$161,452.95 |
| Intestinal Acidifiers (5240) | 6,831 | \$97,050.97 | 3,446 | \$34,428.53 | 3,277 | \$48,896.92 |
| Lubiprostone (5245) | 4 | \$413.68 | 47 | \$7,720.47 | 202 | \$35,539.14 |
| Inflammatory Bowel Agents (5250) | 2,960 | \$429,012.47 | 1,736 | \$352,706.54 | 1,846 | \$438,011.35 |
| Irritable Bowel Syndrome (IBS) Agents (5255) | 4,002 | \$620,712.31 | 368 | \$66,130.12 | 26 | \$17,577.80 |
| Phosphate Binder Agents (5280) | 4,287 | \$882,876.37 | 1,218 | \$298,771.09 | 1,349 | \$393,206.33 |
| (52) MISC. GI TOTAL | 44,890 | \$2,394,324.35 | 25,362 | \$978,483.02 | 25,030 | \$1,156,058.42 |

(53) URINARY ANTI-INFECTIVES

| | 2006 | | 2007 | | 2008 | |
|--|---------------|---------------------|---------------|---------------------|---------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Urinary anti-infectives (5300) | 21,855 | \$623,887.43 | 17,729 | \$402,691.66 | 17,461 | \$374,017.10 |
| Combination Urinary Anti-infectives (5399) | 1,387 | \$32,543.14 | 566 | \$14,579.38 | 446 | \$16,486.56 |
| (53) URINARY ANTI-INFECTIVES TOTAL | 23,242 | \$656,430.57 | 18,295 | \$417,271.04 | 17,907 | \$390,503.66 |

(54) URINARY ANTISPASMODICS

| | 2006 | | 2007 | | 2008 | |
|---|---------------|-----------------------|---------------|---------------------|---------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Urinary antispasmodics (5400) | 28,226 | \$2,911,253.21 | 11,233 | \$949,785.89 | 12,215 | \$1,073,227.27 |
| Urinary Antispasmodic Combinations (5499) | 102 | \$4,475.00 | 81 | \$1,884.80 | 34 | \$982.86 |
| (54) URINARY ANTISPASMODICS TOTAL | 28,328 | \$2,915,728.21 | 11,314 | \$951,670.69 | 12,249 | \$1,074,210.13 |

(55) VAGINAL PRODUCTS

| | 2006 | | 2007 | | 2008 | |
|---|---------------|---------------------|--------------|---------------------|--------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Vaginal products (5500) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Vaginal Anti-infectives (5510) | 7,634 | \$387,141.69 | 7,536 | \$326,646.88 | 7,230 | \$296,191.52 |
| Vaginal Anti-inflammatory Agents (5515) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Douche Products (5520) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Spermicides (5530) | 40 | \$362.97 | 34 | \$298.83 | 37 | \$343.59 |
| Vaginal Estrogens (5535) | 2,205 | \$156,580.85 | 1,390 | \$112,904.00 | 1,241 | \$111,860.77 |
| Vaginal Progestins (5537) | 14 | \$3,649.46 | 17 | \$4,361.05 | 17 | \$5,732.62 |
| Miscellaneous Vaginal Products (5540) | 107 | \$2,330.02 | 51 | \$1,210.48 | 36 | \$857.41 |
| (55) VAGINAL PRODUCTS TOTAL | 10,000 | \$550,064.99 | 9,028 | \$445,421.24 | 8,561 | \$414,985.91 |

(56) MISCELLANEOUS GENITOURINARY PRODUCTS

| | 2006 | | 2007 | | 2008 | |
|--|---------------|-----------------------|--------------|---------------------|--------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Miscellaneous GU Products (5600) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Acidifiers (5610) | 3 | \$47.72 | 1 | \$19.43 | 0 | \$0.00 |
| Alkalinizers (5620) | 937 | \$29,265.71 | 740 | \$20,351.13 | 753 | \$16,990.79 |
| Urinary Analgesics (5630) | 4,364 | \$22,332.00 | 3,961 | \$21,405.87 | 3,672 | \$24,974.71 |
| Cystinosis Agents (5640) | 2 | \$324.28 | 0 | \$0.00 | 0 | \$0.00 |
| Interstitial Cystitis Agents (5650) | 246 | \$61,076.19 | 194 | \$48,523.64 | 159 | \$43,110.59 |
| Urinary Stone Agents (5660) | 22 | \$1,834.55 | 18 | \$1,631.91 | 2 | \$302.82 |
| G U Irrigants (5670) | 2,248 | \$65,282.27 | 812 | \$18,699.73 | 844 | \$20,447.14 |
| Prostatic Hypertrophy Agents (5685) | 9,882 | \$875,292.66 | 3,340 | \$316,490.78 | 3,988 | \$408,651.81 |
| (56) MISCELLANEOUS GENITOURINARY PRODUCTS TOTAL | 17,704 | \$1,055,455.38 | 9,066 | \$427,122.49 | 9,418 | \$514,477.86 |

(57) ANTIANXIETY AGENTS

| | 2006 | | 2007 | | 2008 | |
|--------------------------------------|----------------|-----------------------|----------------|-----------------------|----------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antianxiety agents (5700) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Benzodiazepines (5710) | 142,586 | \$1,169,571.86 | 148,635 | \$1,191,163.77 | 155,019 | \$1,449,290.94 |
| Misc. Antianxiety Agents (5720) | 53,932 | \$906,762.23 | 44,777 | \$600,329.41 | 48,561 | \$657,035.47 |
| (57) ANTIANXIETY AGENTS TOTAL | 196,518 | \$2,076,334.09 | 193,412 | \$1,791,493.18 | 203,580 | \$2,106,326.41 |

(58) ANTIDEPRESSANTS

| | 2006 | | 2007 | | 2008 | |
|--|----------------|------------------------|----------------|------------------------|----------------|------------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antidepressants (5800) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alpha-2 Receptor Antagonists (Tetracyclics) (5803) | 20,292 | \$520,012.81 | 10,390 | \$233,082.98 | 10,964 | \$153,836.31 |
| MAO Inhibitors (5810) | 45 | \$4,530.75 | 48 | \$17,531.38 | 60 | \$27,417.84 |
| Modified Cyclics (5812) | 40,088 | \$375,665.32 | 32,426 | \$286,953.09 | 35,565 | \$313,642.66 |
| Selective Serotonin Reuptake Inhibitors (SSRIs) (5816) | 199,567 | \$12,729,872.14 | 140,617 | \$6,526,997.88 | 143,725 | \$3,660,722.44 |
| Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) | 39,512 | \$5,221,329.72 | 28,125 | \$3,737,179.03 | 27,681 | \$4,035,700.50 |
| Tricyclic Agents (5820) | 37,876 | \$407,760.41 | 24,947 | \$326,122.53 | 24,573 | \$340,129.79 |
| Misc. Antidepressants (5830) | 25,735 | \$2,579,248.63 | 21,887 | \$2,161,632.36 | 19,956 | \$1,653,835.31 |
| (58) ANTIDEPRESSANTS TOTAL | 363,115 | \$21,838,419.78 | 258,440 | \$13,289,499.25 | 262,524 | \$10,185,284.85 |

(59) ANTIPSYCHOTICS

| | 2006 | | 2007 | | 2008 | |
|----------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antipsychotics (5900) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Benzisoxazoles (5907) | 60,877 | \$14,553,769.24 | 49,005 | \$12,732,999.08 | 56,404 | \$16,537,913.78 |
| Butyrophenones (5910) | 9,204 | \$281,048.67 | 5,614 | \$172,750.36 | 5,241 | \$163,579.31 |
| Dibenzapines (5915) | 89,057 | \$27,423,557.97 | 62,231 | \$20,186,214.08 | 65,011 | \$22,926,819.53 |
| Dihydroindolones (5916) | 188 | \$32,096.76 | 66 | \$16,533.10 | 54 | \$11,350.43 |
| Phenothiazines (5920) | 11,274 | \$197,880.53 | 7,323 | \$118,116.81 | 7,118 | \$122,602.51 |
| Quinoline Derivatives (5925) | 33,714 | \$12,854,171.17 | 32,040 | \$12,823,096.44 | 35,097 | \$15,178,330.26 |
| Thioxanthenes (5930) | 1,289 | \$26,479.43 | 703 | \$14,075.48 | 573 | \$14,098.91 |
| Misc. Antipsychotics (5940) | 15,109 | \$3,937,139.58 | 13,127 | \$3,453,950.80 | 12,571 | \$3,999,144.25 |
| Lithium (5950) | 9,917 | \$189,955.21 | 7,395 | \$127,960.27 | 7,487 | \$117,261.36 |
| (59) ANTIPSYCHOTICS TOTAL | 230,629 | \$59,496,098.56 | 177,504 | \$49,645,696.42 | 189,556 | \$59,071,100.34 |

(60) HYPNOTICS

| | 2006 | | 2007 | | 2008 | |
|---|--------------|----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Hypnotics (6000) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Barbiturate Hypnotics (6010) | 14,482 | \$109,045.79 | 14,591 | \$103,526.92 | 13,804 | \$105,973.54 |
| Non-Barbiturate Hypnotics (6020) | 61,672 | \$3,381,065.34 | 46,499 | \$2,406,448.69 | 54,504 | \$1,632,858.83 |
| Ramelteon (6025) | 771 | \$56,476.14 | 1,737 | \$144,170.41 | 2,020 | \$203,081.74 |
| Antihistamine Hypnotics (6030) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Hypnotic Combinations (6099) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (60) HYPNOTICS TOTAL | 76,925 | \$3,546,587.27 | 62,827 | \$2,654,146.02 | 70,328 | \$1,941,914.11 |

(61) ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS

| | 2006 | | 2007 | | 2008 | |
|--|--------------|-----------------|--------------|-----------------|--------------|-----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Adhd/anti-narcolepsy/anti-obesity/anorexiant (6100) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Amphetamines (6110) | 57,800 | \$4,258,160.17 | 64,311 | \$5,196,505.61 | 74,925 | \$6,951,225.24 |
| Anorexiant Non-Amphetamine (6120) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Anti-Obesity Agents (6125) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Analeptics (6130) | 178 | \$81,635.48 | 269 | \$214,831.66 | 337 | \$289,486.15 |
| Attention-Deficit/Hyperactivity Disorder (ADHD) Age | 22,584 | \$3,011,107.84 | 20,108 | \$2,757,417.64 | 18,122 | \$2,602,174.77 |
| Misc. Stimulants (6140) | 67,573 | \$5,219,357.52 | 82,642 | \$7,513,339.44 | 88,996 | \$8,925,000.93 |
| (61) ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIA | 148,135 | \$12,570,261.01 | 167,330 | \$15,682,094.35 | 182,380 | \$18,767,887.09 |

(62) MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS

| | 2006 | | 2007 | | 2008 | |
|--|---------------|-----------------------|---------------|-----------------------|---------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Misc Psychotherapeutic and Neurological Agents (6200) | 329 | \$28,253.72 | 278 | \$21,231.36 | 279 | \$20,875.73 |
| Antidementia (6205) | 31,661 | \$4,562,885.69 | 3,519 | \$503,552.09 | 3,280 | \$536,775.02 |
| Smoking Deterrents (6210) | 7,954 | \$697,475.89 | 13,512 | \$1,237,851.83 | 14,964 | \$1,523,625.03 |
| Multiple Sclerosis Agents (6240) | 1,883 | \$2,673,545.49 | 1,030 | \$1,639,843.87 | 1,054 | \$2,129,342.34 |
| Anti-Cataleptic Agents (6245) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Agents for Chemical Dependency (6280) | 362 | \$35,123.05 | 316 | \$33,412.84 | 455 | \$54,393.03 |
| Combination Psychotherapeutics (6299) | 1,906 | \$323,208.48 | 801 | \$172,642.78 | 784 | \$179,909.70 |
| (62) MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL AGENTS TOTAL | 44,101 | \$8,321,574.64 | 19,457 | \$3,608,658.75 | 20,816 | \$4,444,920.85 |

(64) ANALGESICS - NonNarcotic

| | 2006 | | 2007 | | 2008 | |
|--|---------------|---------------------|---------------|---------------------|---------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Analgesics - nonnarcotic (6400) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Salicylates (6410) | 1,677 | \$43,884.61 | 837 | \$24,260.97 | 736 | \$17,133.42 |
| Analgesics-Pedtid Channel Blockers (6415) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Analgesics Other (6420) | 1 | \$8.17 | 6,928 | \$52,963.97 | 27,603 | \$210,257.61 |
| Analgesic Combinations (6499) | 12,963 | \$165,968.22 | 12,498 | \$162,117.88 | 12,865 | \$171,859.30 |
| (64) ANALGESICS - NonNarcotic TOTAL | 14,641 | \$209,861.00 | 20,263 | \$239,342.82 | 41,204 | \$399,250.33 |

(65) ANALGESICS - Narcotic

| | 2006 | | 2007 | | 2008 | |
|---|----------------|------------------------|----------------|------------------------|----------------|------------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Analgesics - narcotic (6500) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Narcotic Agonists (6510) | 108,457 | \$12,678,633.90 | 79,948 | \$7,679,622.46 | 89,580 | \$10,289,078.91 |
| Narcotic Partial Agonists (6520) | 2,710 | \$132,930.53 | 2,351 | \$166,301.03 | 3,275 | \$346,776.66 |
| Narcotic Antagonists (6540) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Narcotic Combinations (6599) | 424,871 | \$5,302,658.33 | 342,936 | \$3,871,694.93 | 352,617 | \$4,181,195.07 |
| (65) ANALGESICS - Narcotic TOTAL | 536,038 | \$18,114,222.76 | 425,235 | \$11,717,618.42 | 445,472 | \$14,817,050.64 |

(66) ANALGESICS - ANTI-INFLAMMATORY

| | 2006 | | 2007 | | 2008 | |
|---|----------------|-----------------------|----------------|-----------------------|----------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Analgesics - anti-inflammatory (6600) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| NSAIDs (6610) | 142,843 | \$4,386,780.62 | 115,860 | \$1,734,342.52 | 139,296 | \$1,806,272.41 |
| Gold Compounds (6620) | 22 | \$5,115.64 | 2 | \$491.71 | 4 | \$704.38 |
| Antirheumatic Antimetabolite (6625) | 1 | \$77.86 | 14 | \$1,317.14 | 5 | \$967.90 |
| Interleukin-1 Receptor Antagonist (IL-1Ra) (6626) | 77 | \$91,335.01 | 18 | \$23,780.88 | 40 | \$55,559.71 |
| Anti-TNF-alpha - Monoclonal Antibodies (6627) | 499 | \$831,368.58 | 370 | \$674,932.98 | 551 | \$1,148,551.46 |
| Pyrimidine Synthesis Inhibitors (6628) | 671 | \$157,579.67 | 305 | \$12,782.45 | 304 | \$6,627.13 |
| Soluble Tumor Necrosis Factor Receptor Agents (6629) | 1,734 | \$2,435,549.60 | 1,334 | \$1,987,133.07 | 1,360 | \$2,222,737.40 |
| (66) ANALGESICS - ANTI-INFLAMMATORY TOTAL | 145,847 | \$7,907,806.98 | 117,906 | \$4,442,212.20 | 141,560 | \$5,241,420.39 |

(67) MIGRAINE PRODUCTS

| | 2006 | | 2007 | | 2008 | |
|-------------------------------------|---------------|-----------------------|---------------|-----------------------|--------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Migraine products (6700) | 109 | \$23,085.72 | 103 | \$25,546.02 | 61 | \$20,977.12 |
| Carboxylic Acid Derivatives (6730) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Serotonin Agonists (6740) | 9,987 | \$1,693,135.84 | 9,518 | \$1,711,104.03 | 9,590 | \$2,163,908.09 |
| Migraine Combinations (6799) | 575 | \$10,414.12 | 407 | \$9,900.32 | 120 | \$11,258.14 |
| (67) MIGRAINE PRODUCTS TOTAL | 10,671 | \$1,726,635.68 | 10,028 | \$1,746,550.37 | 9,771 | \$2,196,143.35 |

(68) GOUT

| | 2006 | | 2007 | | 2008 | |
|-------------------------------|--------------|--------------------|--------------|--------------------|--------------|--------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Gout (6800) | 8,518 | \$62,490.30 | 2,775 | \$19,963.28 | 2,954 | \$21,845.43 |
| Uricosurics (6810) | 243 | \$6,028.53 | 53 | \$1,389.19 | 50 | \$2,006.82 |
| Combination Gout Drugs (6899) | 152 | \$6,124.09 | 16 | \$738.07 | 28 | \$1,421.41 |
| (68) GOUT TOTAL | 8,913 | \$74,642.92 | 2,844 | \$22,090.54 | 3,032 | \$25,273.66 |

(69) LOCAL ANESTHETICS-Parenteral

| | 2006 | | 2007 | | 2008 | |
|--|--------------|-------------------|--------------|-------------------|--------------|-------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Local anesthetics-parenteral (6900) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Local Anesthetics - Amides (6910) | 1,170 | \$6,144.93 | 463 | \$2,620.18 | 463 | \$2,890.92 |
| Local Anesthetics - Esters (6920) | 40 | \$272.98 | 210 | \$995.09 | 378 | \$1,658.70 |
| Local Anesthetic Combinations (6999) | 1 | \$6.57 | 5 | \$35.42 | 7 | \$57.81 |
| (69) LOCAL ANESTHETICS-Parenteral TOTAL | 1,211 | \$6,424.48 | 678 | \$3,650.69 | 848 | \$4,607.43 |

(70) GENERAL ANESTHETICS

| | 2006 | | 2007 | | 2008 | |
|---------------------------------------|--------------|---------------|--------------|---------------|--------------|---------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| General anesthetics (7000) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Barbiturate Anesthetics (7010) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Volatile Anesthetics (7020) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Misc. Anesthetics (7040) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (70) GENERAL ANESTHETICS TOTAL | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |

(72) ANTICONVULSANT

| | 2006 | | 2007 | | 2008 | |
|---|----------------|------------------------|----------------|------------------------|----------------|------------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Anticonvulsant (7200) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Anticonvulsant - Benzodiazepines (7210) | 46,034 | \$1,282,316.89 | 50,516 | \$1,562,280.70 | 56,110 | \$1,586,755.13 |
| Carbamates (7212) | 566 | \$169,157.01 | 574 | \$162,391.22 | 603 | \$185,383.69 |
| GABA Modulators (7217) | 1,584 | \$291,121.75 | 793 | \$167,359.78 | 659 | \$151,842.73 |
| Hydantoins (7220) | 30,232 | \$1,057,720.03 | 16,571 | \$591,625.48 | 15,660 | \$546,881.69 |
| Succinimides (7240) | 847 | \$71,264.64 | 795 | \$63,199.03 | 800 | \$65,297.20 |
| Valproic Acid (7250) | 51,063 | \$6,555,794.34 | 38,295 | \$5,034,838.36 | 38,047 | \$5,664,598.73 |
| Misc. Anticonvulsants (7260) | 127,459 | \$16,306,117.32 | 103,378 | \$15,450,253.70 | 118,980 | \$18,972,201.28 |
| (72) ANTICONVULSANT TOTAL | 257,785 | \$25,733,491.98 | 210,922 | \$23,031,948.27 | 230,859 | \$27,172,960.45 |

(73) ANTIPARKINSONIAN

| | 2006 | | 2007 | | 2008 | |
|---|---------------|-----------------------|---------------|---------------------|---------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antiparkinsonian (7300) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antiparkinsonian Anticholinergic (7310) | 17,691 | \$191,684.69 | 11,788 | \$129,833.54 | 11,868 | \$127,642.58 |
| Antiparkinsonian COMT Inhibitors (7315) | 325 | \$62,772.46 | 75 | \$15,460.65 | 65 | \$15,392.17 |
| Antiparkinsonian Dopaminergic (7320) | 15,812 | \$1,050,426.63 | 7,980 | \$527,588.67 | 9,620 | \$749,586.73 |
| Antiparkinsonian Monoamine Oxidase Inhibitor (7330) | 142 | \$2,508.57 | 42 | \$7,142.30 | 27 | \$2,983.22 |
| Antiparkinsonian Adjuvants (7340) | 16 | \$787.11 | 1 | \$61.07 | 22 | \$1,472.67 |
| (73) ANTIPARKINSONIAN TOTAL | 33,986 | \$1,308,179.46 | 19,886 | \$680,086.23 | 21,602 | \$897,077.37 |

(74) NEUROMUSCULAR AGENTS

| | 2006 | | 2007 | | 2008 | |
|---|--------------|---------------------|--------------|---------------------|--------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Neuromuscular agents (7400) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Depolarizing Muscle Relaxants (7410) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Nondepolarizing Muscle Relaxants (7420) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Neuromuscular Blocking Agent - Neurotoxins (7440) | 93 | \$180,200.56 | 69 | \$354,205.39 | 84 | \$171,764.32 |
| ALS Agents (7450) | 47 | \$37,735.98 | 36 | \$27,304.78 | 12 | \$11,003.11 |
| (74) NEUROMUSCULAR AGENTS TOTAL | 140 | \$217,936.54 | 105 | \$381,510.17 | 96 | \$182,767.43 |

(75) MUSCULOSKELETAL THERAPY AGENTS

| | 2006 | | 2007 | | 2008 | |
|--|----------------|-----------------------|---------------|-----------------------|---------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Musculoskeletal therapy agents (7500) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Central Muscle Relaxants (7510) | 104,904 | \$2,491,497.04 | 71,764 | \$1,545,693.74 | 73,755 | \$1,330,718.54 |
| Direct Muscle Relaxants (7520) | 592 | \$65,601.58 | 341 | \$35,155.64 | 315 | \$27,941.39 |
| Viscosupplements (7580) | 35 | \$34,576.82 | 16 | \$9,430.66 | 23 | \$17,116.94 |
| Articular Cartilage Repair Therapy (7584) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Muscle Relaxant Combinations (7599) | 680 | \$22,241.80 | 253 | \$11,214.59 | 274 | \$10,569.28 |
| (75) MUSCULOSKELETAL THERAPY AGENTS TOTAL | 106,211 | \$2,613,917.24 | 72,374 | \$1,601,494.63 | 74,367 | \$1,386,346.15 |

(76) ANTIMYASTHENIC AGENTS

| | 2006 | | 2007 | | 2008 | |
|---|--------------|--------------------|--------------|--------------------|--------------|--------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antimythasthenic agents (7600) | 356 | \$20,251.24 | 171 | \$11,679.40 | 166 | \$11,065.03 |
| Antimythasthenic Combinations (7699) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (76) ANTIMYASTHENIC AGENTS TOTAL | 356 | \$20,251.24 | 171 | \$11,679.40 | 166 | \$11,065.03 |

(77) VITAMINS

| | 2006 | | 2007 | | 2008 | |
|----------------------------------|--------------|--------------------|--------------|--------------------|--------------|--------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Vitamins (7700) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Water Soluble Vitamins (7710) | 0 | \$0.00 | 14 | \$731.92 | 22 | \$956.29 |
| Oil Soluble Vitamins (7720) | 1,550 | \$95,541.21 | 1,041 | \$66,613.87 | 1,619 | \$83,636.50 |
| Misc. Nutritional Factors (7730) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (77) VITAMINS TOTAL | 1,550 | \$95,541.21 | 1,055 | \$67,345.79 | 1,641 | \$84,592.79 |

(78) MULTIVITAMINS

| | 2006 | | 2007 | | 2008 | |
|---|--------------|----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Multivitamins (7800) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Vitamin Mixtures (7810) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| B-Complex Vitamins (7811) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| B-Complex w/ C (7812) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| B-Complex w/ Folic Acid (7813) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| B-Complex w/ Iron (7814) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| B-Complex w/ Minerals (7815) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Bioflavonoid Products (7816) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Multivitamins (7820) | 1 | \$4.73 | 0 | \$0.00 | 0 | \$0.00 |
| Multiple Vitamins w/ Iron (7821) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Multiple Vitamins w/ Minerals (7831) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Multiple Vitamins w/ Calcium (7835) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Multiple Vitamins w/ Minerals & Calcium-Folic Acid (7840) | 92 | \$2,418.06 | 14 | \$277.64 | 7 | \$144.88 |
| Pediatric Vitamins (7840) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Pediatric Multiple Vitamins (7841) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Ped Multiple Vitamins w/ Minerals (7842) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Not Classified (7843) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Ped MV w/ Iron (7843) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Ped MV w/ Fluoride (7844) | 1,936 | \$23,752.15 | 1,971 | \$23,280.49 | 1,881 | \$21,440.03 |
| Ped Multi Vitamins w/FI & FE (7845) | 630 | \$6,626.07 | 711 | \$7,038.47 | 553 | \$4,682.29 |
| Specialty Vitamins Products (7850) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Prenatal Vitamins (7851) | 41,229 | \$1,382,491.66 | 47,941 | \$1,886,326.48 | 50,008 | \$2,218,258.08 |
| Vitamins w/ Lipotropics (7852) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Iron w/ Vitamins (7861) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |

| | 2006 | | 2007 | | 2008 | |
|--|--------------|----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Iron & B12 w/ Vitamins (7863) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (78) MULTIVITAMINS TOTAL | 43,888 | \$1,415,292.67 | 50,637 | \$1,916,923.08 | 52,449 | \$2,244,525.28 |

(79) MINERALS & ELECTROLYTES

| | 2006 | | 2007 | | 2008 | |
|---|--------------|----------------|--------------|--------------|--------------|--------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Minerals & electrolytes (7900) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Bicarbonates (7905) | 446 | \$9,299.80 | 510 | \$14,187.81 | 666 | \$15,452.59 |
| Calcium (7910) | 17 | \$758.69 | 20 | \$403.05 | 34 | \$848.61 |
| Chloride (7920) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Fluoride (7930) | 2,278 | \$18,615.54 | 2,245 | \$16,919.43 | 2,345 | \$15,765.05 |
| Iodine Products (7935) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Magnesium (7940) | 19 | \$260.43 | 18 | \$153.50 | 44 | \$446.25 |
| Manganese (7950) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Phosphate (7960) | 155 | \$2,680.63 | 84 | \$1,935.65 | 147 | \$3,086.13 |
| Potassium (7970) | 75,762 | \$1,029,175.78 | 23,997 | \$287,751.58 | 23,845 | \$298,273.63 |
| Sodium (7975) | 2,299 | \$127,697.23 | 1,633 | \$108,497.13 | 1,653 | \$117,984.68 |
| Zinc (7980) | 17 | \$1,416.36 | 0 | \$0.00 | 0 | \$0.00 |
| Mineral Combinations (7985) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Trace Minerals (7990) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Electrolyte Mixtures (7999) | 255 | \$9,075.25 | 196 | \$5,716.81 | 355 | \$7,085.90 |
| (79) MINERALS & ELECTROLYTES TOTAL | 81,248 | \$1,198,979.71 | 28,703 | \$435,564.96 | 29,089 | \$458,942.84 |

(80) NUTRIENTS

| | 2006 | | 2007 | | 2008 | |
|--|--------------|-------------|--------------|-------------|--------------|-------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Nutrients (8000) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Carbohydrate (8010) | 344 | \$10,151.50 | 310 | \$9,606.71 | 253 | \$18,303.55 |
| Lipids (8020) | 0 | \$0.00 | 0 | \$0.00 | 2 | \$75.06 |
| Protein (8030) | 0 | \$0.00 | 16 | \$9,623.72 | 0 | \$0.00 |
| Lipotropics (8040) | 8 | \$70.88 | 13 | \$58.34 | 13 | \$57.39 |
| Misc. Nutritional Substances (8050) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (80) NUTRIENTS TOTAL | 352 | \$10,222.38 | 339 | \$19,288.77 | 268 | \$18,436.00 |

(81) DIETARY PRODUCTS

| | 2006 | | 2007 | | 2008 | |
|---------------------------------------|--------------|-------------|--------------|-------------|--------------|-------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Dietary products (8100) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Infant Foods (8110) | 19 | \$3,792.06 | 29 | \$5,999.52 | 19 | \$4,226.39 |
| Nutritional Supplements (8120) | 62 | \$26,408.96 | 106 | \$54,770.04 | 112 | \$59,218.34 |
| Nutritional Substitutes (8140) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (81) DIETARY PRODUCTS TOTAL | 81 | \$30,201.02 | 135 | \$60,769.56 | 131 | \$63,444.73 |

(82) HEMATOPOIETIC AGENTS

| | 2006 | | 2007 | | 2008 | |
|--|--------------|----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Hematopoietic agents (8200) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Cobalamins (8210) | 0 | \$0.00 | 0 | \$0.00 | 7 | \$19.02 |
| Folic Acid/Folates (8220) | 11,455 | \$67,548.43 | 10,898 | \$63,439.11 | 11,998 | \$75,380.90 |
| Iron (8230) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Hematopoietic Growth Factors (8240) | 2,325 | \$3,348,712.53 | 1,074 | \$1,903,823.52 | 927 | \$1,671,788.74 |
| Agents for Gaucher Disease (8270) | 5 | \$27,360.85 | 35 | \$156,782.60 | 24 | \$225,327.10 |

| | 2006 | | 2007 | | 2008 | |
|---|--------------|----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Agents for Sickle Cell Anemia (8280) | 0 | \$0.00 | 4 | \$288.34 | 0 | \$0.00 |
| Hematopoietic Mixtures (8299) | 515 | \$14,332.25 | 275 | \$6,507.60 | 0 | \$0.00 |
| (82) HEMATOPOIETIC AGENTS TOTAL | 14,300 | \$3,457,954.06 | 12,286 | \$2,130,841.17 | 12,956 | \$1,972,515.76 |

(83) ANTICOAGULANTS

| | 2006 | | 2007 | | 2008 | |
|---|--------------|----------------|--------------|----------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Anticoagulants (8300) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Heparins And Heparinoid-Like Agents (8310) | 3,662 | \$1,594,701.57 | 3,196 | \$1,899,542.10 | 3,484 | \$2,664,212.95 |
| Coumarin Anticoagulants (8320) | 26,544 | \$341,316.94 | 8,732 | \$111,622.09 | 8,871 | \$104,784.64 |
| Indanedione Anticoagulants (8330) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Thrombin Inhibitors (8333) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| In Vitro Anticoagulants (8340) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (83) ANTICOAGULANTS TOTAL | 30,206 | \$1,936,018.51 | 11,928 | \$2,011,164.19 | 12,355 | \$2,768,997.59 |

(84) HEMOSTATICS

| | 2006 | | 2007 | | 2008 | |
|--------------------------------------|--------------|-------------|--------------|-------------|--------------|-------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Hemostatics (8400) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Hemostatics - Systemic (8410) | 39 | \$11,850.45 | 48 | \$24,626.07 | 33 | \$14,606.62 |
| Hemostatics - Topical (8420) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (84) HEMOSTATICS TOTAL | 39 | \$11,850.45 | 48 | \$24,626.07 | 33 | \$14,606.62 |

(85) MISC. HEMATOLOGICAL

| | 2006 | | 2007 | | 2008 | |
|--|---------------|------------------------|---------------|------------------------|---------------|------------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Misc. hematological (8500) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antihemophilic Products (8510) | 686 | \$14,872,638.31 | 732 | \$19,353,278.78 | 622 | \$22,987,128.34 |
| Platelet Aggregation Inhibitors (8515) | 32,751 | \$4,629,945.65 | 10,778 | \$1,626,543.80 | 12,203 | \$1,923,488.24 |
| Hematorheological (8520) | 2,837 | \$36,697.65 | 610 | \$8,753.58 | 601 | \$7,547.18 |
| Hemin (8525) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| In Vitro Hematologic Agents (8527) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Plasma Expanders (8530) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Plasma Proteins (8540) | 48 | \$9,680.10 | 19 | \$2,441.17 | 44 | \$20,275.45 |
| Protamine (8550) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Thrombolytic Enzymes (8560) | 13 | \$108,922.00 | 14 | \$94,895.41 | 23 | \$33,158.56 |
| (85) MISC. HEMATOLOGICAL TOTAL | 36,335 | \$19,657,883.71 | 12,153 | \$21,085,912.74 | 13,493 | \$24,971,597.77 |

(86) OPHTHALMIC

| | 2006 | | 2007 | | 2008 | |
|--|--------------|--------------|--------------|--------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Ophthalmic (8600) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Ophthalmic Anti-infectives (8610) | 40,818 | \$929,114.90 | 38,949 | \$907,828.91 | 41,939 | \$1,047,499.42 |
| Artificial Tears and Lubricants (8620) | 3 | \$94.64 | 13 | \$357.54 | 40 | \$1,142.99 |
| Beta-blockers - Ophthalmic (8625) | 5,363 | \$278,928.87 | 1,255 | \$89,467.61 | 1,191 | \$84,969.73 |
| Ophthalmic Steroids (8630) | 8,792 | \$334,763.66 | 6,241 | \$277,007.92 | 6,297 | \$287,398.00 |
| Prostaglandins - Ophthalmic (8633) | 8,910 | \$679,134.15 | 2,470 | \$220,570.57 | 2,585 | \$250,842.13 |
| Cycloplegics (8635) | 841 | \$10,459.93 | 777 | \$8,876.32 | 776 | \$8,948.09 |
| Ophthalmic Decongestants (8640) | 36 | \$333.05 | 68 | \$501.30 | 69 | \$547.04 |
| Miotics (8650) | 416 | \$6,727.62 | 84 | \$2,833.59 | 84 | \$3,874.02 |
| Adrenergic Agents (8660) | 3,223 | \$238,200.89 | 810 | \$63,852.30 | 730 | \$57,332.56 |

| | 2006 | | 2007 | | 2008 | |
|--|---------------|-----------------------|---------------|-----------------------|---------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Ophthalmic - Angiogenesis Inhibitors (8665) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Ophthalmic Photodynamic Therapy Agents (8670) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Ophthalmic Immunomodulators (8672) | 1,069 | \$109,972.77 | 313 | \$38,218.33 | 314 | \$53,465.67 |
| Ophthalmic Local Anesthetics (8675) | 55 | \$373.09 | 63 | \$400.45 | 32 | \$457.89 |
| Ophthalmic Surgical Aids (8678) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Misc. Ophthalmics (8680) | 10,539 | \$777,083.24 | 7,395 | \$594,844.33 | 7,865 | \$662,996.65 |
| Contact Lens Solutions (8690) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (86) OPHTHALMIC TOTAL | 80,065 | \$3,365,186.81 | 58,438 | \$2,204,759.17 | 61,922 | \$2,459,474.19 |

(87) OTIC

| | 2006 | | 2007 | | 2008 | |
|--|---------------|-----------------------|---------------|-----------------------|---------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Otic (8700) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Otic Anti-infectives (8710) | 9,562 | \$594,263.12 | 9,775 | \$735,847.51 | 10,594 | \$807,855.62 |
| Otic Analgesics (8720) | 34 | \$525.32 | 36 | \$518.63 | 26 | \$346.72 |
| Otic Steroids (8730) | 414 | \$9,432.10 | 382 | \$8,150.01 | 390 | \$8,293.48 |
| Otic Miscellaneous (8740) | 226 | \$6,715.25 | 187 | \$6,367.45 | 294 | \$8,882.21 |
| Otic Agents - For External Ear (8770) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Otic Combinations (8799) | 34,111 | \$1,241,570.69 | 35,666 | \$1,479,254.95 | 39,542 | \$1,844,919.89 |
| (87) OTIC TOTAL | 44,347 | \$1,852,506.48 | 46,046 | \$2,230,138.55 | 50,846 | \$2,670,297.92 |

(88) MOUTH & THROAT (Local)

| | 2006 | | 2007 | | 2008 | |
|--|---------------|---------------------|---------------|---------------------|---------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Mouth & throat (local) (8800) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Anti-infectives - Throat (8810) | 13,188 | \$321,701.01 | 13,646 | \$336,783.55 | 13,811 | \$277,431.19 |
| Antiseptics - Mouth/Throat (8815) | 2,664 | \$22,390.50 | 2,224 | \$17,747.19 | 2,653 | \$21,650.42 |
| Lozenges (8820) | 20 | \$99.31 | 86 | \$381.06 | 38 | \$175.84 |
| Steroids - Mouth (8825) | 602 | \$9,908.05 | 495 | \$9,152.91 | 506 | \$10,696.52 |
| Antiallergy Agents (8827) | 23 | \$502.96 | 3 | \$66.56 | 3 | \$66.56 |
| Mouthwashes (8830) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Anesthetics Topical Oral (8835) | 2,205 | \$17,776.36 | 2,118 | \$16,703.70 | 2,497 | \$25,550.69 |
| Dental Products (8840) | 1,319 | \$16,485.09 | 1,918 | \$21,339.82 | 2,305 | \$25,881.87 |
| Periodontal Products (8845) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Misc. Throat Products (8850) | 323 | \$41,525.05 | 70 | \$8,236.13 | 91 | \$11,657.84 |
| (88) MOUTH & THROAT (Local) TOTAL | 20,344 | \$430,388.33 | 20,560 | \$410,410.92 | 21,904 | \$373,110.93 |

(89) ANORECTAL

| | 2006 | | 2007 | | 2008 | |
|---|--------------|--------------------|--------------|--------------------|--------------|--------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Anorectal (8900) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Rectal Steroids (8910) | 1,128 | \$14,941.70 | 829 | \$9,278.89 | 696 | \$10,183.92 |
| Intra-rectal Steroids (8915) | 58 | \$7,105.74 | 53 | \$6,403.15 | 40 | \$4,541.72 |
| Rectal Local Anesthetics (8920) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Misc. Rectal Products (8930) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Rectal Protectants-Emollients (8940) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Rectal Combinations (8999) | 1,226 | \$68,643.16 | 885 | \$55,291.26 | 680 | \$49,011.68 |
| (89) ANORECTAL TOTAL | 2,412 | \$90,690.60 | 1,767 | \$70,973.30 | 1,416 | \$63,737.32 |

(90) DERMATOLOGICAL

| | 2006 | | 2007 | | 2008 | |
|---|--------------|----------------|--------------|--------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Dermatological (9000) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Acne Products (9005) | 8,580 | \$778,748.54 | 8,307 | \$791,545.65 | 5,837 | \$264,261.88 |
| Rosacea Agents (9006) | 926 | \$67,575.15 | 268 | \$22,419.33 | 181 | \$13,783.74 |
| Analgesics (9007) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antibiotics - Topical (9010) | 26,032 | \$950,410.81 | 25,199 | \$895,147.78 | 32,931 | \$1,415,761.32 |
| Antifungals - Topical (9015) | 47,660 | \$1,080,981.69 | 41,647 | \$764,487.61 | 44,195 | \$715,037.25 |
| Antihistamines-Topical (9020) | 0 | \$0.00 | 0 | \$0.00 | 2 | \$81.35 |
| Antipruritics (9022) | 71 | \$3,875.92 | 37 | \$2,904.00 | 19 | \$1,237.40 |
| Antipsoriatics (9025) | 1,820 | \$381,626.19 | 1,882 | \$432,833.91 | 1,531 | \$517,417.30 |
| Antiseborrheic Products (9030) | 1,316 | \$21,809.76 | 1,057 | \$15,611.78 | 1,080 | \$16,068.97 |
| Antiviral - Topical (9035) | 3,032 | \$258,960.43 | 2,726 | \$275,054.15 | 2,884 | \$344,423.63 |
| Antineoplastic or Premalignant Lesions - Topical (903) | 255 | \$36,937.93 | 181 | \$32,553.68 | 109 | \$27,530.49 |
| Bath Products (9040) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Burn Products (9045) | 5,917 | \$85,349.39 | 4,039 | \$50,117.79 | 4,625 | \$50,709.63 |
| Cauterizing Agents (9050) | 0 | \$0.00 | 1 | \$63.20 | 0 | \$0.00 |
| Tar Products (9052) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Corticosteroids - Topical (9055) | 51,198 | \$1,073,190.33 | 49,203 | \$982,902.29 | 53,543 | \$1,255,749.59 |
| Diaper Rash Products (9060) | 0 | \$0.00 | 1 | \$7.21 | 0 | \$0.00 |
| Emollients (9065) | 2,305 | \$50,923.39 | 3,437 | \$195,077.29 | 3,064 | \$137,168.82 |
| Emollient/Keratolytic (9066) | 772 | \$54,471.02 | 605 | \$39,674.81 | 438 | \$17,415.30 |
| Enzymes - Topical (9070) | 12,092 | \$733,519.07 | 2,718 | \$175,108.12 | 1,098 | \$77,564.80 |
| Hair Growth Agents (9073) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Hair Reduction Agents (9074) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Keratolytics/Antimitotics (9075) | 298 | \$38,976.28 | 370 | \$41,147.73 | 492 | \$58,124.80 |
| Immunomodulating Agents - Topical (9077) | 1,777 | \$316,327.39 | 1,579 | \$330,542.20 | 1,559 | \$396,046.53 |

| | 2006 | | 2007 | | 2008 | |
|--|----------------|------------------------|----------------|-----------------------|----------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Immunosuppressive Agents - Topical (9078) | 12,896 | \$1,513,629.54 | 6,513 | \$803,268.89 | 5,239 | \$711,638.67 |
| Liniments (9080) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Local Anesthetics - Topical (9085) | 5,796 | \$943,854.70 | 4,714 | \$690,885.42 | 4,073 | \$561,169.09 |
| Pigmenting-Depigmenting Agents (9087) | 133 | \$7,701.23 | 55 | \$5,925.99 | 40 | \$4,615.35 |
| Agents for Facial Wrinkles (9088) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Glabellar Lines (Frown Lines) Agents (9089) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Scabicides & Pediculicides (9090) | 19,970 | \$1,531,809.49 | 19,087 | \$1,441,325.46 | 19,815 | \$1,432,243.23 |
| Sunscreens (9092) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Scar Treatment Products (9093) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Wound Care Products (9094) | 218 | \$88,178.11 | 167 | \$30,184.38 | 145 | \$36,630.61 |
| Poison Ivy Products (9095) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Misc. Topical (9097) | 480 | \$5,743.12 | 408 | \$4,473.15 | 403 | \$4,302.00 |
| Podiatric Products (9098) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Misc. Dermatological Products (9099) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (90) DERMATOLOGICAL TOTAL | 203,544 | \$10,024,599.48 | 174,201 | \$8,023,261.82 | 183,303 | \$8,058,981.75 |

(92) ANTISEPTICS & DISINFECTANTS

| | 2006 | | 2007 | | 2008 | |
|---|--------------|--------------------|--------------|--------------------|--------------|--------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antiseptics & disinfectants (9200) | 11 | \$424.94 | 11 | \$337.57 | 5 | \$129.93 |
| Chlorine Antiseptics (9210) | 833 | \$25,109.48 | 923 | \$29,213.35 | 950 | \$34,750.76 |
| Iodine Antiseptics (9220) | 32 | \$1,464.24 | 3 | \$156.45 | 0 | \$0.00 |
| Mercury Antiseptics (9230) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Silver Antiseptics (9240) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antiseptic Combinations (9299) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (92) ANTISEPTICS & DISINFECTANTS TOTAL | 876 | \$26,998.66 | 937 | \$29,707.37 | 955 | \$34,880.69 |

(93) ANTIDOTES

| | 2006 | | 2007 | | 2008 | |
|--|--------------|--------------|--------------|--------------|--------------|----------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Antidotes (9300) | 216 | \$224,010.15 | 12 | \$22,197.16 | 33 | \$50,031.03 |
| Antidotes - Chelating Agents (9310) | 99 | \$291,767.54 | 264 | \$818,682.32 | 255 | \$978,193.73 |
| Benzodiazepine Antagonists (9320) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Narcotic Antagonists (9340) | 411 | \$38,187.00 | 624 | \$48,319.30 | 892 | \$66,691.34 |
| Antidote Kits (9399) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (93) ANTIDOTES TOTAL | 726 | \$553,964.69 | 900 | \$889,198.78 | 1,180 | \$1,094,916.10 |

(94) DIAGNOSTIC PRODUCTS

| | 2006 | | 2007 | | 2008 | |
|---|--------------|------------|--------------|------------|--------------|------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Diagnostic products (9400) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Diagnostic Reagents (9410) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Diagnostic Drugs (9420) | 9 | \$3,615.02 | 4 | \$129.72 | 8 | \$3,943.91 |
| Diagnostic Biologicals (9430) | 83 | \$2,858.61 | 73 | \$1,044.04 | 44 | \$494.18 |
| Diagnostic Radiopharmaceuticals (9435) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Radiographic Contrast Media (9440) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Non-Radiographic Contrast Media (9450) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Diagnostic Products, Misc. (9460) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (94) DIAGNOSTIC PRODUCTS TOTAL | 92 | \$6,473.63 | 77 | \$1,173.76 | 52 | \$4,438.09 |

(95) ALTERNATIVE MEDICINES

| | 2006 | | 2007 | | 2008 | |
|--|--------------|---------------|--------------|---------------|--------------|---------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Alternative medicines (9500) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - A's (9503) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - B's (9506) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - C's (9509) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - D's (9512) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - E's (9515) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - F's (9518) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - G's (9521) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - H's (9524) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - K's (9533) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - L's* (9536) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - M's (9539) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - N's (9542) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - P's (9548) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - R's (9554) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - S's (9557) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - T's (9560) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - V's (9566) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - W's (9569) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine - Y's (9575) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alternative Medicine Combinations (9599) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (95) ALTERNATIVE MEDICINES TOTAL | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |

(96) CHEMICALS

| | 2006 | | 2007 | | 2008 | |
|--------------------------------|--------------|------------|--------------|------------|--------------|------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Chemicals (9600) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Acids, Bases, & Buffers (9610) | 1 | \$11.95 | 1 | \$5.59 | 0 | \$0.00 |
| Liquids (9620) | 14 | \$340.50 | 46 | \$1,023.47 | 99 | \$1,499.26 |
| Solids (9630) | 22 | \$566.95 | 14 | \$145.32 | 32 | \$679.36 |
| Semi-Solids (9640) | 1 | \$5.10 | 1 | \$6.02 | 2 | \$5.80 |
| Bulk Chemicals - A's (9642) | 8 | \$65.97 | 1 | \$25.15 | 1 | \$4.47 |
| Bulk Chemicals - B's (9644) | 242 | \$9,026.16 | 0 | \$0.00 | 1 | \$2,271.03 |
| Bulk Chemicals - C's (9646) | 14 | \$2,040.15 | 107 | \$768.22 | 676 | \$3,800.70 |
| Bulk Chemicals - D's (9648) | 3 | \$12.80 | 5 | \$23.31 | 1 | \$4.34 |
| Bulk Chemicals - E's (9650) | 6 | \$26.10 | 0 | \$0.00 | 0 | \$0.00 |
| Bulk Chemicals - F's (9652) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Bulk Chemicals - G's (9654) | 6 | \$292.49 | 3 | \$126.35 | 0 | \$0.00 |
| Bulk Chemicals - H's (9656) | 7 | \$68.15 | 7 | \$302.95 | 70 | \$1,620.51 |
| Bulk Chemicals - I's (9658) | 0 | \$0.00 | 0 | \$0.00 | 1 | \$4.22 |
| Bulk Chemicals - J's (9660) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Bulk Chemicals - K's (9662) | 8 | \$4,688.58 | 5 | \$96.91 | 3 | \$111.33 |
| Bulk Chemicals - L's (9664) | 30 | \$1,033.49 | 1 | \$46.20 | 4 | \$3.51 |
| Bulk Chemicals - M's (9666) | 6 | \$250.58 | 6 | \$31.97 | 10 | \$76.14 |
| Bulk Chemicals - N's (9668) | 1 | \$144.41 | 1 | \$284.68 | 0 | \$0.00 |
| Bulk Chemicals - O's (9670) | 1 | \$201.27 | 47 | \$1,646.17 | 21 | \$660.37 |
| Bulk Chemicals - P's (9672) | 2 | \$29.53 | 0 | \$0.00 | 0 | \$0.00 |
| Bulk Chemicals - Q's (9674) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Bulk Chemicals - R's (9676) | 8 | \$218.30 | 2 | \$260.66 | 0 | \$0.00 |
| Bulk Chemicals - S's (9678) | 2 | \$78.29 | 2 | \$148.24 | 12 | \$656.75 |
| Bulk Chemicals - T's (9680) | 89 | \$1,280.02 | 0 | \$0.00 | 0 | \$0.00 |

| | 2006 | | 2007 | | 2008 | |
|-----------------------------|--------------|--------------------|--------------|-------------------|--------------|--------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Bulk Chemicals - U's (9682) | 23 | \$2,285.59 | 3 | \$57.91 | 17 | \$12,511.87 |
| Bulk Chemicals - V's (9684) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Bulk Chemicals - W's (9686) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Bulk Chemicals - X (9687) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Bulk Chemicals - Y's (9688) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Bulk Chemicals - Z's (9689) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Bulk Chemicals (9690) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (96) CHEMICALS TOTAL | 494 | \$22,666.38 | 252 | \$4,999.12 | 950 | \$23,909.66 |

(97) MEDICAL DEVICES

| | 2006 | | 2007 | | 2008 | |
|---|--------------|--------------|--------------|--------------|--------------|--------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Medical devices (9700) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Parenteral Therapy Supplies (9705) | 0 | \$0.00 | 3 | \$12.96 | 5 | \$17.78 |
| Cardiology Supplies (9708) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Respiratory Therapy Supplies (9710) | 13,673 | \$608,178.83 | 15,664 | \$734,965.04 | 17,472 | \$847,311.82 |
| Respiratory Aids (9712) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Medical Gases (9714) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| GI-GU Ostomy & Irrigation Supplies (9715) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Peritoneal Dialysis (9717) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Diabetic Supplies (9720) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Enteral Nutrition Supplies (9725) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Bandages-Dressings-Tape (9730) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Elastic Bandages & Supports (9735) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Surgical Supplies (9736) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Heating/Cooling Aids (9737) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |

| | 2006 | | 2007 | | 2008 | |
|---|---------------|---------------------|---------------|---------------------|---------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Back Plasters (9739) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Contraceptives (9740) | 155 | \$2,803.57 | 143 | \$2,865.34 | 161 | \$3,693.82 |
| Fertility Monitoring Test Supplies (9742) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Female Personal Care Products (9745) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Impotence Aids (9747) | 0 | \$0.00 | 0 | \$0.00 | 1 | \$301.15 |
| Oral Hygiene Products (9750) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Infant Care Products (9755) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Optical Supplies (9760) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Misc. Devices (9770) | 366 | \$2,532.92 | 884 | \$4,919.74 | 584 | \$3,368.94 |
| Blood Pressure Devices (9775) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Foot Care Products (9780) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| First Aid Kits (9785) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (97) MEDICAL DEVICES TOTAL | 14,194 | \$613,515.32 | 16,694 | \$742,763.08 | 18,223 | \$854,693.51 |

(98) PHARMACEUTICAL ADJUVANTS

| | 2006 | | 2007 | | 2008 | |
|--|--------------|--------------|--------------|--------------|--------------|--------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Pharmaceutical adjuvants (9800) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Alkalinizing Agents (9805) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Antimicrobial Agents (9810) | 1 | \$5.52 | 8 | \$375.80 | 18 | \$436.71 |
| Coloring Agents (9830) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Flavoring Agents (9833) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Pharmaceutical Excipients (9835) | 324 | \$7,439.81 | 659 | \$13,079.36 | 1,090 | \$9,381.07 |
| Internal Vehicle Ingredients/Agents (9836) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Surfactants (9837) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Liquid Vehicle (9840) | 1,663 | \$127,927.65 | 1,855 | \$122,698.61 | 2,348 | \$166,278.15 |


| | 2006 | | 2007 | | 2008 | |
|--|--------------|---------------------|--------------|---------------------|--------------|---------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Semi Solid Vehicle (9860) | 12 | \$236.13 | 38 | \$1,125.29 | 73 | \$826.32 |
| Gelatin Capsules (Empty) (9870) | 2 | \$12.35 | 0 | \$0.00 | 0 | \$0.00 |
| Not Classified (9871) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Placebo (9880) | 96 | \$2,646.53 | 54 | \$1,056.97 | 7 | \$58.65 |
| Not Classified (9890) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (98) PHARMACEUTICAL ADJUVANTS TOTAL | 2,098 | \$138,267.99 | 2,614 | \$138,336.03 | 3,536 | \$176,980.90 |

(99) ASSORTED CLASSES

| | 2006 | | 2007 | | 2008 | |
|--------------------------------------|--------------|-----------------------|--------------|-----------------------|--------------|-----------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| Assorted classes (9900) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Chelating Agents (9920) | 38 | \$5,246.79 | 28 | \$7,183.72 | 42 | \$18,127.27 |
| Enzymes (9935) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Immunomodulators (9939) | 149 | \$593,720.99 | 51 | \$309,292.90 | 46 | \$148,718.88 |
| Immunosuppressive Agents (9940) | 4,308 | \$1,661,976.04 | 3,809 | \$1,563,637.85 | 4,232 | \$1,836,908.58 |
| K Removing Resin (9945) | 449 | \$23,275.57 | 161 | \$8,265.66 | 127 | \$7,237.08 |
| Prostaglandins (9950) | 1 | \$200.15 | 0 | \$0.00 | 0 | \$0.00 |
| Sclerosing Agents (9965) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Peritoneal Dialysis Solutions (9970) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Irrigation Solutions (9975) | 222 | \$2,881.07 | 161 | \$2,816.70 | 256 | \$5,630.77 |
| Organ Preservation Solution (9980) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Misc Natural Products (9985) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| Homeopathic Products (9987) | 0 | \$0.00 | 0 | \$0.00 | 0 | \$0.00 |
| (99) ASSORTED CLASSES TOTAL | 5,316 | \$2,881,021.60 | 4,261 | \$2,200,489.73 | 4,749 | \$2,165,341.46 |

| | 2006 | | 2007 | | 2008 | |
|--------------------|--------------|------------------|--------------|------------------|--------------|------------------|
| | Total Claims | Total Paid | Total Claims | Total Paid | Total Claims | Total Paid |
| GRAND TOTAL | 5,962,351 | \$403,534,106.83 | 4,704,107 | \$322,402,357.51 | 5,047,873 | \$356,350,055.11 |

| | 2006 | | 2007 | | 2008 | |
|-------------------------------------|----------------------|--|----------------------|--|----------------------|--|
| Total Pharmacy Reimbursement | \$403,534,107 | | \$322,402,357 | | \$356,350,055 | |
| Federal Rebate Amount | \$120,162,532 | | \$81,398,186 | | \$97,289,086 | |
| Supplemental Rebate Amount | \$7,896,562 | | \$5,135,371 | | \$5,480,277 | |
| TOTAL NET EXPENDITURE | \$275,475,013 | | \$235,868,800 | | \$253,580,692 | |



Appendix H



[FDA Home Page](#) | [CDER Home Page](#) | [CDER Site Info](#) | [Contact CDER](#) | [What's New @ CDER](#)



Search powered by Google™

Questions and Answers on Medication Guides for Erythropoiesis-Stimulating Agents (ESAs)

Epoetin alfa (marketed as Procrit, Epogen)
Darbepoetin alfa (marketed as Aranesp)

1. Why were Medication Guides for ESAs developed?

The Medication Guides were developed to provide patients with important information about the risks of using ESAs. The information in the Medication Guides may affect a patient's decision to take the drug and it gives patients a starting point for discussion with their healthcare provider about the medical decision to prescribe an ESA.

2. What are Erythropoiesis-Stimulating Agents (ESAs)?

ESAs are man-made forms of the protein human erythropoietin. ESAs are given to patients with low red blood counts due to kidney failure, or due to side effects from other drugs (chemotherapy or zidovudine), or given to patients scheduled for certain types of elective surgery. ESAs work by stimulating the bone marrow to make more red blood cells so that there is a lower chance that the patient will need red blood cell transfusions.

3. What are these important risks of using ESAs and how can they be managed?

Using ESAs can lead to serious side effects which may result in death. Some of these side effects are more likely to happen if the patient has cancer or chronic kidney failure.

In patients with all types of cancer for which ESA use is FDA-approved:

- The tumor may grow faster and the patient may die sooner when ESA treatment is used.
- The healthcare provider should prescribe the lowest dose of the ESA that is needed to avoid red blood cell transfusions.
- ESAs work by stimulating the bone marrow to make more red blood cells. ESAs have not been shown to improve the symptoms of anemia, quality of

The FDA is working with Amgen on a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of the ESAs outweigh their risks.

[↑ Back to Top](#) [↖ Back to ESA](#)

 PDF requires the free [Adobe Acrobat Reader](#)

Date created: December 2, 2008

[CDER Home Page](#) | [CDER Site Info](#) | [Contact CDER](#) | [What's New @ CDER](#)
[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#) | [Privacy](#) | [Accessibility](#) | [HHS Home Page](#)

FDA/Center for Drug Evaluation and Research



[FDA Home Page](#) | [CDER Home Page](#) | [CDER Site Info](#) | [Contact CDER](#) | [What's New @ CDER](#)



Search GO powered by Google™

Update of Safety Review Follow-up to the October 1, 2007 Early Communication about the Ongoing Safety Review of Bisphosphonates

Bisphosphonates: Alendronate (Fosamax, Fosamax Plus D), Etidronate (Didronel), Ibandronate (Boniva), Pamidronate (Aredia), Risedronate (Actonel, Actonel W/Calcium), Tiludronate (Skelid), and Zoledronic acid (Reclast, Zometa)

This information reflects FDA's current analysis of available data concerning these drugs.

On October 1, 2007, FDA announced that it was reviewing safety data that raised concerns about a potential increased risk for atrial fibrillation in patients treated with a bisphosphonate drug (http://www.fda.gov/cder/drug/early_comm/bisphosphonates.htm). An article and an accompanying letter to the editor in the May 3, 2007, issue of *The New England Journal of Medicine* described increased rates of serious atrial fibrillation in two different studies of women ages 65 to 89 years old with osteoporosis treated with the bisphosphonates, Reclast and Fosamax. Data available to FDA at that time, including data from the NDA approval of Reclast for osteoporosis, showed an increased risk of serious atrial fibrillation and this risk was reflected in the Reclast labeling. After our review, based on the data available at this time, healthcare professionals should not alter their prescribing patterns for bisphosphonates and patients should not stop taking their bisphosphonate medication.

On October 1, 2007, FDA began requesting placebo-controlled clinical trial information from the sponsors of alendronate, ibandronate, risedronate, and zoledronic acid in order to explore the potential risk for atrial fibrillation in male and female patients treated with these bisphosphonate drugs.

The data submitted by the four sponsors included data on 19,687 bisphosphonate-treated patients and 18,358 placebo-treated patients who were followed for 6 months to 3 years.

The occurrence of atrial fibrillation was rare within each study, with most studies containing 2 or fewer events. The absolute difference in event rates between each of the bisphosphonate and placebo arms varied from 0-3 per 1,000.

One large study of zoledronic acid showed a statistically significant increase in the rate of serious atrial fibrillation events. However, across all studies, no clear association between overall bisphosphonate exposure and the rate of serious or non-serious atrial fibrillation was observed. Increasing dose or duration of bisphosphonate therapy was also not associated with

life, fatigue, or well-being for patients with cancer. For that reason, ESAs should be used only to reduce the chance that a patient with low red blood counts (anemia) will get a blood transfusion.

- Treatment with an ESA should be stopped when chemotherapy treatment is finished.

In all patients taking an ESA:

There is risk of serious heart problems such as heart attack, stroke, heart failure, and a higher chance of death if patients are treated with an ESA to a hemoglobin level above 12 g/dL.

Patients may get blood clots at any time while taking an ESA. Patients who are receiving an ESA and scheduled for surgery should talk to their healthcare provider about whether or not to also take a blood thinner to reduce the chance of blood clots during or following surgery. Clots can form in blood vessels (veins), especially in the leg (deep venous thrombosis or DVT). Pieces of a blood clot may travel to the lungs and block the blood circulation in the lungs (pulmonary embolus). The possible symptoms of blood clots are:

- Chest pain
- Trouble breathing or shortness of breath
- Pain in the legs, with or without swelling
- A cool or pale arm or leg
- Sudden confusion, or trouble speaking or understanding speech
- Sudden numbness or weakness of the face, an arm, or leg, especially on one side of the body
- Sudden trouble seeing
- Sudden trouble walking, dizziness, loss of balance or coordination
- Loss of consciousness (fainting)
- Hemodialysis vascular access stops working. In patients with chronic kidney failure and a hemodialysis vascular access, blood clots may form in this access.

4. When should the Medication Guide be given to patients?

The Medication Guide must be given directly to a patient or the patient's caregiver when the drug is dispensed to the patient.

5. Some dialysis centers are preparing their own guides, perhaps to use in lieu of Amgen's FDA-approved Medication Guide. Is this acceptable?

The FDA-approved Medication Guide must be provided to patients or the patient's caregiver when the drug is dispensed to the patient. Dialysis centers may supplement the Medication Guide with additional information for patients. Additional information provided by the manufacturer, such as promotional labeling and advertising pieces, may be distributed provided the information in such pieces is compliant with promotional regulations (i.e., it is not false or misleading, it does not omit material facts, and it presents a fair balance of risk and benefit information).

6. Are the FDA and Amgen considering other actions to improve the safe use of ESAs?

an increased rate of atrial fibrillation.

The FDA is aware of discordant results from the literature and from other epidemiological studies about the incidence and clinical course of atrial fibrillation in patients taking bisphosphonates. FDA is exploring the feasibility of conducting additional epidemiologic studies to examine this issue. In addition, FDA is continuing to monitor post-market reports of atrial fibrillation in patients who have taken bisphosphonates.

Bisphosphonates are a class of drugs used primarily to increase bone mass and reduce the risk for fracture in patients with osteoporosis. Bisphosphonates are also used to slow bone turnover in patients with Paget's disease of the bone and to treat bone metastases and lower elevated levels of blood calcium in patients with cancer. There are 7 FDA-approved bisphosphonates: alendronate (Fosamax, Fosamax Plus D), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Actonel W/Calcium), tiludronate (Skelid), and zoledronic acid (Reclast, Zometa).

This follow-up communication is in keeping with FDA's commitment to inform the public about its ongoing safety reviews of drugs.

The FDA urges both healthcare professionals and patients to report side effects from the use of bisphosphonates to the FDA's MedWatch Adverse Event Reporting program.

- on-line at www.fda.gov/medwatch/report.htm
- by returning the postage-paid FDA form 3500 (available in PDF format at www.fda.gov/medwatch/getforms.htm) to 5600 Fishers Lane, Rockville, MD 20852-9787
- faxing the form to 1-800-FDA-0178
- by phone at 1-800-332-1088

[↑ Back to Top](#) [↖ Back to Bisphosphonates](#)

 PDF requires the free [Adobe Acrobat Reader](#)

Date created: November 12, 2008

[CDER Home Page](#) | [CDER Site Info](#) | [Contact CDER](#) | [What's New @ CDER](#)
[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#) | [Privacy](#) | [Accessibility](#) | [HHS Home Page](#)

FDA/Center for Drug Evaluation and Research



[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#)

Recall -- Firm Press Release

FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.

ETHEX Corporation Initiated Nationwide Voluntary Recalls of Specific Lots of Five Generic Products Due to the Potential for Oversized Tablets

Propafenone HCl Tablets - 150 mg, 225 mg, and 300 mg
Isosorbide Mononitrate Extended Release Tablets – 30 mg and 60 mg
Morphine Sulfate Extended Release Tablets - 15 mg
Morphine Sulfate Immediate Release Tablets - 15 mg and 30 mg
Dextroamphetamine Sulfate Tablets - 10 mg

Contact:

Ann McBride, ETHEX Corporation
1-800-748-1472

FOR IMMEDIATE RELEASE -- St. Louis, MO- November 7, 2008 – ETHEX Corporation announced today that it has voluntarily recalled to the consumer level specific lots of five generic /non-branded products that it markets. These lots have been recalled as a precaution, due to the possibility that they may contain oversized tablets. Oversized tablets may contain more than the intended levels of the active drug ingredient, which could result in patients receiving as much as about twice the expected dosage of these drugs.

Overdoses of Propafenone HCl, Isosorbide Mononitrate, Morphine sulfate and Dextroamphetamine Sulfate can have serious or life-threatening consequences. In the case of Propafenone HCl, these consequences can include arrhythmias (irregular heartbeat) and low blood pressure. In the case of Isosorbide Mononitrate, these consequences can include fainting and low blood pressure. In the case of Morphine Sulfate, these consequences can include respiratory depression (difficulty or lack of breathing) and low blood pressure. In the case of Dextroamphetamine Sulfate, these consequences can include rapid heart rate and high blood pressure.

The lots involved in the recall were all shipped prior to May 22, 2008 and are as follows:

Propafenone HCl Tablets, 150 mg: Lots: 73761, 78184, 79373, 81240, 81241, 81242, 83470, 84357, 90525, and 90526 with expiration dates ranging from 3/2009 to 3/2011

Propafenone HCl Tablets, 225 mg: Lots: 71720, 74831, 76014-15, 81243-45, 89731, 90527-29, and 90657 with expiration dates ranging from 3/2009 to 2/2011

Propafenone HCl Tablets, 300 mg: Lots: 72834, 76016-18, 81246, 89092, 89732, 90530, 90532, and 91641-42 with expiration dates ranging from 6/2009 to 3/2011

Isosorbide Mononitrate Extended Release Tablets, 30 mg: Lots: 62355, 66423, and 68102 with expiration dates ranging from 11/2008 to 8/2009

Isosorbide Mononitrate Extended Release Tablets, 60 mg: Lots: 63466, 66034, 67351, and 67354 with expiration dates ranging from 12/2008 to 11/2009

Morphine Sulfate Extended Release Tablets, 15 mg: Lots: 81175, 82514-16, 89660, 89664,

89667, 90249-51, and 91687 with expiration dates ranging from 12/2008 to 2/2010

Morphine Sulfate Immediate Release Tablets, 15 mg: Lots: 77852-54, 81746, 82519-20, 84113, and 90276-78 with expiration dates ranging from 9/2009 to 1/2011

Morphine Sulfate Immediate Release Tablets, 30 mg: Lots: 75093, 77855-57, 82297, 82521-22, 87239, 88925, and 90288-98 with expiration dates ranging from 8/2009 to 3/2011

Dextroamphetamine Sulfate Tablets, 10 mg: Lots: 73934, 75892, 77945, 81137, 86320 with expiration dates ranging from 6/2009 to 5/2011

The 150 mg Propafenone Hydrochloride Tablets is a white, scored round film coated tablet with "ETH" on one side and "331" with a bisect on the reverse. The 225 mg Propafenone Hydrochloride Tablets is a white, scored round film coated tablet with "ETH" on one side and "332" with a bisect on the reverse. The 300 mg Propafenone Hydrochloride Tablets is a white, scored round film coated tablet with "ETH" on one side and "333" with a bisect on the reverse.

The 30 mg Isosorbide Mononitrate Extended Release Tablet is an oval, reddish-pink, film-coated tablet with a debossed "E" bisecting "30" on one side and bisect on the other side. The 60 mg Isosorbide Mononitrate Extended Release Tablet is an oval, yellow film-coated tablet with a debossed "E" bisect "60" on one side and bisect on the other side.

The 15 mg Morphine Sulfate Extended Release Tablet is a green oval tablet with "15" on one side and an "E" on the reverse. The 15 mg Morphine Sulfate Immediate Release Tablet is a round brown tablet with a "15" on one side and an "ETH" on the reverse. The 30 mg Morphine Sulfate Immediate Release Tablet is a capsule shaped brown tablet with "30" on one side and an "ETHEX" on the reverse.

The 10 mg Dextroamphetamine Sulfate Tablet is a round, flat-face, bevel edge, orange mottled tablet debossed "ETHEX" and "312" on one side and double-scored on the other side.

ETHEX Corporation has initiated recall notifications to wholesalers and retailers who have received any inventory of the recalled product lots with instructions for returning the recalled products. The notification also includes instructions for the retailers/pharmacies to contact consumers who were dispensed these drugs for replacement of the product and/or refund. If the wholesalers and retailers have not already done so, they are urged to contact the number below regarding procedures for returning the recalled products. If consumers have any questions about the recall, they should call the number listed below for customer inquiries, their physician, their pharmacist or other health care provider.

Consumers who experience any adverse reactions to these drugs should contact their physician and/or healthcare provider immediately.

Any customer inquiries related to this action should be addressed to ETHEX Customer Service at 1-800-748-1472, or fax to ETHEX Customer Service at 314-646-3751 or sent via email to: customer-service@ethex.com with representatives available Monday through Friday, 8:00 am to 5:00 pm Central Standard Time (CST).

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA).

Any adverse reactions experienced with the use of these products, and/or quality problems may also be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by Fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch.

#

[RSS Feed for FDA Recalls Information](#) [what's this?]

 [Sign up for Recall email updates.](#)

[FDA Newsroom](#)